

Christopher S. Coffey

College of Public Health Curriculum Vitae

Department of Biostatistics

christopher-coffey@uiowa.edu

March 2026

Educational and Professional History

Degrees Earned

- 1992 BS in Business Administration and Statistics, University of Tennessee
- 1996 MS in Biostatistics, University of North Carolina, Chapel Hill
- 1999 PhD in Biostatistics, University of North Carolina, Chapel Hill

Employment History

- 1993 SPC Statistician, Iowa Division, Schlegel, Keokuk, Iowa
- 1993 - 1994 Advanced Quality Planning Engineer, Schlegel, Tennessee, Inc, Maryville, Tennessee
- 1995 SAS Programmer, Collaborative Studies Coordinating Center, Chapel Hill, North Carolina
- 1998 Statistician II, RHO, Inc, Chapel Hill, North Carolina
- 1995 - 1999 Graduate Research Assistant, Department of Biostatistics, University of North Carolina, Chapel Hill, North Carolina
- 1999 - 2001 Assistant Professor, Division of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
- 2001 - 2004 Assistant Professor, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama
- 2005 - 2008 Adjunct Associate Professor, Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
- 2004 - 2009 Associate Professor, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama
- 2006 - 2009 Director, Graduate Studies, University of Alabama, Birmingham, Alabama
- 2009 - 2010 Deputy Director, Clinical Trials and Statistical Data Management Center, Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa
- 2009 - Present Adjunct Professor, Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama
- 2009 - Present Professor, Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa
- 2010 - Present Director, Clinical Trials and Statistical Data Management Center, Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa

Honors and Awards

- 1992 Epsilon Eta Chapter of Sigma Nu Fraternity Scholar of the Year

- 1992 Named "Top Graduate" in University of Tennessee College of Business Administration
- 1996 Inducted into Delta Omega Public Health Honor Society
- 1997 Special Commendation, Applied Doctoral Exam, University of North Carolina Department of Biostatistics
- 1997 Special Commendation, Theory Doctoral Exam, University of North Carolina Department of Biostatistics
- 1997 UNC School of Public Health Student Award
- 1999 Barry H. Margolin Dissertation Award, University of North Carolina Department of Biostatistics
- 2003 Nomination for the Charles C. Shepard Science Award for most outstanding peer-reviewed paper published by CDC/ATSDR scientists during the preceding year (Prevention and Control Category)
- 2004 Science Unbound Foundation Award for Best Paper by a UAB Based Investigator in the Area of General Statistics
- 2004 University of Alabama at Birmingham President's Award for Excellence in Teaching-School of Public Health
- 2005 Grizzle Distinguished Alumni Award, University of North Carolina Department of Biostatistics
- 2008 Science Unbound Foundation Award for Best Paper by a UAB Based Investigator in the Area of General Statistics
- 2013 CPH Faculty Research Award, University of Iowa College of Public Health
- 2015 Fellow, Society for Clinical Trials
- 2016 Fellow, American Statistical Association
- 2016 Faculty Service Award, University of Iowa College of Public Health
- 2018 Distinguished Faculty Lecture, College of Public Health, The University of Iowa, Iowa City, Iowa
- 2020 Fellow, American Academy of Neurology
- 2024 41st Presidential Lecture, University of Iowa, Iowa City, Iowa

Teaching

Course Teaching

University of Iowa

- Aug 2008 Short Course "Clinical Trials Methods in Neurology", Vail, Colorado
Role: Primary Instructor
- Aug 2009 Short Course "Clinical Trials Methods in Neurology", Vail, Colorado
Role: Primary Instructor
- Spring 2010 Clinical Trials, 171:290, Credit Hours: 3, Enr: 5, Percent of Course: 100.0%
- Summer 2010 "Overview of Randomized Clinical Trials", Iowa Summer Institute of Biostatistics
Role: Guest Lecturer

Aug 2010	Short Course "Clinical Trials Methods in Neurology", Vail, Colorado Role: Primary Instructor
Spring 2011	Applied Cohort Data Analysis, 171:243, Credit Hours: 1, Enr: 1, Percent of Course: 100.0%
Spring 2011	Applied Survival and Cohort Data Analysis, 171:242, Credit Hours: 3, Enr: 21, Percent of Course: 100.0%
Summer 2011	"Overview of Randomized Clinical Trials", Iowa Summer Institute of Biostatistics Role: Guest Lecturer
Aug 2011	Short Course "Clinical Trials Methods in Neurology", Vail, Colorado Role: Primary Instructor
Fall 2011	Advanced Biostatistics Seminar: Advanced Clinical Trials, 171:290, Credit Hours: 3, Enr: 7, Percent of Course: 100.0%
Fall 2011	Intervention and Clinical Trials, 173:290
Summer 2012	"Overview of Randomized Clinical Trials", Iowa Summer Institute of Biostatistics Role: Guest Lecturer
Spring 2013	Applied Survival Analysis, 171:242, Credit Hours: 3, Enr: 18, Percent of Course: 100.0%
Spring 2013	Cohort Data Analysis, 171:243, Credit Hours: 1, Enr: 8, Percent of Course: 100.0%
Summer 2013	"Overview of Randomized Clinical Trials", Iowa Summer Institute of Biostatistics Role: Guest Lecturer
Fall 2013	Advanced Biostatistics Seminar: Clinical Trials, 171:290, Credit Hours: 3, Enr: 7, Percent of Course: 50.0%
Summer 2014	"Overview of Randomized Clinical Trials", Iowa Summer Institute of Biostatistics Role: Guest Lecturer
Aug 2014	Short Course "Clinical Trials Methods in Neurology", Iowa City, Iowa Role: Primary Instructor
Fall 2014	Advanced Biostatistics Seminar: Clinical Trials, BIOS:7600:0001, Credit Hours: 3, Enr: 6
Spring 2015	Thesis/Dissertation, BIOS:7900:0168, Percent of Course: 100.0%
Summer 2015	"Overview of Randomized Clinical Trials & CTSDMC", Iowa Summer Institute of Biostatistics Role: Guest Lecturer
Jul 2015	Short Course "Clinical Trials Methods in Neurology", Ann Arbor, Michigan Role: Primary Instructor
Spring 2016	Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 11, Percent of Course: 87.0%
Spring 2016	Thesis/Dissertation, BIOS:7900:0168, Percent of Course: 100.0%
Aug 2016	Short Course "Clinical Trials Methods in Neurology", Ann Arbor, Michigan Role: Primary Instructor
Fall 2016	Advanced Biostatistics Seminar, BIOS:7600:0001, Credit Hours: 3, Enr: 6, Percent of Course: 100.0%
Fall 2016	Thesis/Dissertation, BIOS:7900:3323, Percent of Course: 100.0%

Spring 2017 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 8, Percent of Course: 100.0%

Spring 2017 Thesis/Dissertation, BIOS:7900:4826, Percent of Course: 100.0%

Aug 2017 Short Course "Clinical Trials Methods in Neurology", Iowa City, Iowa
Role: Primary Instructor

Fall 2017 Thesis/Dissertation, BIOS:7900:6843, Percent of Course: 100.0%

Spring 2018 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 16, Percent of Course: 100.0%

Spring 2018 Thesis/Dissertation, BIOS:7900:9794, Percent of Course: 100.0%

Aug 2018 Short Course "Clinical Trials Methods in Neurology", Ann Arbor, Michigan
Role: Primary Instructor

Fall 2018 Advanced Clinical Trials, BIOS:7230:0001, Credit Hours: 3, Enr: 5

Fall 2018 Thesis/Dissertation, BIOS:7900:1730, Enr: 1, Percent of Course: 100.0%

Spring 2019 Preceptorship in Biostatistics, BIOS:7500:4630, Enr: 1, Percent of Course: 100.0%

Spring 2019 Thesis/Dissertation, BIOS:7900:3793, Enr: 2, Percent of Course: 100.0%

Summer 2019 Thesis/Dissertation, BIOS:7900:5404, Enr: 1, Percent of Course: 100.0%

Jul 2019 Short Course "Clinical Trials Methods in Neurology", Iowa City, Iowa
Role: Primary Instructor

Fall 2019 Thesis/Dissertation, BIOS:7900:5405, Enr: 2, Percent of Course: 100.0%

Spring 2020 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 17, Percent of Course: 50.0%

Spring 2020 Thesis/Dissertation, BIOS:7900:8354, Enr: 1, Percent of Course: 100.0%

Fall 2020 Advanced Clinical Trials, BIOS:7230:0001, Credit Hours: 3, Enr: 7, Percent of Course: 100.0%

Spring 2021 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 18, Percent of Course: 50.0%

May 2021 Short Course "Essentials of Randomized Clinical Trials"/Virtual due to COVID-19,
Percent of Course: 100.0%
Role: Primary Instructor

Jul 2021 Short Course "Clinical Trials Methods in Neurology"/Virtual due to COVID-19), Percent of Course: 100.0%
Role: Primary Instructor

Spring 2022 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 18, Percent of Course: 50.0%

Fall 2022 Advanced Clinical Trials, BIOS:7230:0001, Credit Hours: 3, Enr: 6, Percent of Course: 100.0%

Spring 2023 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 14, Percent of Course: 50.0%

Spring 2024 Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 14, Percent of Course: 50.0%

Fall 2024	Advanced Clinical Trials, BIOS:7230:0001, Credit Hours: 3, Enr: 5, Percent of Course: 50.0%
Spring 2025	Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 13, Percent of Course: 50.0%
Spring 2026	Statistical Methods in Clinical Trials, BIOS:6610:0001, Credit Hours: 3, Enr: 17, Percent of Course: 50.0%

Other Institutions

1991	Self-Paced College Algebra, ***:***:***, University of Tennessee
1992	Self-Paced College Algebra, ***:***:***, University of Tennessee
1997	Principles of Statistical Inference, ***:***:***, University of North Carolina at Chapel Hill
1999	Introduction to Statistical Consulting, ***:***:***, University of North Carolina at Chapel Hill
Fall 2000	Introductory Biostatistics, ***:***:***, Vanderbilt University
Summer 2001	BST 665: Introduction to Survival Analysis, BST:665:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 15, Percent of Course: 50.0%
Fall 2001	BST 626/627 Introduction to Data Management and Computing Using the SAS System, University of Alabama at Birmingham, Credit Hours: 3, Enr: 11, Percent of Course: 100.0%
Summer 2002	BST 633: Theory of Linear Models, BST:633:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 1, Percent of Course: 100.0%
Fall 2002	BST 603: Applied Regression Analysis, BST:603:***, University of Alabama at Birmingham
Fall 2002	BST 626/627: Introduction to Data Management and Computing Using the SAS System, University of Alabama at Birmingham, Credit Hours: 3, Enr: 16, Percent of Course: 100.0%
Spring 2003	BST 665: Introduction to Survival Analysis, BST:665:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 13, Percent of Course: 100.0%
Summer 2003	BST 795: Readings Course on Internal Pilot Designs, BST:795:***, University of Alabama at Birmingham, Percent of Course: 100.0%
Fall 2003	BST 603: Applied Regression Analysis, BST:603:***, University of Alabama at Birmingham
Fall 2003	BST 723: Theory of Linear Models, BST:723:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 8, Percent of Course: 100.0%
Fall 2004	BST 603: Applied Regression Analysis, BST:603:***, University of Alabama at Birmingham
Spring 2005	BST 665: Introduction to Survival Analysis, BST:665:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 34, Percent of Course: 100.0%
Fall 2005	Advanced Clinical Trials I, BST:725:***, University of Alabama at Birmingham
Fall 2005	BST 603: Applied Regression Analysis, BST:603:***, University of Alabama at Birmingham

Fall 2005 BST 723: Theory of Linear Models, BST:723:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 10, Percent of Course: 100.0%

Spring 2006 BST 795: Advanced Clinical Trials II, BST:795:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 5, Percent of Course: 75.0%

Spring 2007 BST 725: Quantitative Methods, BST:725:***, University of Alabama at Birmingham

Spring 2007 Introduction to Survival Analysis, BST:665:***, University of Alabama at Birmingham

Fall 2007 BST 725: Advanced Clinical Trials I, BST:725:***, University of Alabama at Birmingham

Spring 2008 BST 726: Advanced Clinical Trials II, BST:726:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 5, Percent of Course: 100.0%

Spring 2009 BST 665: Introduction to Survival Analysis, BST:665:***, University of Alabama at Birmingham, Credit Hours: 3, Enr: 32, Percent of Course: 100.0%

Apr 2017 Short Course "Clinical Trials in the Drug Development Pipeline", American Academy of Neurology Annual Meeting, Boston, Massachusetts
Role: Primary Instructor

Sep 2017 American Statistical Association Traveling Course "Adaptive Designs: Overview, Hurdles, & Examples", San Diego Chapter, San Diego, California
Role: Primary Instructor

Oct 2017 Short Course "Medical Monitoring", Annual Northeast ALS Consortium Meeting, Clearwater, Florida
Role: Primary Instructor

Nov 2017 American Statistical Association Traveling Course "Adaptive Designs: Overview, Hurdles, & Examples", Trenton/Princeton Chapter, Piscataway, New Jersey
Role: Primary Instructor

Apr 2018 American Statistical Association Traveling Course "Adaptive Designs: Overview, Hurdles, & Examples", Washington Statistical Society, Washington, District of Columbia
Role: Primary Instructor

Apr 2018 Short Course "Clinical Trials in the Drug Development Pipeline", American Academy of Neurology Annual Meeting, Los Angeles, California
Role: Primary Instructor

May 2018 Pre-Conference Workshop "Adaptive Designs - How Can We Achieve the Promise?", Society for Clinical Trials Annual Meeting, Portland, Oregon
Role: Primary Instructor

Oct 2018 Short Course "Medical Monitoring", Annual Northeast ALS Consortium Meeting, Clearwater, Florida
Role: Primary Instructor

May 2019 Short Course "How to Design Meaningful Clinical Trials", American Academy of Neurology Annual Meeting, Philadelphia, Pennsylvania
Role: Primary Instructor

Oct 2019 Short Course "Medical Monitoring", Annual Northeast ALS Consortium Meeting, Clearwater, Florida
Role: Primary Instructor

Scholarship/Professional Productivity

Publications or creative works

Peer-reviewed papers and journal articles

1. **Coffey, C. S.** & Muller, K. E. (1999). Exact test size and power of a gaussian error linear model for an internal pilot study. (Vols. 18). pp. 1199-1214. *Statistics in Medicine*.
2. Bullitt, E., Liu, A., Aylward, S., **Coffey, C.**, Stone, J., Mukherji, S. K., Muller, K. & Pizer, S. M. (1999). Registration of 3D cerebral vessels with 2D digital angiograms: Clinical evaluation. (Vols. 6). pp. 539-546. *Academic Radiology*.
3. Boxwala, A. A., Chaney, E. L., Fritsch, D. S., Raghavan, S., **Coffey, C. S.**, Major, S. A. & Muller, K. E. (1999). Comparison of computer workstation with light box for detecting setup errors from portal images. (Vols. 44). pp. 711-716. *International Journal of Radiation Oncology, Biology, Physics*.
4. Hemminger, B. M., Dillon, A., Johnston, R. E., Muller, K. E., Pisano, E., Deluca, M. & **Coffey, C.** (1999). Effect of display luminance on the feature detection rates of masses in mammograms. (Vols. 26). (11), pp. 2266-2272. *Medical Physics*.
5. **Coffey, C. S.** & Muller, K. E. (2000). Some distributions and their implications for an internal pilot study with a univariate linear model. (Vols. 29). (12), pp. 2677-2691. *Communications in Statistics-Theory and Methods*.
6. **Coffey, C. S.** & Muller, K. E. (2000). Properties of doubly-truncated gamma variables. (Vols. 29). (4), pp. 851-857. *Communications in Statistics-Theory and Methods*.
7. Jackson, P. A., Cardin, S., **Coffey, C. S.**, Neal, D. W., Allen, E. J., Penzola, A. R., Snead, W. L. & Cherrington, A. D. (2000). Effect of hepatic denervation on the counterregulatory response to insulin-induced hypoglycemia in the dog. (Vols. 279). pp. E1249-E1257. *American Journal of Physiology-Endocrinology and Metabolism*.
8. Jack, G. S., Brash, A. R., Olson, S. J., Manning, S., **Coffey, C. S.**, Smith, J. & Shappell, S. B. (2000). Reduced 15-lipoxygenase-2 immunostaining in prostate adenocarcinoma: correlation with grade and expression in high grade prostatic intraepithelial neoplasia. (Vols. 31). (9), pp. 1146-1154. *Human Pathology*.
9. Hemminger, B. M., Zong, S., Muller, K. E., **Coffey, C. S.**, DeLuca, M. C., Johnston, R. E. & Pisano, E. D. (2001). Improving the detection of simulated masses in mammograms through two different image processing techniques. (Vols. 8). pp. 845-855. *Academic Radiology*.
10. Dutta, S. C., Smith, J. A., Shappell, S. B., **Coffey, C. S.**, Chang, S. S. & Cookson, M. S. (2001). Clinical understaging of high risk nonmuscle invasive urothelial carcinoma treated with radical cystectomy. (Vols. 166). pp. 490-493. *Journal of Urology*.
11. Cardin, S., Jackson, P. A., Edgerton, D. S., Neal, D. W., **Coffey, C. S.** & Cherrington, A. D. (2001). Effect of vagal cooling on the counterregulatory response to hypoglycemia induced by a low dose of insulin in the conscious dog. (Vols. 50). pp. 588-564. *Diabetes*.
12. Shappell, S. B., Manning, S., Boeglin, W. E., Guan, Y. F., Roberts, R. L., Davis, L., Olson, S. J., Jack, G. S., **Coffey, C. S.**, Wheeler, T. M., Breyer, M. D. & Brash, A. R. (2001). Alterations in lipoxygenase and cyclooxygenase-2 catalytic activity and mRNA expression in prostate carcinoma. (Vols. 3). pp. 287-303. *Neoplasia*. [PMID: PMC1505867](https://pubmed.ncbi.nlm.nih.gov/1505867/).
13. Grossklaus, D. J., **Coffey, C. S.**, Shappell, S. B., Jack, G. S. & Cookson, M. S. (2001). Prediction of tumor volume and pathologic stage in radical prostatectomy specimens is not enhanced by increasing the number of prostate needle biopsy cores. (Vols. 88). pp. 722-726. *BJU International*.
14. **Coffey, C. S.** & Muller, K. E. (2001). Controlling test size while gaining the benefits of an internal pilot design. (Vols. 57). pp. 625-631. *Biometrics*.
15. Grossklaus, D. J., Smith, J. A., Shappell, S. B., **Coffey, C. S.**, Chang, S. S. & Cookson, M. S. (2002). The free/total prostate-specific antigen ratio (% fPSA) is the best predictor of tumor involvement in the

- radical prostatectomy specimen among men with elevated PSA. (Vols. 7). (5), pp. 195-198. *Urologic Oncology*.
16. Allison, D. B. & **Coffey, C. S.** (2002). Two-stage testing in microarray analysis: what is gained?. (Vols. 57). pp. B189-B192. *Journal of Gerontology: Biological Sciences*.
 17. Perz, J. F., Craig, A. S., **Coffey, C. S.**, Jorgensen, D. M., Mitchel, E., Hall, S., Schaffner, W. & Griffin, M. R. (2002). Changes in antibiotic prescribing for children after a community-wide campaign. (Vols. 287). (23), pp. 3103-3109. *Journal of the American Medical Association*.
 18. Griffin, M. R., **Coffey, C. S.**, Neuzil, K. M., Mitchell, E. F., Wright, P. F. & Edwards, K. M. (2002). Winter viruses: influenza- and respiratory syncytial virus-related morbidity in chronic lung disease. (Vols. 162). (11), pp. 1229-1236. *Archives of Internal Medicine*.
 19. Grossklaus, D. J., **Coffey, C. S.**, Shappell, S. B., Jack, G. S., Chang, S. S. & Cookson, M. S. (2002). Percent of cancer in the biopsy set correlates with pathologic findings after prostatectomy. (Vols. 167). (5), pp. 2032-2036. *Journal of Urology*.
 20. Ko, D. T., Hebert, P. R., **Coffey, C. S.**, Sedrakyan, A., Curtis, J. P. & Krumholz, H. M. (2002). Beta blocker therapy and symptoms of depression, fatigue, and sexual dysfunction. (Vols. 288). (3), pp. 351-357. *Journal of the American Medical Association*.
 21. Jack, G. S., Cookson, M. S., **Coffey, C. S.**, Vader, V., Roberts, R. L., Chang, S. S., Smith, J. A. & Shappell, S. B. (2002). Pathological parameters of radical prostatectomy for clinical stages T1c versus T2 prostate adenocarcinoma: decreased pathological stage and increased detection of transition zone tumors. (Vols. 168). (2), pp. 519-524. *Journal of Urology*.
 22. Dutta, S. C., Chang, S. C., **Coffey, C. S.**, Smith, J. A., Jack, G. & Cookson, M. S. (2002). Health related quality of life assessment after radical cystectomy: comparison of ileal conduit with continent orthotopic neobladder. (Vols. 168). (1), pp. 164-167. *Journal of Urology*.
 23. Ellis, S. E., **Coffey, C. S.**, Mitchel, E. F., Dittus, R. S. & Griffin, M. R. (2003). Influenza and respiratory syncytial virus-associated morbidity and mortality in the nursing home population. (Vols. 51). (6), pp. 761-767. *Journal of the American Geriatrics Society*.
 24. Morgan, T. M., **Coffey, C. S.** & Krumholz, H. M. (2003). Overestimation of gene-associated risks due to small sample size in cardiovascular genetic case-control studies. (Vols. 64). pp. 7-17. *Clinical Genetics*.
 25. Gadbury, G. L., **Coffey, C. S.** & Allison, D. B. (2003). Modern statistical methods for handling missing repeated measurements in obesity trial data: beyond LOCF. (Vols. 4). pp. 175-184. *Obesity Reviews*.
 26. Aqel, R. A., Zoghbi, G. J., Baldwin, S. A., Abo Auda, W. S., Calhoun, D. A., **Coffey, C. S.**, Perry, G. J. & Iskandrian, A. E. (2003). Prevalence of renal artery stenosis in high-risk veterans referred to cardiac catheterization. (Vols. 21). pp. 1157-1162. *Journal of Hypertension*.
 27. Neuzil, K. M., **Coffey, C. S.**, Mitchel, E. F. & Griffin, M. R. (2003). Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. (Vols. 34). pp. 304-307. *Journal of Acquired Immune Deficiency Syndromes*.
 28. **Coffey, C. S.** & Muller, K. E. (2003). Properties of internal pilots with the univariate approach to repeated measures. (Vols. 22). pp. 2469-2485. *Statistics in Medicine*.
 29. Goldstein, D. R., **Coffey, C. S.**, Benza, R. L., Nanda, N. C. & Bourge, R. C. (2003). Relative perioperative bradycardia does not lead to adverse outcomes after cardiac transplantation. (Vols. 3). (4), pp. 484-491. *American Journal of Transplantation*.
 30. **Coffey, C. S.**, Hebert, P. R., Krumholz, K. M., Morgan, T. M., Williams, S. M. & Moore, J. H. (2004). Reporting of model validation procedures in human studies of genetic interactions. (Vols. 20). pp. 69-73. *Nutrition*.
 31. **Coffey, C. S.**, Steiner, D., Baker, B. A. & Allison, D. B. (2004). A randomized double-blind placebo controlled clinical trial of a product containing ephedrine, caffeine, and other ingredients from herbal sources for treatment of overweight and obesity in the absence of lifestyle treatment. (Vols. 28). (11), pp. 1411-1419. *International Journal of Obesity*.

32. Yang, D., Howard, G., **Coffey, C. S.** & Roseman, J. (2004). The confounding of race and geography: how much of the excess mortality among african americans is explained by geography. (Vols. 23). pp. 118-122. *Neuroepidemiology*.
33. **Coffey, C. S.**, Hebert, P. R., Ritchie, M. D., Krumholz, H. M., Gaziano, J. M., Ridker, P. M., Brown, N. J., Vaughan, D. E. & Moore, J. H. (2004). An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene interactions on risk of myocardial infarction: the importance of model validation. (Vols. 5). pp. 49. *BMC Bioinformatics*. [PMID: PMC419697](#).
34. Ko, D. T., Hebert, P. R., **Coffey, C. S.**, Curtis, J. P., Foody, J. M., Sedrakyan, A. & Krumholz, H. M. (2004). Adverse effects of beta blocker therapy for heart failure patients: a quantitative overview of randomized trials. (Vols. 164). (13), pp. 1389-1394. *Archives of Internal Medicine*.
35. Wang, C., Weindruch, R., Fernandez, J. R., **Coffey, C. S.**, Patel, P. & Allison, D. B. (2004). Caloric restriction and body weight independently affect longevity in wistar rats. (Vols. 27). pp. 357-362. *International Journal of Obesity*.
36. **Coffey, C. S.**, Gadbury, G. L., Fontaine, K. R., Wang, C., Weindruch, R. & Allison, D. B. (2005). The effects of intentional weight loss as a latent variable problem. (Vols. 24). (6), pp. 941-954. *Statistics in Medicine*.
37. Howard, G. H., **Coffey, C. S.** & Cutter, G. R. (2005). Is bayesian analysis ready for use in phase III randomized clinical trials 'beware the sound of the sirens'. (Vols. 36). pp. 1622-1623. *Stroke*.
38. Hemminger, B. M., Molina, P. L., Egan, T. M., Detterback, F. C., Muller, K. E., **Coffey, C. S.** & Lee, J. (2005). Assessment of realtime 3d visualization for cardiothoracic diagnostic evaluation and surgery planning. (Vols. 18). (2), pp. 145-153. *Journal of Digital Imaging*.
39. Alexander, D., Jhala, N., Chatla, C., Funkhouser, E., **Coffey, C. S.**, Grizzle, W. E. & Manne, U. (2005). High grade tumor differentiation is an indicator of poor prognosis in african americans with colonic adenocarcinomas. (Vols. 103). (10), pp. 2163-2170. *Cancer*. [PMID: PMC2667688](#).
40. Asselbergs, F. W., Williams, S. M., Hebert, P. R., **Coffey, C. S.**, Hillege, H. L., Navis, G., Vaughan, D. E., van Gilst, W. H. & Moore, J. H. (2006). The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. (Vols. 96). pp. 471-477. *Thrombosis and Haemostasis*.
41. Del Brutto, O. H., Roos, K. L., **Coffey, C. S.** & Garcia, H. H. (2006). Albendazole and praziquantel therapy for neurocysticercosis: a meta-analysis of randomized trials. (Vols. 145). pp. 43-51. *Annals of Internal Medicine*.
42. Benza, R. L., Rayburn, B. K., Tallaj, J. A., **Coffey, C. S.**, Pinderski, L. J., Pamoukian, S. V. & Bourge, R. C. (2006). Efficacy of bosentan in a small cohort of adult patients with pulmonary arterial hypertension related to congenital heart disease. (Vols. 129). (4), pp. 1009-1015. *Chest*.
43. Qian, H. Z., Vermund, S. H., Kaslow, R. A., **Coffey, C. S.**, Chamot, E., Yang, Z., Qiao, X., Zhang, Y., Shi, X., Jiang, Y., Shao, Y. & Wang, N. (2006). Coinfection with HIV and hepatitis C virus in former plasma/blood donors: challenge for patient care in rural china. (Vols. 20). pp. 1429-1435. *AIDS*. [PMID: PMC2749723](#).
44. Newsome, B. B., McClellan, W. M., **Coffey, C. S.**, Allison, J. J., Kiefe, C. L. & Warnock, D. G. (2006). Survival advantage of african american with kidney disease after acute myocardial infarction. (Vols. 1). pp. 993-1000. *Clinical Journal of the American Society of Nephrology*.
45. Asselbergs, F. W., Williams, S. M., Hebert, P. R., **Coffey, C. S.**, Hillege, H. L., Sneider, H., Navis, G., Vaughan, D. E., van Gilst, W. H. & Moore, J. H. (2007). The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-pa and pai-1 levels are dependent on environmental context. (Vols. 122). pp. 275-281. *Human Genetics*.
46. Asselbergs, F. W., Williams, S. M., Hebert, P. R., **Coffey, C. S.**, Hillege, H. L., Navis, G., Vaughan, D. E., Van Gilst, W. H. & Moore, J. H. (2007). Epistatic effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels. (Vols. 89). pp. 362-369. *Genomics*. [PMID: PMC1808222](#).
47. Gurka, M. J., **Coffey, C. S.** & Muller, K. E. (2007). Internal pilots for a class of linear mixed models with gaussian and compound symmetric data. (Vols. 26). pp. 4083-4099. *Statistics in Medicine*.

48. **Coffey, C. S.**, Kairalla, J. A. & Muller, K. E. (2007). Practical methods for bounding type I error rate with an internal pilot design. (Vols. 36). pp. 2143-2157. *Communications in Statistics – Theory and Methods*.
49. Pergola, P. E., White, C. L., Graves, J. W., **Coffey, C. S.**, Tonarelli, S. B., Hart, R. G. & Benavente, O. R. (2007). Reliability and validity of blood pressure measurement in the secondary prevention of small sub-cortical strokes study. (Vols. 12). pp. 1-8. *Blood Pressure Monitoring*.
50. Benza, R. L., Cavender, M. A., Barchue, J. A., Tallaj, J. A., Bourge, R. C., Kirklin, J. K. & **Coffey, C. S.** (2007). Alterations in the fibrinolytic cascade post transplant: evidence of a bimodal expression pattern. (Vols. 26). pp. 494-497. *Journal of Heart and Lung Transplantation*. [PMID: PMC1950728](#).
51. Ritchie, M. D., Motsinger, A. A., Bush, W. S., **Coffey, C. S.** & Moore, J. H. (2007). Genetic programming neural networks: a powerful bioinformatics tool for human genetics. (Vols. 7). pp. 471-479. *Applied Soft Computing Journal*.
52. Howard, G. H., McClure, L. A., Krakauer, J. E. & **Coffey, C. S.** (2007). Stroke and the statistics of the aspirin/clopidogrel secondary prevention trials. (Vols. 20). pp. 71-77. *Current Opinions in Neurology*.
53. Musani, S. K., Shriner, D., Liu, N., Feng, R., **Coffey, C. S.**, Yi, N., Tiwari, H. K. & Allison, D. B. (2007). Detection of gene x gene interactions in genome-wide association studies of human population data. (Vols. 63). pp. 67-84. *Human Heredity*.
54. Asselbergs, F. W., Williams, S. M., Hebert, P. R., **Coffey, C. S.**, Hillege, H. L., Navis, G., Vaughan, D. E., Van Glist, W. H. & Moore, J. H. (2007). Gender-specific correlations of PAI-1 and t-PA levels with cardiovascular disease-related traits. (Vols. s5). pp. 313-320. *Journal of Thrombosis and Haemostasis*.
55. Gadbury, G. L., Supapakorn, T., **Coffey, C. S.**, Keith, S. W. & Allison, D. B. (2008). Application of potential outcomes to an intentional weight loss latent variable problem. (Vols. 8). pp. 87-97. *Statistics and Its Interface*.
56. Hebert, P. R., **Coffey, C. S.**, Byrne, D. W., Scott, T. A., Fagard, R. H., Rottman, J. N., Murray, K. T. & Oates, J. A. (2008). Treatment of elderly hypertensive patients with epithelial sodium channel inhibitors combined with a thiazied diuretic reduces coronary mortality and sudden cardiac death. (Vols. 2). pp. 355-365. *Journal of the American Society of Hypertension*. [PMID: PMC2633478](#).
57. **Coffey, C. S.** & Kairalla, J. A. (2008). Adaptive clinical trials: progress and challenges. (Vols. 9). (4), pp. 229-242. *Drugs in R & D*.
58. Yi, N., Ding, S., Keith, S. W., **Coffey, C. S.** & Allison, D. B. (2008). Bayesian analysis of the effect of intentional weight loss on mortality rate. (Vols. 6). pp. 185-192. *International Journal of Body Composition Research*.
59. Newsome, B. B., McClellan, W. M., Allison, J. J., Eggers, P. W., Chen, S. C., Collins, A. J., Kiefe, C. I., **Coffey, C. S.** & Warnock, D. G. (2008). Racial differences in the competing risks of mortality and end-stage renal disease after acute myocardial infarction. (Vols. 52). pp. 251-261. *American Journal of Kidney Diseases*.
60. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2008). GLUMIP 2.0: SAS/IML software for planning internal pilots. (Vols. 28). (7), pp. 1-32. *Journal of Statistical Software*.
61. Benza, R. L., **Coffey, C. S.**, Pekarek, D. M., Barchue, J. P., Tallaj, J. A., Passineau, M. J. & Grenett, H. E. (2009). Transforming growth factor-beta polymorphisms and cardiac allograft rejection. (Vols. 28). (10), pp. 1057-62. *Journal of Heart and Lung Transplantation*. [PMID: PMC2796559](#).
62. Bretz, F., Branson, M., Burmann, C. F., Chuang-Stein, C. & **Coffey, C. S.** (2009). Adaptivity in drug discovery and development. (Vols. 70). pp. 169-190. *Drug Development Research*.
63. Hines, R. B., Chatla, C., Bumpers, H., Waterbor, J., McGwin, G., Funkhouser, E., **Coffey, C.**, Posey, J. & Manne, U. (2009). Predictive capacity of three comorbidity indices in estimating mortality following surgery for colon cancer. (Vols. 27). (26), pp. 4339-45. *Journal of Clinical Oncology*. [PMID: PMC2744274](#).
64. Brown, D. L. & **Coffey, C. S.** (2009). A shift to shift analysis?. (Vols. 72). (15), pp. 1292-1293. *Current Opinions in Neurology*.

65. Hines, R. B., Shanmugam, C., Waterbor, J. W., McGwin, G., Funkhouser, E., **Coffey, C. S.**, Posey, J. & Manne, U. (2009). Effect of comorbidity and body mass index on the survival of african-american and caucasian patients with colon cancer. (Vols. 115). (24), pp. 5798-506. *Cancer*. PMID: [PMC2795032](#).
66. Elobeid, M., Padilla, M., McVie, T., Thomas, O., Brock, D., Musser, B., Lu, K., **Coffey, C.**, Desmond, R., St-Onge, M., Gadde, K., Heymsfield, S. & Allison, D. (2009). Missing data in randomized clinical trials for weight loss: scope of the problem, state of the field, and performance of statistical methods. (Vols. 4). (8), pp. e6624. *PLoS One*. PMID: [PMC2720539](#).
67. Elkind, M., Luna, J. M., **Coffey, C. S.**, McClure, L. A., Liu, K. M., Spitalnik, S., Paik, M. C., Roldan, A., White, C., Hart, R. & Benavente, O. (2010). The levels of inflammatory markers in the treatment of stroke (limits) study: inflammatory biomarkers as risk predictors after lacunar stroke. pp. 117-125. *International Journal of Stroke*. DOI: [10.1111/j.1747-4949.2010.00420.x](#).
68. Gurka, M. J., **Coffey, C. S.** & Gurka, K. K. (2010). Internal pilots for observations studies. (Vols. 52). (5), pp. 590-603. *Biometrical Journal*. DOI: [10.1002/bimj.201000050](#). PMID: [20857422](#).
69. Benza, R. L., Miller, D. P., Gomberg-Maitland, M., Frantz, R. P., Foreman, A. J., **Coffey, C. S.**, Frost, A., Barst, R. J., Badesch, D. B., Elliot, G., Liou, T. G. & McGoon, M. D. (2010). Predicting survival in pulmonary arterial hypertension: insights from the registry to evaluate early and long-term pulmonary arterial hypertension disease management (reveal). (Vols. 122). (2), pp. 164-172. *Circulation*. DOI: [10.1161/CIRCULATIONAHA.109.898122](#). PMID: [20585012](#).
70. Kairalla, J. A., Muller, K. E. & **Coffey, C. S.** (2010). Combining an internal pilot with an interim analysis for single degree of freedom tests. (Vols. 39). (20), pp. 3717-3738. *Communications in Statistics – Theory & Methods*. DOI: <https://doi.org/10.1080/03610920903353709>. PMID: [21037942](#). PMCID: [PMC2965034](#).
71. Bentley, J. P., Asselbergs, F. W., **Coffey, C. S.**, Hebert, P. R., Moore, J. H., Hillege, H. L. & van Gilst, W. H. (2010). Cardiovascular risk associated with interactions among polymorphisms in genes from the renin-angiotensin. (Vols. 5). (9), pp. e12757. *PLoS One*. DOI: [10.1371/journal.pone.0012757](#). PMID: [20856803](#). PMCID: [PMC2939877](#).
72. **Coffey, C. S.**, Asselbergs, F. W., Hebert, P. R., Hillege, H. L., Li, Q., Moore, J. H. & van Gilst, W. H. (2011). The association of the metabolic syndrome with pai-1 and t-pa levels. (Vols. 2011). *Cardiology Research and Practice*. PMID: [21559217](#). PMCID: [PMC3087975](#).
73. The Parkinson Progression Markers Initiative Investigators (2011). The Parkinson Progression Marker Initiative. (Vols. 95). (4), pp. 629-635. *Progress in Neurobiology*. DOI: [10.1016/j.pneurobio.2011.09.005](#). PMID: [21930184](#). PMCID: [PMC3087975](#).
74. Benavente, O. R., White, C. L., Pearce, L., Pergola, P., Roldan, A., Benavente, M., **Coffey, C.**, McClure, L. A., Szychowski, J. M., Conwit, R., Heberling, P. A., Howard, G., Bazan, C., Vidal-Pergola, G., Talbert, T. & Hart, R. G. (2011). The secondary prevention of small subcortical strokes (sps3) study. (Vols. 6). (2), pp. 164-175. *International Journal of Stroke*. DOI: [10.1111/j.1747-4949.2010.00573.x](#). PMID: [21371282](#). PMCID: [PMC4214141](#).
75. Clifton, G. L., Valadka, A., Zygun, D., **Coffey, C. S.**, Drever, P., Fourwinds, S., Janis, L. S., Wilder, E., Taylor, P., Harshman, K., Conley, A., Puccio, A., Levin, H. S., McCauley, S. R., Bucholz, R. D., Smith, K. R., Schmidt, J. H., Scott, J. N., Yonas, H. & Okonkwo, D. (2011). Very early hypothermia induction in patients with severe brain injury (national acute brain injury study: hypothermia ii): a randomized trial. (Vols. 10). (2), pp. 131-139. *Lancet Neurology*. DOI: [10.1016/s1474-4422\(10\)70300-8](#). PMID: [21169065](#). PMCID: [PMC3628679](#).
76. McClure, L. A., Szychowski, J. M., Benevente, O. & **Coffey, C. S.** (2012). Sample size re-estimation in an ongoing NIH-sponsored clinical trial: TehSecondary Prevention of Small Subcortical Strokes experience. (Vols. 33). (5), pp. 1088-1093. *Contemporary Clinical Trials*. DOI: <https://doi.org/10.1016/j.cct.2012.06.007>. PMID: [PMC3408857](#). PMCID: [22750086](#).
77. Graves, J. W., White, C. L., Szychowski, J. M., Pergola, P. E., Benavente, O. R., **Coffey, C. S.**, Hornung, L. N., Hart, R. G. & for the SPS3 Study Investigators (2012). Predictors of lowering systolic blood pressure to assigned targets at twelve months in the Secondary Prevention of Small Subcortical Strokes (SPS3)

- study. (Vols. 30). pp. 1233-1240. Journal of Hypertension. DOI: [10.1097/hjh.0b013e328353968d](https://doi.org/10.1097/hjh.0b013e328353968d). PMID: [22499292](https://pubmed.ncbi.nlm.nih.gov/22499292/). PMCID: [PMC3970550](https://pubmed.ncbi.nlm.nih.gov/PMC3970550/).
78. Clifton, G. L., **Coffey, C. S.**, Fourwinds, S., Zygun, D., Valadka, A., Smith, K. R., Frisby, M. L., Bucholz, R. D., Wilde, E. A., Levin, H. S. & Okonkwo, D. O. (2012). Early induction of hypothermia for evacuated hematomas: A post hoc analysis of two clinical trials. (Vols. 117). (4), pp. 714-720. Journal of Neurosurgery. DOI: [10.3171/2012.6.jns111690](https://doi.org/10.3171/2012.6.jns111690). PMID: [22839656](https://pubmed.ncbi.nlm.nih.gov/22839656/).
 79. **Coffey, C. S.**, LeBouf, R. F., Lee, L., Slaven, J. & Martin, S. (2012). Effect of calibration and environmental condition on the performance of direct-reading organic vapor monitors. (Vols. 9). (11), pp. 670-680. Journal of Occupational and Environmental Hygiene. DOI: [10.1080/15459624.2012.725015](https://doi.org/10.1080/15459624.2012.725015). PMID: [23016630](https://pubmed.ncbi.nlm.nih.gov/23016630/).
 80. The SPS3 Investigators, Benavente, O. R., Hart, R. G., McClure, L. A., Szychowski, J. M., **Coffey, C. S.** & Pearce, L. A. (2012). Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. (Vols. 367). (9), pp. 817-825. New England Journal of Medicine. DOI: [10.1056/NEJMoa1204133](https://doi.org/10.1056/NEJMoa1204133). PMID: [22931315](https://pubmed.ncbi.nlm.nih.gov/22931315/). PMCID: [PMC4067036](https://pubmed.ncbi.nlm.nih.gov/PMC4067036/).
 81. Kairalla, J. A., **Coffey, C. S.**, Thomann, M. A. & Muller, K. E. (2012). Adaptive trial designs: A review of barriers and opportunities. (Vols. 13). pp. 145. Trials. DOI: [10.1186/1745-6215-13-145](https://doi.org/10.1186/1745-6215-13-145). PMID: [22917111](https://pubmed.ncbi.nlm.nih.gov/22917111/). PMCID: [PMC2519822](https://pubmed.ncbi.nlm.nih.gov/PMC2519822/).
 82. **Coffey, C. S.**, Levin, B., Clark, C., Timmerman, C., Wittes, J., Gilbert, P. & Harris, S. (2012). Overview, hurdles, and future work in adaptive designs: Perspectives from a National Institutes of Health-funded workshop. (Vols. 9). (6), pp. 671-680. Clinical Trials. DOI: [10.1177/1740774512461859](https://doi.org/10.1177/1740774512461859). PMID: [23250942](https://pubmed.ncbi.nlm.nih.gov/23250942/).
 83. White, C. L., Szychowski, J. M., Roldan, A., Benavente, M. F., Pretell, E. J., Del Brutto, O. H., Kase, C. S., Arauz, A., Meyer, B. C., Meissner, I., Demaerschalk, B. M., McClure, L. A., **Coffey, C. S.**, Pearce, L. A., Ronwit, R., Irby, L. H., Peri, K., Pergola, P. E., Hart, R. G. & Benevent, for the SPS3 Investigators, O. R. (2013). Clinical features and racial/ethnic difference among the 3020 participants in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. (Vols. 22). (6), pp. 764-774. Journal of Stroke and Cerebrovascular Diseases. DOI: [j.jstrokecerebrovasdis.2012.03.002](https://doi.org/10.1177/1077501912461859). PMID: [22516427](https://pubmed.ncbi.nlm.nih.gov/22516427/).
 84. The SPS3 Investigators, Benevente, O. R., **Coffey, C. S.**, Conwit, R., Hart, R. G., McClure, L. A., Pearce, L. A., Pergola, P. E. & Szychowski, J. M. (2013). Effects of blood pressure targets in patients with recent lacunar stroke: The SPS3 randomized trial. (Vols. 382). (9891), pp. 507-515. Lancet. DOI: [10.1016/S0140-6736\(13\)60852-1](https://doi.org/10.1016/S0140-6736(13)60852-1). PMID: [23726159](https://pubmed.ncbi.nlm.nih.gov/23726159/).
 85. Leira, E. C., **Coffey, C. S.**, Jorge, R. E., Morton, S. M., Froehler, M. T., Davis, P. H. & Adams, H. P. (2013). The NIHSS supplementary motor scale: A valid tool for multidisciplinary recovery trials. (Vols. 36). (1), pp. 69-73. Cerebrovascular Diseases. DOI: [10.1159/000351514](https://doi.org/10.1159/000351514). PMID: [23921195](https://pubmed.ncbi.nlm.nih.gov/23921195/).
 86. McClure, L. A., **Coffey, C. S.** & Howard, G. H. (2013). Monitoring futility in a two-by-two factorial design: the SPS3 experience. (Vols. 10). (2), pp. 250-256. Clinical Trials. DOI: [10.1177/1740774512474374](https://doi.org/10.1177/1740774512474374). PMID: [23378483](https://pubmed.ncbi.nlm.nih.gov/23378483/). PMCID: [PMC3731445](https://pubmed.ncbi.nlm.nih.gov/PMC3731445/).
 87. Hershey, A. D., Powers, S. W., **Coffey, C. S.**, Ecklund, D., Chamberlin, L. A., Korbee, L. L. & on behalf of the CHAMP Study Group (2013). Childhood and adolescent migraine prevention (CHAMP) study: A double-blinded, placebo-controlled, comparative effectiveness study of amitriptyline. (Vols. 53). (5), pp. 799-816. Headache. DOI: [10.1111/head.12105](https://doi.org/10.1111/head.12105). PMID: [23594025](https://pubmed.ncbi.nlm.nih.gov/23594025/). PMCID: [PMC3637406](https://pubmed.ncbi.nlm.nih.gov/PMC3637406/).
 88. LeBouf, R. F., Slaven, J. E. & **Coffey, C. S.** (2013). Effect of calibration environment on the performance of direct-reading organic vapor monitors. (Vols. 63). (5), pp. 528-533. The Journal of the Air & Waste Management Association. DOI: [10.1080/10962247.2013.772926](https://doi.org/10.1080/10962247.2013.772926). PMID: [23786144](https://pubmed.ncbi.nlm.nih.gov/23786144/).
 89. Carter, B. L., **Coffey, C. S.**, Uribe, L., James, P. A., Egan, B. M., Arderu, G., Chrischilles, E. A., Ecklund, D., VanderWeg, M., Vaughn, T. & on behalf of the Collaboration Among Pharmacists and Physicians to Improve Outcomes Now (CAPTION) Trial Investigators (2013). Similar blood pressure values across racial and economic groups: Baseline data from a group randomized trial. (Vols. 15). (6), pp. 404-412. The Journal of Clinical Hypertension. DOI: [10.1111/jch.12091](https://doi.org/10.1111/jch.12091). PMID: [23730989](https://pubmed.ncbi.nlm.nih.gov/23730989/). PMCID: [PMC3683891](https://pubmed.ncbi.nlm.nih.gov/PMC3683891/).

90. Kang, J. H., Irwin, D. J., Chen-Plotkin, A. S., Siderowf, A., Caspell, C., **Coffey, C. S.**, Waligorska, T., Taylor, P., Pan, S., Frasier, M., Marek, L., Kieburtz, K., Jennings, D., Simuni, T., Tanner, C. M., Singleton, A., Toga, A. W., Chowdhury, S., Mollenhauer, B., Trojanowski, J. Q., Shaw, L. M. & the Parkinson's Progression Marker Initiative Investigators (2013). Association of cerebrospinal β -amyloid 1-42, T-tau, P-tau181, and α -synuclein levels with clinical features of early drug naive Parkinson's Disease patients. (Vols. 70). (10), pp. 1277-1287. *JAMA Neurology*. DOI: [10.1001/jamaneurol.2013.3861](https://doi.org/10.1001/jamaneurol.2013.3861). PMID: 23979011. PMCID: [PMC4034348](https://pubmed.ncbi.nlm.nih.gov/PMC4034348/).
91. DeMik, D. E., VanderWeg, W. M., Lundt, E. S., **Coffey, C. S.**, Arderu, G. & Carter, B. L. (2013). Using theory to predict implementation of a physician-pharmacist collaborative intervention within a practice-based research network. (Vols. 9). (6), pp. 719-730. *Research in Social and Administrative Pharmacy*. DOI: [10.1016/j.sapharm.2013.01.003](https://doi.org/10.1016/j.sapharm.2013.01.003). PMID: 23506651. PMCID: [PMC3830625](https://pubmed.ncbi.nlm.nih.gov/PMC3830625/).
92. Galpern, W. R., **Coffey, C. S.**, Albanese, A., Cheung, K., Comella, C. L., Ecklund, D. J., Fahn, S., Jankovic, J., Kieburtz, K., Lang, A. E., McDermott, M. P., Shefner, J. M., Teller, J. K., Thompson, J. L., Yeatts, S. D. & Jinnah, H. A. (2014). Designing clinical trials for dystonia. (Vols. 11). (1), pp. 117-127. *Neurotherapeutics*. DOI: [10.1007/s13311-013-0221-6](https://doi.org/10.1007/s13311-013-0221-6). PMID: 24282121. PMCID: [PMC3899487](https://pubmed.ncbi.nlm.nih.gov/PMC3899487/).
93. Morgan, C., Huyck, S., Jenkins, M., Chen, L., Bedding, A., **Coffey, C. S.**, Gaydos, B. & Wathen, J. (2014). Adaptive design: Results of 2012 survey on perception and use. (Vols. 48). (4), pp. 473-481. *Therapeutic Innovation & Regulatory Science*. DOI: [10.1177/2168479014522468](https://doi.org/10.1177/2168479014522468)
94. Elkind, M. S., Luna, J. M., McClure, L. A., Zhang, Y., **Coffey, C. S.**, Roldan, A., Del Brutto, O., Pretell, E. J., Pettigrew, L. C., Meyer, B. C., Tapia, J., White, C., Benevente, O. R. & on behalf of the MIMITS Investigators (2014). C-reactive protein as a prognostic marker after lacunar stroke: Levels of inflammatory markers in the treatment of stroke study. (Vols. 45). (3), pp. 707-716. *Stroke*. DOI: [10.1161/STROKEAHA.113.004562](https://doi.org/10.1161/STROKEAHA.113.004562). PMID: 24523037. PMCID: [PMC4114338](https://pubmed.ncbi.nlm.nih.gov/PMC4114338/).
95. Yeatts, S. D., Martin, R. H., **Coffey, C. S.**, Lyden, P. D., Foster, L. D., Woolson, R. F., Broderick, J. P. & Palesch, Y. Y. (2014). Challenges of decision making regarding futility in a randomized trial: the Interventional Management of Stroke III experience. (Vols. 45). (5), pp. 1408-1414. *Stroke*. DOI: [10.1161/STROKEAHA.113.003925](https://doi.org/10.1161/STROKEAHA.113.003925). PMID: 24699059. PMCID: [PMC4018452](https://pubmed.ncbi.nlm.nih.gov/PMC4018452/).
96. Sharma, M., Pearch, L. A., Benavente, O. R., Anderson, D. C., Connolly, S. J., Palacio, S., **Coffey, C. S.** & Hart, R. G. (2014). Predictors of mortality in patients with lacunar stroke in the secondary prevention of small subcortical strokes trial. (Vols. 45). (10), pp. 2989-2994. *Stroke*. DOI: [10.1161/STROKEAHA.114.005789](https://doi.org/10.1161/STROKEAHA.114.005789). PMID: 25158772. PMCID: [PMC4175186](https://pubmed.ncbi.nlm.nih.gov/PMC4175186/).
97. Gums, T. H., Carter, B. L., Milavetz, G., Buys, L., Rosenkrans, K., Uribe, L., **Coffey, C. S.**, MacLaughlin, E. J., Young, R. B., Ables, A. Z., Patel-Shori, N. & Wisniewski, A. (2014). Physician-pharmacist collaborative management of asthma in primary care. (Vols. 34). (10), pp. 1033-1042. *Pharmacotherapy*. DOI: [10.1002/phar.1468](https://doi.org/10.1002/phar.1468). PMID: 25142870. PMCID: [PMC4188693](https://pubmed.ncbi.nlm.nih.gov/PMC4188693/).
98. Kairalla, J. A., **Coffey, C. S.**, Thomann, M. A., Shorr, R. I. & Muller, K. E. (2014). Adaptive designs for comparative effectiveness research trials. (Vols. 32). (1), pp. 36-44. *Clinical Research and Regulatory Affairs*. DOI: [10.3109/10601333.2014.977490](https://doi.org/10.3109/10601333.2014.977490)
99. Lau, H., White, C. L., **Coffey, C. S.**, Kase, C. S., Babikian, V. L. & et al. (2015). Clinical trial participation and health behavior modification: Secondary Prevention of Small Subcortical Strokes (SPS3). (Vols. 3). (1), pp. 1094. *Journal of Neurological Disorders and Stroke*.
100. Zhuang, Z., Liu, Y., **Coffey, C. S.**, Miller, C. & Szalajda, J. (2015). Inward Leakage Variability between Respirator Fit Test Panels - Part I. Deterministic Approach. (Vols. 12). (11), pp. 753-760. *Journal of Occupational and Environmental Hygiene*. DOI: [10.1080/15459624.2015.1047025](https://doi.org/10.1080/15459624.2015.1047025). PMID: 26011282. PMCID: [PMC4664190](https://pubmed.ncbi.nlm.nih.gov/PMC4664190/).
101. **Coffey, C. S.** (2015). You may have worked on more adaptive designs than you think. (Vols. 46). (2), pp. e26-e28. *Stroke*. DOI: [10.1161/STROKEAHA.114.004288](https://doi.org/10.1161/STROKEAHA.114.004288). PMID: 25572412. PMCID: [PMC4308449](https://pubmed.ncbi.nlm.nih.gov/PMC4308449/).
102. LeBouf, R. F. & **Coffey, C. S.** (2015). Effect of interferents on the performance of direct-reading organic vapor monitors. (Vols. 65). (3), pp. 261-269. *Journal of the Air & Waste Management Association*. DOI: [10.1080/10962247.2014.986308](https://doi.org/10.1080/10962247.2014.986308). PMID: 25947122. PMCID: [PMC4657743](https://pubmed.ncbi.nlm.nih.gov/PMC4657743/).

103. Rengasamy, S., Walbert, G., Newcomb, W., **Coffey, C. S.**, Wassell, J. T. & Szaladja, J. (2015). Protection factor for N95 filtering facepiece respirators exposed to laboratory aerosols containing different concentrations of nanoparticles. (Vols. 59). (3), pp. 373-381. *The Annals of Occupational Hygiene*. [DOI: 10.1093/annhyg/meu095](https://doi.org/10.1093/annhyg/meu095). [PMID: 25429023](https://pubmed.ncbi.nlm.nih.gov/25429023/). [PMCID: PMC4589166](https://pubmed.ncbi.nlm.nih.gov/PMC4589166/).
104. Carter, B. L., **Coffey, C. S.**, Ardery, G., Uribe, L., Ecklund, D., James, P., Egan, B., Vander Weg, M., Chrischilles, E. & Vaughn, T. (2015). Cluster-randomized trial of a physician/pharmacist collaborative model to improve blood pressure control. (Vols. 8). (3), pp. 235-243. *Circulation: Cardiovascular Quality & Outcomes*. [DOI: 10.1161/CIRCOUTCOMES.114.001283](https://doi.org/10.1161/CIRCOUTCOMES.114.001283). [PMID: 25805647](https://pubmed.ncbi.nlm.nih.gov/25805647/). [PMCID: PMC4618490](https://pubmed.ncbi.nlm.nih.gov/PMC4618490/).
105. Weintraub, D., Simuni, T., Caspell-Garcia, C., **Coffey, C. S.**, Lasch, S., Siderowf, A., Aarsland, D., Barone, P., Burn, D., Chahine, L. M., Eberling, J., Espay, A. J., Foster, E. D., Leverenz, J. B., Litvan, I., Richard, I., Troyer, M. D., Hawkins, K. A. & the Parkinson's Progression Markers Initiative (2015). Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's Disease. (Vols. 30). (7), pp. 919-927. *Movement Disorders*. [DOI: 10.1002/mds.26170](https://doi.org/10.1002/mds.26170). [PMID: 25737166](https://pubmed.ncbi.nlm.nih.gov/25737166/). [PMCID: PMC4855523](https://pubmed.ncbi.nlm.nih.gov/PMC4855523/).
106. Gums, T. H., Uribe, L., Vander Weg, M. W., James, P., **Coffey, C. S.** & Carter, B. L. (2015). Pharmacist intervention for blood pressure control: Medication intensification and adherence. (Vols. 9). (7), pp. 569-578. *Journal of the American Society for Hypertension*. [DOI: 10.1016/j.jash.2015.05.005](https://doi.org/10.1016/j.jash.2015.05.005). [PMID: 26077795](https://pubmed.ncbi.nlm.nih.gov/26077795/). [PMCID: PMC4508208](https://pubmed.ncbi.nlm.nih.gov/PMC4508208/).
107. Carter, B. L., **Coffey, C. S.**, Chrischilles, E. A., Ardery, G., Ecklund, D., Gryzlak, B., Vander Weg, M. W., James, P. A., Christensen, A. J., Parker, C. P., Gums, T., Finkelstein, R. J., Uribe, L., Polgreen, L. A. & on behalf of the MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) Trial Investigators (2015). A cluster-randomized trial of a centralized clinical pharmacy cardiovascular risk service to improve guideline adherence. (Vols. 35). (7), pp. 653-662. *Pharmacotherapy*. [DOI: 10.1002/phar.1603](https://doi.org/10.1002/phar.1603). [PMID: 26111939](https://pubmed.ncbi.nlm.nih.gov/26111939/). [PMCID: PMC4686257](https://pubmed.ncbi.nlm.nih.gov/PMC4686257/).
108. Zhang, Y., Wu, I. W., Buckley, S., **Coffey, C. S.**, Foster, E., Mendick, S., Seibyl, J. & Schuff, N. (2015). Diffusion tensor imaging of the nigrostriatal fibers in Parkinson's Disease. (Vols. 30). (9), pp. 1229-1236. *Movement Disorders*. [DOI: 10.1002/mds.26251](https://doi.org/10.1002/mds.26251). [PMID: 25920732](https://pubmed.ncbi.nlm.nih.gov/25920732/). [PMCID: PMC4418199](https://pubmed.ncbi.nlm.nih.gov/PMC4418199/).
109. Simuni, T., Caspell-Garcia, C., **Coffey, C. S.**, Chahine, L. M., Lasch, S., Oertel, W. H., Mayer, G., Hogl, B., Postuma, R., Videnovic, A., Amara, A. W., Marek, K. & for the PPMI Sleep Working Group on behalf of the PPMI Investigators (2015). Correlates of excessive daytime sleepiness in de novo Parkinson's Disease: A case control study. (Vols. 30). (10), pp. 1371-1381. *Movement Disorders*. [DOI: 10.1002/mds.26248](https://doi.org/10.1002/mds.26248). [PMID: 26095202](https://pubmed.ncbi.nlm.nih.gov/26095202/). [PMCID: PMC4822999](https://pubmed.ncbi.nlm.nih.gov/PMC4822999/).
110. Powers, W. J., Derdeyn, C. P., Biller, J., **Coffey, C. S.**, Hoh, B. L., Jauch, E. C., Johnston, K. C., Johnston, S. C., Khalessi, A. A., Kidwell, C. S., Meschia, J. F., Ovbiagele, B., Yavagal, D. R. & on behalf of the American Heart Association Stroke Council (2015). 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: A guideline for healthcare professionals from the American Heart Association/American Stroke Association. (Vols. 46). (10), pp. 3020-3035. *Stroke*. [DOI: 10.1161/STR.0000000000000074](https://doi.org/10.1161/STR.0000000000000074). [PMID: 26123479](https://pubmed.ncbi.nlm.nih.gov/26123479/).
111. Schuff, N., Wu, I. W., Foster, E. D., **Coffey, C. S.**, Gitelman, D. R., Mendick, S., Seibyl, J., Simuni, T., Zhang, Y., Jankovic, J., Hunter, C., Tanner, C. M., Rees, L., Factor, S., Berg, D., Wurster, I., Gauss, K., Sprenger, F., Seppi, K., Poewe, W., Mollenhauer, B., Knake, S., Mari, Z., McCoy, A., Rowe, D., Ranola, M. & Marek, K. (2015). Diffusion imaging of nigral alterations in early Parkinson's Disease with dopaminergic deficits. (Vols. 30). (14), pp. 1885-1892. *Movement Disorders*. [DOI: 10.1002/mds.26325](https://doi.org/10.1002/mds.26325). [PMID: 26260437](https://pubmed.ncbi.nlm.nih.gov/26260437/).
112. Polgreen, L. A., Han, J., Carter, B. L., Ardery, G. P., **Coffey, C. S.**, Chrischilles, E. A. & James, P. A. (2015). Cost-effectiveness of a physician-pharmacist collaboration intervention to improve blood pressure control. (Vols. 66). (6), pp. 1145-1151. *Hypertension*. [DOI: 10.1161/HYPERTENSIONAHA.115.06023](https://doi.org/10.1161/HYPERTENSIONAHA.115.06023). [PMID: 26527048](https://pubmed.ncbi.nlm.nih.gov/26527048/). [PMCID: PMC4644092](https://pubmed.ncbi.nlm.nih.gov/PMC4644092/).
113. Kolb, S. J., **Coffey, C. S.**, Yankey, J. W., Krosschell, K., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sankoku, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Iannaccone, S. T., Parsons, J., Connolly, A. M., Chiriboga, C. A., McDonald, C., Burnette, W. B., Werner, K., Thangarajh, M., Shieh, P. B.,

- Finanger, E., Cudkowicz, M. E., McGovern, M. M., McNeil, D. E., Finkel, R., Kaye, E., Kingsley, A., Renusch, S. R., McGovern, V. L., Wang, X., Zaworkski, P. G., Prior, T. W., Bartlett, A. M., Kissell, J. T. & and the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2016). Baseline results of the NeuroNEXT spinal muscular atrophy infant biomarker study. (Vols. 3). (2), pp. 132-145. *Annals of Clinical and Translational Neurology*. DOI: [10.1002/acn3.283](https://doi.org/10.1002/acn3.283). PMID: [26900585](https://pubmed.ncbi.nlm.nih.gov/26900585/). PMID: [PMC4748311](https://pubmed.ncbi.nlm.nih.gov/PMC4748311/).
114. Smith, S. M., Carris, N. W., Dietrich, E., Gums, J. G., Uribe, L., **Coffey, C. S.**, Gums, T. H. & Carter, B. L. (2016). Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. (Vols. 10). (4), pp. 307-317. *Journal of the American Society for Hypertension*. DOI: [10.1016/j.jash.2016.01.010](https://doi.org/10.1016/j.jash.2016.01.010). PMID: [26852290](https://pubmed.ncbi.nlm.nih.gov/26852290/). PMID: [PMC4829453](https://pubmed.ncbi.nlm.nih.gov/PMC4829453/).
115. Powers, S. W., Hershey, A. D., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D. J., Sullivan, S. M., Klingner, E. A., Yankey, J. W., Kashikar-Zuck, S., Korbee, L. L., Costigan, M. L., Riss, H. H. & Porter, L. L. (2016). The Childhood and Adolescent Migraine Prevention (CHAMP) Study: A report on baseline characteristics of participants. (Vols. 56). (5), pp. 859-870. *Headache*. DOI: [10.1111/head.12810](https://doi.org/10.1111/head.12810). PMID: [27039826](https://pubmed.ncbi.nlm.nih.gov/27039826/). PMID: [PMC5050048](https://pubmed.ncbi.nlm.nih.gov/PMC5050048/).
116. Kang, J. H., Mollenhauer, B., **Coffey, C. S.**, Toledo, J. B., Weintraub, D., Galasko, D. R., Irwin, D. J., Van Deerlin, V., Chen-Plotkin, A. S., Caspell-Garcia, C., Waligorska, T., Taylor, P., Shah, N., Pan, S., Zero, P., Frasier, M., Marek, K., Keiburtz, K., Jennings, D., Tanner, C. M., Simuni, T., Singleton, A., Toga, A. W., Chowdhury, S., Trojanowski, J. Q., Shaw, L. M. & on behalf of the Parkinson's Progression Markers Initiative (2016). CSF biomarkers associated with disease heterogeneity in early Parkinson's Disease. (Vols. 131). (6), pp. 935-949. *Acta Neuropathologica*. DOI: [10.1007/s00401-016-1552-2](https://doi.org/10.1007/s00401-016-1552-2). PMID: [27021906](https://pubmed.ncbi.nlm.nih.gov/27021906/). PMID: [PMC5031365](https://pubmed.ncbi.nlm.nih.gov/PMC5031365/).
117. Simuni, T., Caspell-Garcia, C., **Coffey, C. S.**, Lasch, S., Tanner, C., Marek, K. & on behalf of the PPMI Investigators (2016). How stable are Parkinson's Disease subtypes in De Novo patients: Analysis of the PPMI Cohort. (Vols. 28). pp. 62-7. *Parkinsonism and Related Disorders*. DOI: [10.1016/j.parkreldis.2016.04.027](https://doi.org/10.1016/j.parkreldis.2016.04.027). PMID: [27132498](https://pubmed.ncbi.nlm.nih.gov/27132498/).
118. Simuni, T., Long, J. D., Caspell-Garcia, C., **Coffey, C. S.**, Lasch, S., Tanner, C. M., Jennings, D., Kieburz, K. D., Marek, K. & on behalf of the PPMI Investigators (2016). Predictors of time to initiation of symptomatic therapy in early Parkinson's Disease. (Vols. 3). (7), pp. 482-94. *Annals of Clinical and Translational Neurology*. DOI: [10.1002/acn3.317](https://doi.org/10.1002/acn3.317). PMID: [27386498](https://pubmed.ncbi.nlm.nih.gov/27386498/). PMID: [PMC4931714](https://pubmed.ncbi.nlm.nih.gov/PMC4931714/).
119. Liu, Y., Zhuang, Z., **Coffey, C. S.**, Rengasamy, S. & Niezgod, G. (2016). Inward leakage variability between respirator fit test panels - Part II. Probabilistic approach. (Vols. 13). (8), pp. 604-611. *Journal of Occupational and Environmental Hygiene*. DOI: [10.1080/15459624.2016.1161198](https://doi.org/10.1080/15459624.2016.1161198). PMID: [26954018](https://pubmed.ncbi.nlm.nih.gov/26954018/).
120. Marras, C., Alcalay, R. N., Caspell-Garcia, C., **Coffey, C. S.**, Chan, P., Duda, J. E., Facheris, M. F., Santiago-Fernandez, R., Ruiz-Martinez, J., Mestre, T., Saunders-Pullman, R., Pont-Sunyer, C., Tolosa, E., Waro, B. & on behalf of the LRRK2 Cohort Consortium (2016). Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's Disease. (Vols. 31). (8), pp. 1192-1202. *Movement Disorders*. DOI: [10.1002/mds.26614](https://doi.org/10.1002/mds.26614). PMID: [27091104](https://pubmed.ncbi.nlm.nih.gov/27091104/).
121. Fox, R. J., **Coffey, C. S.**, Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Conwit, R., Naismith, R., Ashokkumar, A., Bermel, R., Ecklund, D., Koeppe, M., Long, J., Natarajan, S., Ramachandran, S., Skaramagas, T., Thornell, B., Yankey, J., Agius, M., Bashir, K., Cohen, B., Coyle, P., Delgado, S., Dewitt, D., Flores, A., Giesser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S., Miravalle, A., Moses, H., Ontaneda, D., Perumal, J., Racke, M., Repovic, P., Riley, C., Severson, C., Shinnar, S., Suski, V., Weinstock-Gutman, B., Yadav, V. & Zabeti, A. (2016). Design, rationale, and baseline characteristics of the randomized double-blind phase II clinical trial of ibudilast in progressive multiple sclerosis. (Vols. 50). pp. 166-177. *Contemporary Clinical Trials*. DOI: [10.1016/j.cct.2016.08.009](https://doi.org/10.1016/j.cct.2016.08.009). PMID: [27521810](https://pubmed.ncbi.nlm.nih.gov/27521810/). PMID: [PMC5035622](https://pubmed.ncbi.nlm.nih.gov/PMC5035622/).
122. Laage, T., Loewy, J., Menon, S., Miller, E., Pulkstenis, E., Kan-Dobrosky, N. & **Coffey, C. S.** (2016). Ethical considerations in adaptive design clinical trials. (Vols. 51). (2), pp. 190-199. *Therapeutic Innovation & Regulatory Science*. DOI: [10.1177/2168479016667766](https://doi.org/10.1177/2168479016667766)

123. McClure, L. A., Szychowski, J. M., Benavente, O., Hart, R. G. & **Coffey, C. S.** (2016). A post hoc evaluation of a sample size re-estimation in the Secondary Prevention of Small Subcortical Strokes Study. (Vols. 13). (5), pp. 537-544. *Clinical Trials*. [DOI: 10.1177/1740774516643689](https://doi.org/10.1177/1740774516643689). [PMID: 27094488](https://pubmed.ncbi.nlm.nih.gov/27094488/). [PMCID: PMC5025324](https://pubmed.ncbi.nlm.nih.gov/PMC5025324/).
124. Anderegg, M. D., Gums, T. H., Uribe, L., **Coffey, C. S.**, James, P. A. & Carter, B. L. (2016). Physician-pharmacist collaborative management: Narrowing the socioeconomic blood pressure gap. (Vols. 68). (5), pp. 1314-1320. *Hypertension*. [DOI: 10.1161/HYPERTENSIONAHA.116.08043](https://doi.org/10.1161/HYPERTENSIONAHA.116.08043). [PMID: 27600181](https://pubmed.ncbi.nlm.nih.gov/27600181/). [PMCID: PMC5063695](https://pubmed.ncbi.nlm.nih.gov/PMC5063695/).
125. Lyden, P., Weymer, S., **Coffey, C. S.**, Cudkowicz, M., Fisher, M., Haley, E. C., Khatri, P., Saver, J., Levine, S., Levy, H., Pryor, K., Rymer, M. & Wechsler, L. (2016). Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection. (Vols. 47). (12), pp. 2979-2958. *Stroke*. [DOI: 10.1161/STROKEAHA.116.013881](https://doi.org/10.1161/STROKEAHA.116.013881). [PMID: 27803392](https://pubmed.ncbi.nlm.nih.gov/27803392/). [PMCID: PMC5134840](https://pubmed.ncbi.nlm.nih.gov/PMC5134840/).
126. Powers, S. W., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D. J., Klingner, E. A., Yankey, J. W., Korbee, L. L., Porter, L. L., Hershey, A. D. & for the CHAMP Investigators (2017). Trial of amitriptyline, topiramate, and placebo for pediatric migraine. (Vols. 376). (2), pp. 115-124. *The New England Journal of Medicine*. [DOI: 10.1056/NEJMoa1610384](https://doi.org/10.1056/NEJMoa1610384). [PMID: 27788026](https://pubmed.ncbi.nlm.nih.gov/27788026/). [PMCID: PMC5226887](https://pubmed.ncbi.nlm.nih.gov/PMC5226887/).
127. Powers, S. W., Hershey, A. D., **Coffey, C. S.** & for the CHAMP Study Group (2017). The Childhood and Adolescent Migraine Prevention (CHAMP) Study: What do we do now?. (Vols. 57). (2), pp. 180-183. *Headache*. [DOI: 10.1111/head.13025](https://doi.org/10.1111/head.13025). [PMID: 28128463](https://pubmed.ncbi.nlm.nih.gov/28128463/).
128. Powers, S. W., **Coffey, C. S.** & Hershey, A. D. (2017). Treatment of pediatric migraine. (Vols. 376). (14), pp. 1388-1389. *New England Journal of Medicine*. [DOI: 10.1056/NEJMc1701674](https://doi.org/10.1056/NEJMc1701674). [PMID: 28379804](https://pubmed.ncbi.nlm.nih.gov/28379804/).
129. Visanji, N. P., Mollenhauer, B., Beach, T. G., Adler, C. H., **Coffey, C. S.**, Kopil, C. M., Dave, K. D., Foroud, T., Chahine, L., Jennings, D. & on behalf of the Systemic Synuclein Sampling Study (S4) Investigators (2017). The Systemic Synuclein Sampling Study: Toward a biomarker for Parkinson's disease. (Vols. 11). (4), pp. 359-368. *Biomarkers in Medicine*. [DOI: 10.2217/bmm-2016-0366](https://doi.org/10.2217/bmm-2016-0366). [PMID: 28353371](https://pubmed.ncbi.nlm.nih.gov/28353371/).
130. Pont-Sunyer, C., Tolosa, E., Caspell-Garcia, C., **Coffey, C. S.**, Alcalay, R. N., Chans, P., Duda, J. E., Facheris, M., Fernandez-Santiago, R., Marek, K., Lomena, F., Marras, C., Mondragon, E., Saunders-Pullman, R., Waro, B. & on behalf of the LRRK2 Cohort Consortium (2017). The prodromal phase of LRRK2 associated Parkinson Disease: Clinical and imaging studies. (Vols. 32). (5), pp. 726-738. *Movement Disorders*. [DOI: 10.1002/mds.26964](https://doi.org/10.1002/mds.26964). [PMID: 28370517](https://pubmed.ncbi.nlm.nih.gov/28370517/).
131. Caspell-Garcia, C., Simuni, T., Tosun-Turgut, D., Wu, I., Zhang, Y., Nalls, M., Singleton, A., Shaw, L. A., Kang, J. H., Trojanowski, J. Q., Siderowf, A., **Coffey, C. S.**, Lasch, S., Aarsland, D., Burn, D., Chahine, L. M., Espay, A. J., Foster, E. D., Hawkins, K. A., Litvan, I., Richard, I., Weintraub, D. & on behalf of the Parkinson's Progression Markers Initiative (PPMI) (2017). Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson's disease. (Vols. 12). (5), pp. e0175674. *PLoS One*. [DOI: 10.1371/journal.pone.0175674](https://doi.org/10.1371/journal.pone.0175674). [PMID: 28520803](https://pubmed.ncbi.nlm.nih.gov/28520803/). [PMCID: PMC5435130](https://pubmed.ncbi.nlm.nih.gov/PMC5435130/).
132. Amara, A. W., Chahine, L. M., Caspell-Garcia, C., Long, J. D., **Coffey, C. S.**, Hogg, B., Videnovic, A., Iranzo, A., Mayer, G., Foldvary-Schaefer, N., Postuma, R., Oertel, W., Lasch, S., Marek, K., Simuni, T. & and the Parkinson's Progression Markers Initiative (2017). Longitudinal assessment of excessive daytime sleepiness in early Parkinson's disease. (Vols. 88). (8), pp. 653-662. *Journal of Neurology, Neurosurgery, & Psychiatry*. [DOI: 10.1136/jnnp-2016-315023](https://doi.org/10.1136/jnnp-2016-315023). [PMID: 28554959](https://pubmed.ncbi.nlm.nih.gov/28554959/).
133. Mollenhauer, B., Batrla, R., El-Agnaf, O., Galasko, D. R., Lashuel, H. A., Merchant, K. M., Shaw, L. M., Selkoe, D. J., Umek, R., Vanderstichele, H., Zetterberg, H., Zhang, J., Caspell-Garcia, C., **Coffey, C. S.**, Hutten, S. J., Frasier, M., Taylor, P. & for the Investigating Synuclein Consortium of the Michael J. Fox Foundation for Parkinson's Research (2017). A user's guide for α -synuclein biomarker studies in biological fluids: Perianalytical considerations. (Vols. 32). (8), pp. 1117-1130. *Movement Disorders*. [DOI: doi: 10.1002/mds.27090](https://doi.org/10.1002/mds.27090). [PMID: 28734051](https://pubmed.ncbi.nlm.nih.gov/28734051/).
134. Mollenhauer, B., Caspell-Garcia, C. J., **Coffey, C. S.**, Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Frasier, M., Marek, K., Galasko, D. & for the PPMI Study (2017). Longitudinal CSF biomarkers in early

- Parkinson Disease and healthy controls. (Vols. 89). (19), pp. 1959-1969. *Neurology*. DOI: [10.1212/WNL.0000000000004609](https://doi.org/10.1212/WNL.0000000000004609). PMID: 29030452. PMCID: PMC5679418.
135. Kolb, S. J., **Coffey, C. S.**, Yankey, J. W., Krosschell, K. P., Arnold, W. D., Rutkove, S. B., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Parsons, J., Connolly, A., Chiriboga, C. A., McDonald, C., Burnette, B., Werner, W., Thangarajh, M., Shieh, P., Finanger, E., Cudkowicz, M., McGovern, M. M., McNeil, D. E., Finkel, R., Iannacone, S. T., Kaye, E., Kingsley, A., Rensch, S. R., McGovern, V. L., Wang, X., Zaworski, P. G., Prior, T. W., Burghes, A., Bartlett, A., Kissell, J. T. & and The NeuroNEXT Clinical Trial Network on behalf of th NN101 SMA Biomarker Investigators (2017). Natural history of infantile-onset spinal muscular atrophy. (Vols. 82). (6), pp. 883-891. *Annals of Neurology*. DOI: [10.1002/ana.25101](https://doi.org/10.1002/ana.25101). PMID: 29149772. PMCID: PMC5776712.
 136. Simuni, T., Caspell-Garcia, C., Walker, M., **Coffey, C. S.**, Weintraub, D., Mollenhauer, B., Lasch, S., Tanner, C., Jennings, D., Kiebertz, K., Chahine, L., Marek, K. & on behalf of the PPMI Investigators (2018). Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's Disease. (Vols. 89). (1), pp. 78-88. *Journal of Neurology, Neurosurgery, & Psychiatry*. DOI: [10.1136/jnnp-2017-316213](https://doi.org/10.1136/jnnp-2017-316213). PMID: 28986467. PMCID: PMC5732865.
 137. Anderegg, M. D., Gums, T. H., Uribe, L., MacLaughlin, E. J., Hoehns, J., Bazaldua, O. V., Ives, T. J., Hahn, D. L., **Coffey, C. S.** & Carter, B. L. (2018). Pharmacist intervention for blood pressure in patients with diabetes and/or chronic kidney disease. (Vols. 38). (3), pp. 309-318. *Pharmacotherapy*. DOI: [10.1002/phar.2083](https://doi.org/10.1002/phar.2083). PMID: 29331037. PMCID: PMC5867244.
 138. Simuni, T., Siderowf, A., Lasch, S., **Coffey, C. S.**, Caspell-Garcia, C., Jennings, D., Tanner, C. M., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Schuff, N., Singleton, A., Kiebertz, K., Toga, A. W., Mollenhauer, B., Galasko, D., Chahine, L. M., Weintraub, D., Foroud, T., Tosun, D., Poston, K., Arnedo, V., Frasier, M., Sherer, T., Chowdhury, S., Marek, K. & on behalf of the PPMI Investigators (2018). Longitudinal change of clinical and biological measures in early Parkinson's Disease: Parkinson's Progression Markers Initiative Cohort. (Vols. 33). (5), pp. 771-782. *Movement Disorders*. DOI: [10.1002/mds.27361](https://doi.org/10.1002/mds.27361). PMID: 29572948. PMCID: PMC6001458.
 139. Bartlett, A., Kolb, S. J., Kingsley, A., Swoboda, K. J., Reyna, S. P., Sakonju, A., Darras, B. T., Shell, R., Kuntz, N., Castro, D., Iannacone, S. T., Parsons, J., Connolly, A. M., Chiriboga, A., McDonald, C., Burnette, B., Werner, K., Thangarajh, M., Shieh, P. B., Finanger, E., **Coffey, C. S.**, Yankey, J. W., Cudkowicz, M. E., McGovern, M. M., McNeil, E., Arnold, W. D., Kissell, J. T. & for the NeuroNext Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators (2018). Recruitment & retention program for the NeuroNEXT SMA Biomarker Study: Super babies for SMA!. (Vols. 11). pp. 113-119. *Contemporary Clinical Trials Communications*. DOI: [10.1016/j.conctc.2018.07.002](https://doi.org/10.1016/j.conctc.2018.07.002). PMID: 30094386. PMCID: PMC6072892.
 140. Chahine, L. M., Uribe, L., Caspell-Garcia, C., Aarsland, D., Alcalay, R., Barone, P., Burn, D., Espay, A. J., Hamilton, J. L., Hawkins, K. A., Lasch, S., Leverenz, J. B., Litvan, I., Richard, I., Siderowf, A., **Coffey, C. S.**, Simuni, T., Weintraub, D. & and the Parkinson's Progression Markers Initiative (2018). Cognition among individuals along a spectrum of increased risk for Parkinson's Disease. (Vols. 13). (8), pp. e0201964. *PLoS One*. DOI: [10.1371/journal.pone.0201964](https://doi.org/10.1371/journal.pone.0201964). PMID: 30125297. PMCID: PMC6101368.
 141. Fox, R. J., **Coffey, C. S.**, Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., Ashokkumar, A., Barnes, J., Ecklund, D., Klingner, E., Koeppe, M., Long, J. D., Natarajan, S., Thornell, B., Yankey, J., Bermel, R. A., Debbins, J. P., Huang, X., Jagodnik, P., Lowe, M. J., Nakamura, K., Narayanan, S., Sakaie, K. E., Thoomukuntla, B., Zhou, X., Krieger, S., Alvarez, E., Apperson, M., Bashir, K., Cohen, B. A., Coyle, P. K., Delgado, S., Dewitt, L. D., Flores, A., Geisser, B. S., Goldman, M. D., Jubelt, B., Lava, N., Lynch, S. G., Moses, H., Ontaneda, D., Perumal, J. S., Racke, M., Repovic, P., Riley, C. S., Severson, C., Shinnar, S., Suski, V., Weinstock-Guttman, B., Yadav, V., Zabeti, A. & on behalf of the NN102/SPRINT-MS Trial Investigators (2018). Phase 2 trial of Ibudilast in progressive multiple sclerosis. (Vols. 379). (9), pp. 846-855. *New England Journal of Medicine*. DOI: [10.1056/NEJMoa1803583](https://doi.org/10.1056/NEJMoa1803583). PMID: 30157388. PMCID: PMC6172944.

142. Beach, T. G., Serrano, G., Kremer, T., Canamero, M., Dziadek, S., Sade, H., Derkinderen, P., Corbille, A. G., Letournel, F., Munoz, D. G., White, C. L., Schneider, J., Cray, J. F., Sue, L. I., Adler, C. H., Glass, M. J., Intorcchia, A. J., Walker, J. E., Foroud, T., **Coffey, C. S.**, Ecklund, D., Riss, H., Goldman, J., Konig, F., Kopil, C. M., Arnedo, V., Riley, L., Linder, C., Dave, K. D., Jennings, D., Seibyl, J., Mollenhauer, B., Chahine, L. & on behalf of the Systemic Synuclein Sampling Study (2018). Immunohistochemical method and histopathology judging for the Systemic Synuclein Sampling Study (S4). (Vols. 77). (9), pp. 793-802. *Journal of Neuropathology and Experimental Neurology*. DOI: [10.1093/jnen/nly056](https://doi.org/10.1093/jnen/nly056). PMID: [30107604](https://pubmed.ncbi.nlm.nih.gov/30107604/). PMID: [PMC6097838](https://pubmed.ncbi.nlm.nih.gov/30107604/).
143. Marek, K., Chowdhury, S., Siderowf, A., Lasch, S., **Coffey, C. S.**, Caspell-Garcia, C., Simuni, T., Jennings, D., Tanner, C. M., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Schuff, N., Singleton, A., Kiebertz, K., Toga, A. W., Mollenhauer, B., Galasko, D., Chahine, L. M., Weintraub, D., Foroud, T., Tosun-Turgut, D., Poston, K., Arnedo, V., Frasier, M., Sherer, T. & and the Parkinson's Progression Markers Initiative (2018). The Parkinson's Progression Markers Initiative (PPMI) - Establishing a PD biomarker cohort. (Vols. 5). (12), pp. 1460-1477. *Annals of Clinical and Translational Neurology*. DOI: [10.1002/acn3.644](https://doi.org/10.1002/acn3.644). PMID: [30564614](https://pubmed.ncbi.nlm.nih.gov/30564614/). PMID: [PMC6292383](https://pubmed.ncbi.nlm.nih.gov/30564614/).
144. Krosschell, K. J., Bosch, M., Nelson, L., Duong, T., Lowes, L. P., Alfano, L. N., Benjamin, D., Carry, T. B., Devine, G., Kelley, C., Gadekan, R., Malkus, E. C., Pasternak, A., Provance-Orr, S., Roenmeiser-Logan, L., Nicorici, A., Trussell, D., Young, S. D., Fetterman, J. R., Montes, J., Powers, P. J., Quinones, R., Quigley, J., **Coffey, C. S.**, Yankey, J. W., Bartlett, A., Kissell, J. T., Kolb, S. J. & and the NeuroNEXT Clinical Trial Network on behalf of the NN101 SMA Biomarker Investigators (2018). Motor function test reliability during the NeuroNeXT spinal muscular atrophy infant biomarker study. (Vols. 5). (4), pp. 509-521. *Journal of Neuromuscular Diseases*. DOI: [10.3233/JND-180327](https://doi.org/10.3233/JND-180327). PMID: [30223401](https://pubmed.ncbi.nlm.nih.gov/30223401/).
145. Chahine, L. M., Beach, T. G., Seedorff, N., Caspell-Garcia, C., **Coffey, C. S.**, Brumm, M., Adler, C. H., Serrano, G. E., Linder, C., Mosovsky, S., Foroud, T., Riss, H., Ecklund, D., Seibyl, J., Jennings, D., Arnedo, V., Riley, L., Dave, K., Mollenhauer, B. & on behalf of the Systemic Synuclein Sampling Study (2018). Feasibility and safety of multicenter tissue and biofluid sampling for α -Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). (Vols. 8). (4), pp. 517-527. *Journal of Parkinson's Disease*. DOI: [10.3233/JPD-181434](https://doi.org/10.3233/JPD-181434). PMID: [30248065](https://pubmed.ncbi.nlm.nih.gov/30248065/). PMID: [PMC6226302](https://pubmed.ncbi.nlm.nih.gov/30248065/).
146. Lyden, P., Pryor, K. E., **Coffey, C. S.**, Cudkowicz, M., Conwit, R., Jadhav, A., Sawyer Jr, R. N., Claassen, J., Adeoye, O., Song, S., Hannon, P., Rost, N. S., Hinduja, A., Torbey, M., Lee, J., Benesch, C., Rippee, M., Rymer, M., Froehler, M. T., Haley, E. C., Johnson, M., Yankey, J. & Magee, K. (2019). Final results of the RHAPSODY trial: A multi-center, phase 2 trial using a continual reassessment method to determine the safety and tolerability of 3K3A-APC, a recombinant variant of human activated protein C, in combination with tissue plasminogen activator, mechanical thrombectomy or both in moderate to severe acute ischemic stroke. (Vols. 85). pp. 125-136. *Annals of Neurology*. DOI: [10.1002/ana.25383](https://doi.org/10.1002/ana.25383). PMID: [30450637](https://pubmed.ncbi.nlm.nih.gov/30450637/). PMID: [PMC6342508](https://pubmed.ncbi.nlm.nih.gov/30450637/).
147. Amara, A. W., Chahine, L., Seedorff, N., Caspell-Garcia, C. J., **Coffey, C. S.**, Simuni, T. & and the Parkinson's Progression Markers Initiative (2019). Self-reported physical activity levels and clinical progression in early Parkinson's Disease. (Vols. 61). pp. 118-125. *Parkinsonism & Related Disorders*. DOI: [10.1016/j.parkreldis.2018.11.006](https://doi.org/10.1016/j.parkreldis.2018.11.006). PMID: [30554993](https://pubmed.ncbi.nlm.nih.gov/30554993/).
148. Prakash, N., Caspell-Garcia, C., **Coffey, C. S.**, Siderowf, A., Tanner, C. M., Kiebertz, K., Mollenhauer, B., Galasko, D., Merchant, K., Foroud, T., Chahine, L. M., Weintraub, D., Casaceli, C., Dorsey, R., Wilson, R., Herzog, M., Daegele, N., Arnedo, V., Frasier, M., Sherer, T., Marek, K., Simuni, T. & on behalf of the Parkinson's Progression Markers Initiative Steering Committee, Study Cores, Site Investigators, Coordinators, and Industry & Scientific Advisory Board (2019). Feasibility and safety of lumbar puncture in the Parkinson's Disease research participants: Parkinson's Progression Marker Initiative (PPMI). (Vols. 62). pp. 201-209. *Parkinsonism & Related Disorders*. DOI: [10.1016/j.parkreldis.2018.12.025](https://doi.org/10.1016/j.parkreldis.2018.12.025). PMID: [30738748](https://pubmed.ncbi.nlm.nih.gov/30738748/).
149. Mollenhauer, B., Caspell-Garcia, C. J., **Coffey, C. S.**, Taylor, P., Singleton, A., Shaw, L. M., Trojanowski, J. Q., Frasier, M., Simuni, T., Iranzo, A., Oertel, W., Siderowf, A., Weintraub, D., Seibyl, J., Toga, A. W.,

- Tanner, C. M., Kiebertz, K., Chahine, L. M., Marek, K., Galasko, D. & for the PPMI Study (2019). Longitudinal analyses of cerebrospinal fluid α -synuclein in prodromal and early Parkinson's Disease. (Vols. 34). (9), pp. 1354-1364. *Movement Disorders*. [DOI: 10.1002/mds.27806](https://doi.org/10.1002/mds.27806). [PMID: 31361367](https://pubmed.ncbi.nlm.nih.gov/31361367/). [PMCID: PMC7098385](https://pubmed.ncbi.nlm.nih.gov/PMC7098385/).
150. Espay, A. J., Foster, E. D., **Coffey, C. S.**, Uribe, L., Caspell-Garcia, C. J., Weintraub, D. & and the Parkinson's Progression Markers Initiative (2019). Lack of independent mood-enhancing effect for dopaminergic medications in early Parkinson's Disease. (Vols. 402). pp. 81-85. *Journal of the Neurological Sciences*. [DOI: 10.1016/j.jns.2019.05.009](https://doi.org/10.1016/j.jns.2019.05.009). [PMID: 31125734](https://pubmed.ncbi.nlm.nih.gov/31125734/).
 151. Chahine, L. M., Siderowf, A., Barnes, J., Seedorff, N., Caspell-Garcia, C., Simuni, T., **Coffey, C. S.**, Galasko, D., Mollenhauer, B., Arnedo, V., Daegle, N., Frasier, M., Tanner, C., Kiebertz, K., Marek, K. & and the Parkinson's Progression Markers Initiative (2019). Predicting progression in Parkinson's Disease using baseline and 1-year change measures. (Vols. 9). (4), pp. 665-679. *Journal of Parkinson's Disease*. [DOI: 10.3233/JPD-181518](https://doi.org/10.3233/JPD-181518). [PMID: 31450510](https://pubmed.ncbi.nlm.nih.gov/31450510/). [PMCID: PMC6839498](https://pubmed.ncbi.nlm.nih.gov/PMC6839498/).
 152. Paulsen, J. S. & **Coffey, C. S.** (2019). Antisense oligonucleotides might change the therapeutic landscape for Huntington's Disease. (Vols. 18). (10), pp. 911-912. *Lancet Neurology*. [DOI: 10.1016/S1474-4422\(19\)30329-1](https://doi.org/10.1016/S1474-4422(19)30329-1). [PMID: 31526747](https://pubmed.ncbi.nlm.nih.gov/31526747/).
 153. Sorkin, B. C., Kuszak, A. J., Fukagawa, N. K., Hoffman, F. A., Jafari, m., Barrett, B., Brown, P. N., Bushman, F. D., Casper, S., Chilton, F. H., **Coffey, C. S.**, Ferruzi, M. G., Hopp, D. C., Kiely, M., Lakens, D., MacMillan, J. B., Meltzer, D. O., Pahor, M., Paul, J., Pritchett-Corning, K., Quinney, S. K., Rehmann, B., Setchell, K., Sipes, N. S., Stephens, J. M., Taylor, D. L., Tiriach, H., Walters, W. A., Xi, D., Zappala, G. & Pauli, G. F. (2020). Improving natural product research translation: From source to clinical trial. (Vols. 34). (1), pp. 41-65. *FASEB Journal*. [DOI: 10.1096/fj.201902143R](https://doi.org/10.1096/fj.201902143R). [PMID: 31914647](https://pubmed.ncbi.nlm.nih.gov/31914647/). [PMCID: PMC7470648](https://pubmed.ncbi.nlm.nih.gov/PMC7470648/).
 154. Simuni, T., Uribe, L., Cho, R. H., Caspell-Garcia, C., **Coffey, C. S.**, Siderowf, A., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Singleton, A., Toga, A. W., Galasko, D., Foroud, T., Tosun-Turgut, D., Poston, K., Poewe, W., Weintraub, D., Mollenhauer, B., Tanner, C. M., Kiebertz, K., Chahine, L. M., Reimer, A., Hutten, S., Bressman, Marek, K. & on behalf of the PPMI Investigators (2020). Clinical and dopamine transporter imaging characteristics of non-manifest LRRK2 and GBA mutation carriers in the Parkinson's Progression Markers Initiative (PPMI): A cross sectional study. (Vols. 19). (1), pp. 71-80. *Lancet Neurology*. [DOI: 10.1016/S1474-4422\(19\)30319-9](https://doi.org/10.1016/S1474-4422(19)30319-9). [PMID: 31678032](https://pubmed.ncbi.nlm.nih.gov/31678032/). [PMCID: PMC6956652](https://pubmed.ncbi.nlm.nih.gov/PMC6956652/).
 155. Espay, A. J., Kalia, L. V., Gan-Or, Z., Williams-Gray, C., Bedard, P. L., Rowe, S. M., Morgante, F., Fasano, A., Stecher, B., Kauffman, M. A., Farrer, M. J., **Coffey, C. S.**, Schwarzschild, M. A., Sherer, T., Postuma, R. B., Strafella, A. P., Singleton, A. B., Barker, R. A., Kiebertz, K., Olanow, C. W., Lozano, A., Kordower, J. H., Cedarbaum, J. M., Brundin, P., Standaert, D. G. & Lang, A. E. (2020). Disease modification and biomarker development in Parkinson Disease: Revision or reconstruction?. (Vols. 94). (11), pp. 481-494. *Neurology*. [DOI: 10.1212/WNL.0000000000009107](https://doi.org/10.1212/WNL.0000000000009107). [PMID: 32102975](https://pubmed.ncbi.nlm.nih.gov/32102975/). [PMCID: PMC7220234](https://pubmed.ncbi.nlm.nih.gov/PMC7220234/).
 156. Weintraub, D., Caspell-Garcia, C., Simuni, T., Cho, H. R., **Coffey, C. S.**, Aarsland, D., Alcalay, R. N., Barrett, M. J., Chahine, L. M., Eber,omg, J., Espay, A. J., Hamilton, J., Hawkins, K. A., Leverenz, J., Litvan, I., Richard, I., Rosenthal, L. S., Siderowf, A. & York on behalf of the Parkinson's Progression Markers Initiative, M. (2020). Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson Disease. (Vols. 7). (4), pp. 449-461. *Annals of Clinical & Translational Neurology*. [DOI: 10.1002/acn3.51022](https://doi.org/10.1002/acn3.51022). [PMID: 32285645](https://pubmed.ncbi.nlm.nih.gov/32285645/). [PMCID: PMC7187707](https://pubmed.ncbi.nlm.nih.gov/PMC7187707/).
 157. Simuni, T., Brumm, M. C., Uribe, L., Caspell-Garcia, C., **Coffey, C. S.**, Siderowf, A., Alcalay, R., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Singleton, A., Toga, A. W., Galasko, D., Foroud, T., Nudelman, K., Tosun-Turgut, D., Poston, K., Weintraub, D., Mollenhauer, B., Tanner, C. M., Kiebertz, K., Chahine, L. M., Reimer, A., Hutten, S., Bressman, S. & Marek on behalf of the Parkinson's Progression Markers Initiative Investigators, K. (2020). Clinical and dopamine transporter imaging characteristics of leucine-rich repeat kinase 2 (LRRK2) and glucosylceramidase beta (GBA) Parkinson's Disease participants in the Parkinson's Progression Markers Initiative: A cross sectional study. (Vols. 35). (5), pp. 833-844. *Movement Disorders*. [DOI: 10.1002/mds.27989](https://doi.org/10.1002/mds.27989). [PMID: 32073681](https://pubmed.ncbi.nlm.nih.gov/32073681/). [PMCID: PMC7231646](https://pubmed.ncbi.nlm.nih.gov/PMC7231646/).

158. Cudkowicz, M., Chase, M. K., **Coffey, C. S.**, Ecklund, D. K., Thornell, B. K., Lungu, C., Mahoney, K., Gutmann, L., Shefner, J., Staley, K. J., Bosch, M., Foster, E., Long, J. D., Bayman, E. O., Torner, J., Yankey, K., Peters, R., Huff, T., Conwit, R. A. & and the NeuroNEXT Clinical Study Sites (2020). Seven-Year experience from the National Institute of Neurological Disorders and Stroke-Supported Network for Excellence in Neuroscience Clinical Trials. (Vols. 35). (5), pp. 833-844. *JAMA Neurology*. DOI: [10.1001/jamaneurol.2020.0367](https://doi.org/10.1001/jamaneurol.2020.0367). PMID: 32202612. PMCID: PMC7483960.
159. Irwin, D. J., Fedler, J., **Coffey, C. S.**, Caspell-Garcia, C., Kang, J. H., Simuni, T., Foroud, T., Toga, A. W., Tanner, C. <, Kiebertz, K., Chahine, L. M., Reimer, A., Hutten, S., Weintraub, D., Mollenhauer, B., Galasko, D. R., Siderowf, A., Marek, K., Trojanowski, J. Q. & Shaw on behalf of the Parkinson's Progression Markers Initiative, L. M. (2020). Evolution of Alzheimer's Disease cerebrospinal fluid biomarkers in early Parkinson's Disease. (Vols. 88). (3), pp. 574-587. *Annals of Neurology*. DOI: [10.1002/ana.25811](https://doi.org/10.1002/ana.25811). PMID: 32542885. PMCID: PMC7497251.
160. Chahine, L. M., Beach, T. G., Brumm, M. C., Adler, C. H., **Coffey, C. S.**, Mosovsky, S., Caspell-Garcia, C., Serrano, G. E., Munoz, D. G., White, C. L., Crary, J. F., Jennings, D., Taylor, P., Foroud, T., Arnedo, V., Kopil, C. M., Riley, L., Dave, K. D. & Mollenhauer for the Systemic Synuclein Sampling Study, B. (2020). In vivo distribution of α -synuclein in multiple tissues and biofluids in Parkinson's Disease. (Vols. 95). (9), pp. e1267-e1284. *Neurology*. DOI: [10.1212/WNL.0000000000010404](https://doi.org/10.1212/WNL.0000000000010404). PMID: 32747521. PMCID: PMC7538226.
161. Mollenhauer, B., Dakna, M., Kruse, N., Liu, T. Y., Galasko, D., Foroud, T., Zetterberg, H., Schade, S., Gera, R. G., Wang, W., Gao, F., Frasier, M., Chahine, L. M., **Coffey, C. S.**, Singleton, A. B., Simuni, T., Weintraub, D., Seibyl, J., Toga, A. W., Tanner, C. M., Kiebertz, K., Marek, K., Siderowf, A., Cedarbaum, J. M., Jittem, S. J., Trenkwalder, C. & Graham, D. (2020). Validation of serum neurofilament light chain as a biomarker of Parkinson's Disease progression. (Vols. 35). (11), pp. 1999-2008. *Movement Disorders*. DOI: [10.1002/mds.28206](https://doi.org/10.1002/mds.28206). PMID: 32798333. PMCID: PMC8017468.
162. Brownstein, M. J., G, N., Long, J. D., Yankey, J., Maibach, H. T., Cudkowicz, M., **Coffey, C. S.**, Conwit, R. A., Lungu, C., Anderson, K. E., Hersch, S. M., Ecklund, D. J., Damiano, E. M., Itzkowitz, D. E., Lu, S., Chase, M. K., Shefner, J. M., McGarry, A., Thornell, B., Gladden, C., Costigan, M., O'Sullivan, P., Marshall, F. J., Chesire, A. M., Deritis, P., Adams, J. L., Hedera, P., Lowen, K., Rosas, H. D., Hiller, A. L., Quinn, J., Keith, K., Duker, A. P., Gruenwald, C., Molloy, A., Jacob, C., Factor, S., Sperin, E., Bega, D., Brown, Z. R., Seeberger, L. C., Sung, V. W., Benge, M., Kostyk, S. K., Daley, A. M., Perlman, S., Suski, V., Conlon, P., Barrett, M. J., Lowenhaupt, S., Quigg, <, Perlmutter, J. S., Wright, B. A., Most, E., Schwartz, G. J., Lamb, J., Chuang, R. S., Singer, C., Marder, K., Moran, J. A., Singleton, K. R., Zorn, M., Wall, P. V., Dubinsky, R. M., Gray, C. & Drazinic, C. (2020). Safety and tolerability of SRX246, a vasopressin 1A antagonist, in irritable Huntington's Disease patients - A randomized Phase 2 clinical trial. (Vols. 9). (11), pp. 3682. *Journal of Clinical Medicine*. DOI: [10.3390/jcm9113682](https://doi.org/10.3390/jcm9113682). PMID: 33207828. PMCID: PMC7696926.
163. Chahine, L. M., Brumm, M., Caspell-Garcia, C., Oertel, W., Mollenhauer, B., Amara, A., Fernandez-Arcos, A., Tolosa, E., Hogg, B., Videnovic, A., Hutten, S., Weintraub, D., Tanner, C., Burghardt, E., **Coffey, C. S.**, Cho, R., Kiebertz, K., Poston, K., Merchant, K., Galasko, D., Foroud, T., Siderowf, A., Marek, K., Simuni, T. & Iranzo, A. (2021). Dopamine transporter imaging predicts clinically-defined α -synucleinopathy in REM sleep behavior disorder. (Vols. 8). (1), pp. 201-212. *Annals of Clinical & Translational Neurology*. DOI: [10.1002/acn3.51269](https://doi.org/10.1002/acn3.51269). PMID: 33321002. PMCID: PMC7818144.
164. Naismith, R. T., Bernel, R. A., **Coffey, C. S.**, Goodman, A. D., Fedler, J. K., Chase, M., Klawiter, E. C., Nakamura, K., Narayanan, S., Goebel, C., Yankey, J. W., Klingner, E. A. & Fox, R. J. (2021). Effects of Ibudilast on MRI measures in the Phase 2 SPRINT-MS Study. (Vols. 96). (4), pp. e491-e500. *Neurology*. DOI: [10.1212/WNL.0000000000011314](https://doi.org/10.1212/WNL.0000000000011314). PMID: 33268562. PMCID: PMC7905793.
165. Chahine, L. M., Brumm, M. C., Caspell-Garcia, C., Oertel, W., Mollenhauer, B., Amara, A., Fernandez-Arcos, A., Tolosa, E., Simonet, C., Hogg, B., Videnovic, A., Hutten, S. J., Tanner, C., Weintraub, D., Burghardt, E., **Coffey, C. S.**, Cho, H. R., Kiebertz, K., Poston, K. L., Merchant, K., Galasko, D., Foroud, T., Siderowf, A., Marek, K., Simuni, T. & Iranzo, A. (2021). Dopamine transporter imaging predicts clinically-

- defined alpha-synucleinopathy in REM sleep behavior disorder. (Vols. 8). (1), pp. 201-212. *Annals of Clinical & Translational Neurology*. DOI: [10.1002/acn3.51269](https://doi.org/10.1002/acn3.51269). PMID: 33321002. PMCID: PMC7818144.
166. Goodman, A. D., Fedler, J. K., Yankey, J., Klingner, E. A., Ecklund, D. J., Goebel, C. V., Bernel, R. A., Chase, M., **Coffey, C. S.**, Klawiter, E. C., Naismith, R. T. & Fox on behalf of the SPRINT-MS Investigators, R. J. (2021). Response to Ibudilast treatment according to progressive multiple sclerosis disease phenotype. (Vols. 8). (1), pp. 111-118. *Annals of Clinical & Translational Neurology*. DOI: [10.1002/acn3.51251](https://doi.org/10.1002/acn3.51251). PMID: 33460301. PMCID: PMC7818089.
 167. Fox, R., Raska, P., Barro, C., Konig, V., Bermel, R., Chase, M., **Coffey, C. S.**, Goodman, A., Klawiter, E., Naismith, R. & Kuhle, J. (2021). Neurofilament light chain in a phase 2 clinical trial of Ibudilast in progressive multiple sclerosis. (Vols. 27). (13), pp. 2014-2022. *Multiple Sclerosis Journal*. DOI: [10.1177/1352458520986956](https://doi.org/10.1177/1352458520986956). PMID: 33635141. PMCID: PMC8387506.
 168. Simuni, T., Fiske, B., Merchant, K., **Coffey, C. S.**, Klingner, E., Caspell-Garcia, C., Lafontant, D. E., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Venuto, C., Dawson, T. M., Baker, L., Kostrzebski, M., Ward, T. & Rafaloff for the Parkinson Study Group NILO-PD Investigators, G. (2021). Efficacy of Nilotinib in patients with moderately advanced Parkinson Disease: A randomized clinical trial. (Vols. 78). (3), pp. 312-320. *JAMA Neurology*. DOI: [10.1001/jamaneurol.2020.4725](https://doi.org/10.1001/jamaneurol.2020.4725). PMID: 33315105. PMCID: PMC7737147.
 169. Simuni, T., Fiske, B., K, M., **Coffey, C. S.**, Klingner, E., Caspell-Garcia, C., Lafontant, D. E., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Venuto, C., Dawson, T. M., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & for the Parkinsons Study Group NILO-PD Investigators (2021). Nilotinib in patients with moderately advanced Parkinson's Disease: A randomized clinical trial. (Vols. 78). (3), pp. 312-320. *JAMA Neurology*. DOI: [10.1001/jamaneurol.2020.4725](https://doi.org/10.1001/jamaneurol.2020.4725). PMID: 33315105. PMCID: PMC7737147.
 170. Kang, D., **Coffey, C. S.**, Smith, B. J., Yuan, Y., Shi, Q. & Yin, J. (2021). Hierarchical Bayesian clustering design of multiple biomarker subgroups (HCOMBS). (Vols. 40). pp. 2893-2921. *Statistics in Medicine*. DOI: [10.1002/sim.8946](https://doi.org/10.1002/sim.8946). PMID: 33772843.
 171. Kennelty, K., **Coffey, C. S.**, Ardery, G., Uribe, L., Yankey, J., Ecklund, D., James, P. A., Vander Weg, M. W., Chrischilles, E. A., Christensen, A. J., Polgreen, L. A., Gryzlak, B. & Carter on behalf of theMEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) Trial Investigators, B. L. (2021). A cluster randomized trial to evaluate a centralized clinical pharmacy service in large, health system primary care clinics. (Vols. 4). pp. 1287-1299. *Journal of the American College of Clinical Pharmacy*. DOI: [10.1002/jac5.1497](https://doi.org/10.1002/jac5.1497)
 172. Powers, S. W., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D. J., Klingner, E. A., Yankey, J. W., Peugh, J. L., Korbee, L. L., Simmons, K., Sullivan, S. M., Kabbouche, M. A., Kacperski, J., Porter, L. L., Reidy, B. L. & Hershey, A. D. (2021). Prevalence of headache days and disability 3 years after participation in the Childhood and Adolescent Migraine Prevention Medication Trial. (Vols. 4). (7), pp. e2114712. *JAMA Network Open*. DOI: [10.1001/jamanetworkopen.2021.14712](https://doi.org/10.1001/jamanetworkopen.2021.14712). PMID: 34251445. PMCID: PMC8276084.
 173. Powers, S. W., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D. J., Klingner, E. A., Yankey, J. W., Peugh, J. L., Korbee, L. L., Simmons, K., Sullivan, S. M., Kabbouche, M. A., Kacperski, J., Porter, L. L., Reidy, B. L. & Hershey, A. D. (2021). Prevalence of headache days and disability 3 years after participation in the Childhood and Adolescent Migraine Prevention Medication Trial. (Vols. 4). (7), pp. e2114712. *JAMA Network Open*. DOI: [10.1001/jamanetworkopen.2021.14712](https://doi.org/10.1001/jamanetworkopen.2021.14712). PMID: 34251445. PMCID: PMC8276084.
 174. Reidy, B., Peugh, J., Hershey, A., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D., Klingner, E., Yankey, J., Korbee, L., Porter, L., Kabbouche, M., Kacperski, J. & Powers, S. (2021). Trajectory of treatment response in the child and adolescent migraine prevention (CHAMP) study: A randomized clinical trial. pp. 3331024211033551. *Cephalgia*. DOI: [10.1177/03331024211033551](https://doi.org/10.1177/03331024211033551). PMID: 34404270.
 175. Bermel, R. A., Fedler, J., Kaiser, P., Novalis, C., Schneebaum, J., Klingner, E., Williams, D., Yankey, J., Ecklund, D., Chase, M., Naismith, R., Klawiter, E. C., Goodman, A., **Coffey, C. S.** & Fox, R. J. (2021). Optical coherence tomography outcomes from the SPRINT-MS trial of Ibudilast in progressive multiple

- sclerosis. (Vols. 27). (9), pp. 1384-1390. Multiple Sclerosis Journal. [DOI: 10.1177/1352458520964409](https://doi.org/10.1177/1352458520964409). [PMID: 33054533](https://pubmed.ncbi.nlm.nih.gov/33054533/). [PMCID: PMC8046841](https://pubmed.ncbi.nlm.nih.gov/PMC8046841/).
176. Kremer, T., Taylor, K. I., Siebourg-Polster, J., Gerken, T., Staempfli, A., Czech, C., Dukart, J., Galasko, D., Foroud, T., Chahine, L. M., **Coffey, C. S.**, Simuni, T., Weintraub, D., Seibyl, J., Poston, K. L., Toga, A. W., Tanner, C. M., Marek, K., Hutten, S. J., Dziadek, S., Trenkwalder, C., Pagano, G. & Mollenhauer, B. (2021). Longitudinal analysis of multiple neurotransmitter metabolites in cerebrospinal fluid in early Parkinson's Disease. (Vols. 36). (8), pp. 1972-1978. Movement Disorders. [DOI: 10.1002/mds.28608](https://doi.org/10.1002/mds.28608). [PMID: 33942926](https://pubmed.ncbi.nlm.nih.gov/33942926/). [PMCID: PMC8453505](https://pubmed.ncbi.nlm.nih.gov/PMC8453505/).
 177. Espay, A. J., Lafontant, D., Poston, K. L., Caspell-Garcia, C., Marsili, L., Cho, H. R., Daniel, C., Kim, N., **Coffey, C. S.**, Mahajan, A., Ezzat, K. & Sturchio, A. (2021). Low soluble amyloid-beta 42 is associated with smaller brain volume in Parkinson's Disease. (Vols. 92). pp. 15-21. Parkinsonism and Related Disorders. [DOI: 10.1016/j.parkreldis.2021.10.010](https://doi.org/10.1016/j.parkreldis.2021.10.010). [PMID: 34656902](https://pubmed.ncbi.nlm.nih.gov/34656902/).
 178. Picillo, M., Lafontant, D., Bressman, S., Caspell-Garcia, C., **Coffey, C. S.**, Cho, H. R., Burghardt, E. L., Dahodwala, N., Sanders-Pullman, R., Tanner, C. M. & Amara for the Parkinson's Progression Markers Initiative, A. W. (2021). Sex-related longitudinal change of motor, non-motor, and biological features in early Parkinson Disease. pp. online ahead of print. Journal of Parkinson Disease. [DOI: 10.3233/JPD-212892](https://doi.org/10.3233/JPD-212892). [PMID: 34744052](https://pubmed.ncbi.nlm.nih.gov/34744052/).
 179. Nowak, R. J., **Coffey, C. S.**, Goldstein, J. M., Dimachkie, M. M., Benatar, M., Kissel, J. T., Wolfe, G. I., Burns, T. M., Freimer, M. L., Nations, S., Granit, V., Smith, A. G., Richman, D. P., Cifaloni, E., Al-Lozi, M. T., Sams, L. A., Quan, D., Ubogu, E., Pearson, B., Sharma, A., Yankey, J. W., Uribe, L., Shy, M., Amato, A. A., Conwit, R., O'Connor, K. C., Hafler, D. A., Cudkowicz, M. E., Barohn, R. J. & on behalf of the NN103 BeatMG Study Team (2021). Phase 2 trial of Rituiximab in acetylcholine receptor antibody-positive generalized myasthenia gravis: The BeatMG Study. pp. online ahead of print. Neurology. [DOI: 10.1212/WNL.00000000000013121](https://doi.org/10.1212/WNL.00000000000013121). [PMID: 34857535](https://pubmed.ncbi.nlm.nih.gov/34857535/).
 180. Russo, M. J., Orru, C. D., Concha-Marambio, L., Giaisi, S., Groveman, B. R., Farris, C. M., Holguin, B., Hughson, A. G., Lafontant, D. E., Caspell-Garcia, C., **Coffey, C. S.**, Mollon, J., Hutton, S. J., Merchant, K., Heym, R. G., Soto, C., Caughey, B. & Kang, U. J. (2021). High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson's Disease. (Vols. 9). (1), pp. 179. Acta Neuropathologica Communications. [DOI: 10.1186/s40478-021-01282-8](https://doi.org/10.1186/s40478-021-01282-8). [PMID: 34742348](https://pubmed.ncbi.nlm.nih.gov/34742348/). [PMCID: PMC8572469](https://pubmed.ncbi.nlm.nih.gov/PMC8572469/).
 181. Carillo, N., Malicdan, M. C., Leoyklang, P., Shrader, J. A., Joe, G., Slota, C., Perreault, J., Heiss, J. D., Class, B., Liu, C. Y., Bradley, K., Jodarski, C., Ciccone, C., Driscoll, C., Parks, R., Van Wart, S., Bayman, L., **Coffey, C. S.**, Quintana, M., Berry, S. M., Huizing, M. & Gahl, W. A. (2021). Safety and efficacy of n-acetylmannosamine (ManNAc) in patients with GNE myopathy: An open-label phase 2 study. (Vols. 23). (11), pp. 2067-2075. Genetics in Medicine. [DOI: 10.1038/s41436-021-01259-x](https://doi.org/10.1038/s41436-021-01259-x). [PMID: 34257421](https://pubmed.ncbi.nlm.nih.gov/34257421/). [PMCID: PMC8553608](https://pubmed.ncbi.nlm.nih.gov/PMC8553608/).
 182. Reidy, B. L., Powers, S. W., **Coffey, C. S.**, Chamberlin, L. A., Ecklund, D. J., Klingner, E. A., Yankey, J. W., Korbee, L. L., Porter, L. L., Peugh, J., Kabbouche, M. A., Kacperski, J., Hershey, A. D. & for the CHAMP Investigators (2021). Multimodal assessment of medication adherence among youth with migraine: An ancillary study of the CHAMP trial. pp. online ahead of print. Journal of Pediatric Psychology. [DOI: 10.1093/jpepsy/jsab123](https://doi.org/10.1093/jpepsy/jsab123). [PMID: 34865085](https://pubmed.ncbi.nlm.nih.gov/34865085/).

Books

1. **Coffey, C. S.** & Cofield, S. S. (2005). Parametric Linear Models. In Edwards, J., Beasley, T., Page, G. & Allison, D. (Eds.) DNA Microarrays and Related Genomic Techniques: Design, Analysis, and Interpretation of Experiments. pp. 223-243. Boca Raton, FL: Chapman & Hall/CRC.
2. **Coffey, C. S.** (2010). Power Analysis. In Salkind, N. (Eds.) Encyclopedia of Research Design. Thousand Oaks, CA: Sage.

3. **Coffey, C. S.** (2012). Adaptive Design across Stages of Development. In Poole, M., McDermott, M., Cummings, J. & Ravina, B. (Eds.) *Clinical Trials in Neurology*. Cambridge University Press. DOI: [10.1017/CBO9781139032445.010](https://doi.org/10.1017/CBO9781139032445.010).

Abstracts

1. Hebert, P. R., **Coffey, C. S.**, Ajani, U. A., Morgan, T. M., Brown, N. J., Vaughan, D. E. & Ridker, P. M. (2001). Is there an interaction between the ACE I/D and the PAI-1 4G/5G gene polymorphisms on risk of myocardial infarction. (Vols. November). American Heart Association Annual Meeting (Anaheim, CA).
2. Goldstein, D. R., Benza, R. L., Rayburn, B. K., Foley, B. A., **Coffey, C. S.**, Thomas, K. L. & Bourge, R. C. (2001). Amiodarone delays cellular rejection in bradycardic transplant patients. (Vols. November). American Heart Association Annual Meeting (Anaheim, CA).
3. Jack, G. S., Vader, V., **Coffey, C. S.**, Cookson, M. S., Smith, J. A. & Shappell, S. B. (2001). Pathological parameters in radical prostatectomies of clinical stage T1c versus T2 prostate carcinoma. (Vols. June). American Urological Association National Meeting (Anaheim, CA).
4. Watterson, M. K., Arrowsmith, E. R., **Coffey, C. S.**, Cookson, M. S., Mitchel, E. & Stein, C. M. (2002). Population based study of methotrexate use and risk of lymphoma in patients with rheumatoid arthritis. (Vols. October). American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (New Orleans, LA).
5. Ko, D. T., Hebert, P. R., **Coffey, C. S.**, Foody, J. M., Curtis, J. P., Sedrakyan, A. & Krumholz, H. M. (2002). Adverse effects of beta blocker therapy for heart failure patients: a quantitative overview. (Vols. November). American Heart Association Annual Meeting (Chicago, IL).
6. Ritchie, M. D., **Coffey, C. S.** & Moore, J. H. (2003). A comparison of data mining and logistic regression approaches for detecting gene-gene interactions. (Vols. November). Intl Genetic Epidemiology Society Meeting (Redondo Beach, CA).
7. Wang, C., Weindruch, R., Fernandez, J. R., **Coffey, C. S.**, Patel, P. & Allison, D. B. (2003). Caloric restriction and body weight independently affect longevity in wistar rats. (Vols. November). North American Association for the Study of Obesity Annual Scientific Meeting (Ft. Lauderdale, FL).
8. Benza, R. L., **Coffey, C. S.**, Barchue, J. P., Cavender, M. A., Rayburn, B. K., Bourge, R. C., Tallaj, J. A., Kirklin, J. K. & Pinderski, L. J. (2003). Fibrinolytic proteins and genotypes: implications for allograft coronary disease. (Vols. November). American Heart Association Annual Meeting (Orlando, FL).
9. Benza, R. L., Barchue, J. P., Grennett, H. E., **Coffey, C. S.**, Tallaj, J. A., Rayburn, B. K., Pinderski, L. J., Pambokian, S. V., McGiffin, D. C., Kirklin, J. K. & Bourge, R. C. (2004). Genotypes and acute chronic rejection in cardiac transplant recipients. (Vols. April). Annual Meeting and Scientific Sessions of the International Society for Heart and Lung Transplantation (San Francisco, CA).
10. Wang, C., **Coffey, C. S.** & Allison, D. B. (2004). Toward unbiased estimation of the effects of risk factors in the presence of latent confounders estimated with error by simulation-extrapolation in cox proportional hazard model: the example of intentional weight loss and mortality rate. (Vols. November). North American Association for the Study of Obesity Annual Scientific Meeting (Las Vegas, NV).
11. Howard, G., Beasley, T. M., **Coffey, C. S.** & George, V. (2004). Restructuring of biostatistics at UAB. (Vols. August). Annual Joint Statistical Meetings (Toronto, ON).
12. Benza, R. L., Mohanty, G. S., Grennett, H. E., **Coffey, C. S.**, Rayburn, B. K., Tallaj, J. A., Law, M. A., Pinderski, L. J., Pambokian, S. V. & Bourge, R. C. (2004). Pharmacogenomics in pulmonary arterial hypertension (PAH): the relationship between an ET-1 gene polymorphism (PM) and efficacy of bosentan. (Vols. May). International Conference of the American Thoracic Society.
13. Ritchie, M. D., **Coffey, C. S.** & Moore, J. H. (2004). Genetic programming neural network has improved power in comparison to logistic regression for detecting gene-gene interactions in studies of human disease. (Vols. June). Annual Genetic and Evolutionary Computation Conference (Seattle, WA).
14. Benza, R. L., Mohanty, G. S., **Coffey, C. S.**, Anderson, P. G., Lyle, K. & George, J. F. (2004). PAI-1 and allograft vasculopathy: insights from a murine model of transplantation. (Vols. April). Annual Meeting

- and Scientific Sessions of the International Society for Heart and Lung Transplantation (San Francisco, CA).
15. Simpson, S. L., **Coffey, C. S.** & Muller, K. E. (2005). Repeated measures for Gaussian Multivariate Linear Models: A tutorial. Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX) March.
 16. Clement, M. E., **Coffey, C. S.** & Muller, K. E. (2005). Avoiding test size bias due to internal pilots with gaussian repeated measures. (Vols. March). Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX).
 17. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2005). GLUMIP 2.0: Free SAS/IML software for planning internal pilots. Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Austin, TX) March.
 18. Graves, J. W. & **Coffey, C. S.** (2005). Quality of blood pressure measurement in the SPS3 (secondary prevention of small subcortical strokes) study. (Vols. May). Annual Meeting of American Society of Hypertension (San Francisco, CA).
 19. Hebert, P. R., Murry, K. T., Rottman, J. N., **Coffey, C. S.**, Byrne, D. W., McCormack, V. A., Fagard, R. H., Meade, T. W. & Oates, J. A. (2005). Treatment of hypertension with epithelial sodium channel inhibitors combined with hydrochlorothiazide reduces sudden coronary death and total coronary mortality. (Vols. November). Annual Meeting of the American Heart Association (Dallas, TX).
 20. Newsome, B. B., McClellan, W. M., Allison, J. J., Kiefe, C. O., **Coffey, C. S.** & Warnock, D. G. (2005). African-americans with kidney disease have better survival than whites after acute myocardial infarction. (Vols. November). Annual Meeting of American Society of Nephrology (Philadelphia, PA).
 21. Newsome, B. B., Warnock, D. G., Allison, J. J., Eggers, P., Kiefe, C. I., Collins, A., Chen, S., **Coffey, C. S.** & McClellan, W. M. (2005). African-americans have a greater risk of end-stage renal disease following hospitalization for acute myocardial infarction. (Vols. November). Annual Meeting of American Society of Nephrology (Philadelphia, PA).
 22. Wolffenbuttel, B. H., van Beek, A. P., Hebert, P. R., **Coffey, C. S.** & de Jong, P. E. (2006). Predictive value of adipokines for development of cardiovascular events in a population-based cohort. (Vols. June). Annual Meeting of the American Diabetes Association (Washington, DC).
 23. Graves, J. W., Wochos, D. N. & **Coffey, C. S.** (2006). Orthostatic hypotension (OH) at six and twelve months in the secondary prevention of small subcortical strokes (SPS3) study. (Vols. October). 21st International Meeting of the International Society of Hypertension (Fukuoka, Japan).
 24. Grimm, R., Pergola, P., Hart, R., Anderson, D., Benavente, O., White, C., Graves, J., **Coffey, C.** & Brauer, D. (2006). Monitoring futility in 2x2 factorial studies. Annual Joint Statistical Meeting (Seattle, WA), August.
 25. Grimm, R., Pergola, P., Hart, R., Anderson, D., Benavente, O., White, C., Graves, J., **Coffey, C.** & Brauer, D. (2006). Monitoring futility in 2x2 factorial studies. (Vols. October). 21st International Meeting of the International Society of Hypertension (Fukuoka, Japan).
 26. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2006). GLUMIP 2.0: Free SAS/IML software for planning internal pilots. Annual Joint Statistical Meeting (Seattle, WA), August.
 27. Graves, J. W., Pergola, P. E., Benavente, O. R., Hart, R. G., **Coffey, C. S.** & White, C. L. (2006). Predictors of achievement of assigned blood pressure target at six months and one year in the SPS3 study. (Vols. October). 21st International Meeting of the International Society of Hypertension (Fukuoka, Japan).
 28. Grimm, R., Pergola, P., Hart, R., Anderson, D., Benavente, O., White, C., Graves, J., **Coffey, C. S.** & Brauer, D. (2006). Secondary prevention of small subcortical strokes with BP lowering and antiplatelet therapies: A 2x2 factorial trial (SPS3). 21st International Meeting of the International Society of Hypertension, Fukuoka, Japan.
 29. Sawrie, D. & **Coffey, C. S.** (2007). Small sample properties of information-based monitoring. (Vols. August). Annual Joint Statistical Meetings (Salt Lake City, UT).
 30. Prucka, W., **Coffey, C. S.**, Cutter, G. & Reich, D. S. (2007). Wavelet-based modeling of clinical outcomes using diffusion tensor image data. Annual Joint Statistical Meetings (Salt Lake City, UT), August.

31. Kairalla, J., Muller, K. E. & **Coffey, C. S.** (2007). An internal pilot study with interim analysis for gaussian linear models. (Vols. August). Annual Joint Statistical Meetings (Salt Lake City, UT).
32. Pekarek, D., **Coffey, C. S.**, Barchue, J., Grennett, H., Tallaj, J., Rayburn, B. & Benza, R. L. (2007). Relationship between u-PA and TGF-beta genotypes and allograft coronary disease. (Vols. April). Annual Meeting of the International Society for Heart and Lung Transplantation (San Francisco, CA).
33. Yi, N., Ding, S., Keith, S. W., **Coffey, C. S.** & Allison, D. B. (2007). Bayesian analysis of the effect of intentional weight loss on mortality rate. (Vols. August). Annual Joint Statistical Meetings (Salt Lake City, UT).
34. Pekarek, D., **Coffey, C. S.**, Barchue, J., Grennett, H., Tallaj, J., Rayburn, B., Kirklin, J. & Benza, R. L. (2007). TGF-beta polymorphisms, gender, age, and their effect on acute cardiac rejection. (Vols. April). Annual Meeting of the International Society for Heart and Lung Transplantation (San Francisco, CA).
35. Prucka, W., **Coffey, C. S.**, Cutter, G. & Reich, D. S. (2007). Wavelet-based modeling of clinical outcomes using diffusion tensor image data. (Vols. August). Annual Joint Statistical Meetings (Salt Lake City, UT).
36. Prucka, W. R. & **Coffey, C. S.** (2007). A wavelet-based method for determining persistent DNA copy number variation across multiple subjects. Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Atlanta, GA), March.
37. Guyton, F., Allcorn, C., Stern, B., McCarthy, S. & **Coffey, C. S.** (2007). Monitoring serious adverse events via a web-based system. (Vols. May). Annual Meeting of the Society for Clinical Trials (Montreal, Quebec, Canada).
38. Gurka, M., **Coffey, C. S.** & Muller, K. E. (2007). Internal pilot designs and mixed models. (Vols. August). Annual Joint Statistical Meetings (Salt Lake City, UT).
39. Sawrie, D. F. & **Coffey, C. S.** (2007). Preemptive power and the consulting statistician. (Vols. March). Annual meeting of the Eastern North American Region (ENAR) of the Biometrics Society (Atlanta, GA).
40. Benavente, O., Bazan, C., Tonarelli, S., Pergola, G., McClure, L., **Coffey, C.** & Hart, H. R. (2007). DWI overestimates the ultimate size of lacunar infarcts. (Vols. February). American Stroke Association Annual Meeting (San Francisco, CA).
41. Prucka, W. R. & **Coffey, C. S.** (2008). Estimating predictive error for left- and right-censored survival data with time-varying covariates. (Vols. August). Joint Statistical Meetings (Denver, CO).
42. Gurka, M. J. & **Coffey, C. S.** (2008). Internal pilot designs for observational studies. (Vols. March). Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA).
43. Benavente, O. R., Arboix, A., Bazan, C., Rubio, F., **Coffey, C. S.**, McClure, L., Nair, N., Roldan, A., White, C. & Hart, R. (2008). Atypical lacunar syndromes: same disease as classical lacunar infarcts? The secondary prevention of small subcortical strokes (SPS3) study. (Vols. May). European Stroke Meeting (Nice, France).
44. Supapkorn, T., Gadbury, G. L., **Coffey, C. S.**, Keith, S. W. & Allison, D. B. (2008). Potential outcomes applied to an intentional weight loss application. (Vols. August). Joint Statistical Meetings (Denver, CO).
45. Luna, J., McClure, L. A., Szychowski, J. M., **Coffey, C. S.**, Benavente, O., White, C., Roldan, A., Liu, K., Wang, H., Fink, D. J. & Elkind, M. S. (2008). HsCRP and SAA among patients with lacunar stroke: preliminary findings from the levels of inflammatory markers in treatment of ischemic stroke (LIMITS) study. (Vols. April). American Academy of Neurology Meeting (Chicago, IL).
46. Benavente, O., Bazan, C., Nair, N., McClure, L., **Coffey, C.**, Pretel, J., Krupinski, Y., Vaishnav, A., Hart, R. & Roldan, A. (2008). Single vs. multiple lacunar infarcts: are they caused by different diseases? The SPS3 study. (Vols. February). American Stroke Association Annual Meeting (New Orleans, LA).
47. Benza, R., Prucka, W., Frost, A., Gomberg, M., Lawrence, E., Barchue, J., **Coffey, C. S.** & Grenett, H. (2008). ET-1 polymorphism and functional capacity interactions in PAH patients treated with endothelin antagonists. (Vols. May). American Thoracic Society Annual Meeting (Toronto, Canada).

48. Chen, L., Beasley, M. B., **Coffey, C. S.** & Page, G. P. (2008). Adjusting for covariates in the analysis of microarray and other high dimensional biological data. Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA), March.
49. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2008). GLUMIP 2.0: SAS/IML software for planning internal pilots. (Vols. August). Joint Statistical Meetings (Denver, CO).
50. Benza, R., Prucka, W., Torbicki, A., Pulido, R., Langleben, D., Barchue, J., **Coffey, C. S.** & Grenett, H. (2008). eNOS polymorphism and 6MWD interactions in PAH patients on endothelin antagonists. (Vols. May). American Thoracic Society Annual Meeting (Toronto, Canada).
51. Kairalla, J. A., Muller, K. E. & **Coffey, C. S.** (2008). Internal pilot with interim analysis for single degree of freedom hypothesis tests. (Vols. March). Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA).
52. Nair, N. K. & **Coffey, C. S.** (2008). A two-stage procedure for factorial designs utilizing a formal futility rule. Annual Meeting of the Eastern North American Region (ENAR) of the International Biometric Society (Alexandria, VA), March.
53. Muller, K. E., **Coffey, C. S.**, Kairalla, J. A. & Johnson, J. L. (2008). GLMIP 1.0: SAS/IML software for planning repeated measures internal pilots. Annual Meeting of the Eastern North America Region (ENAR) of the International Biometrics Society (Alexandria, VA), March.
54. Kairalla, J. A., Muller, K. E. & **Coffey, C. S.** (2009). Achieving the benefits of an internal pilot with interim analysis while controlling type I errors for gaussian linear models. (Vols. August). Joint Statistical Meetings (Washington, DC).
55. Szychowski, J., McClure, L., White, C., Pergola, P., Graves, J., Hart, R., Benavente, O. & **Coffey, C. S.** (2009). Factors affecting time to in-target blood pressure status in a multicenter international trial. (Vols. May). Annual Meeting of the Society of Clinical Trials (Atlanta, GA).
56. Benza, R. L., Foreman, A. J., Prucka, W. R., Gombert-Maitland, M., Frantz, R. P., Miller, D. P., **Coffey, C. S.**, Elliot, C. G. & McGoon, M. D. (2009). Predicting survival in pulmonary arterial hypertension using the REVEAL database. (Vols. May). Annual Meeting of the American Thoracic Society (San Diego, CA).
57. McClure, L. A., Howard, G. & **Coffey, C. S.** (2009). Monitoring futility in two-by-two factorial studies. (Vols. May). Annual Meeting of the Society of Clinical Trials (Atlanta, GA).
58. Pekarek, D., Barchue, J., Grenett, H., Biggio, J., Robin, N., **Coffey, C. S.** & Benza, R. (2009). Cytokine SNP's and their relationship to the development of peripartum cardiomyopathy. (Vols. January). Annual Meeting of the Society for Maternal and Fetal Medicine (San Diego, CA).
59. Howard, K. P. & **Coffey, C. S.** (2009). Ambulatory blood pressure as related to white matter hyperintensity. Annual Meeting of the Society of Clinical Trials (Atlanta, GA), May.
60. Benavente, O., Del Brutto, O., Arauz, A., Ruiz-Sandoval, J. L., Roldan, A., Szychowski, J., Peri, K., **Coffey, C. S.**, White, C. & Hart, R. G. (2009). Are lacunar strokes different in hispanic patients? the sps3 study. (Vols. February). American Stroke Association Annual Meeting (San Diego, CA).
61. McClure, L. A., Szychowski, J. M., Benavente, O. & **Coffey, C. S.** (2010). The effect of an unplanned sample size re-estimation on the type I error rate. Society for Clinical Trials Annual Meeting (Baltimore, MD) May.
62. Frasier, M., Chowdury, S., Sherer, T., Eberling, J., Meunier, C., Ravina, B., Siderwof, A., Scherzer, C., Jennings, D., Tanner, C., Kieburz, K., **Coffey, C.**, Poewe, W., Mollenhaur, B., Seibyl, J., Toga, A., Ansbach, A., Del Blasio, P., Piovella, M., Trojanowski, J., Shaw, L., Singleton, A. & Marek, K. (2010). The parkinson's progression marker's initiative: a prospective biomarkers study. (Vols. June). Annual Movement Disorders Society Meeting (Buenos Aires, Argentina).
63. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2010). Achieving the benefits of both an internal pilot and interim analysis in small samples. (Vols. August). Joint Statistical Meetings (Vancouver, BC).
64. Frasier, M., Marek, K., Schlossmacher, M., Yen, M., Taylor, P., Caspell, C. & **Coffey, C. S.** (2011). Diurnal fluctuations of Parkinson's disease biomarkers in healthy volunteers. International Congress of Parkinson's Disease and Movement Disorders (Toronto, ON), June.

65. Yankey, J., **Coffey, C. S.** & Clarke, W. R. (2011). Some strategies for report generation by biostatisticians in clinical trials. Society for Clinical Trials Annual Meeting (Vancouver, BC), May.
66. Hornung, L. N., Szychowski, J., White, C. L., Graves, J. W., Pergola, P. E., McClure, L. A., **Coffey, C. S.**, Hart, R. G. & Benevente, O. R. (2011). Predictors of blood pressure control at 6 and 12 months in the secondary prevention of small subcortical strokes (sps3) study. (Vols. May). Society for Clinical Trials Annual Meeting (Vancouver, BC).
67. McClure, L. A., Szychowski, J. M., Benevente, O., Hart, R. G., Conwit, R. & **Coffey, C. S.** (2011). The use of an unplanned adaptive design in an NIH-sponsored stroke prevention trial. International Stroke Conference (Los Angeles, CA), February.
68. Ecklund, E., Kearney, M., **Coffey, C. S.**, Cudkowicz, M., McNeil, E., Kaufmann, P. & Koroshetz, W. (2012). NeuroNEXT: Developing infrastructure for phase 2 clinical trials in neurological disorders. Society for Clinical Trials Annual Meeting (Miami, FL), May.
69. Kang, J. H., Chen-Plotkin, A., Irwin, D., Siderowf, A., Caspell, C., **Coffey, C. S.**, Taylor, P., Frasier, M., Marek, K., Trojanowski, J., Shaw, L. M. & and the Parkinson's Progression Marker Initiative (2012). CSF biomarkers in early Parkinson's disease: Predictors of risk for disease progression. Alzheimer's Association International Conference (Vancouver, BC), July.
70. Kairalla, J. A., Thomann, M. A., **Coffey, C. S.** & Muller, K. E. (2012). A class of two-stage internal pilot with interim analysis designs for two group comparative effectiveness trials. Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society (Washington, DC), March.
71. Kairalla, J. A., Thomann, M. A., **Coffey, C. S.**, Shorr, R. I. & Muller, K. E. (2012). Adaptive designs for clinical comparative effectiveness research: Are we ready?. Society for Clinical Trials Annual Meeting (Miami, FL), May.
72. Lau, H., White, C., **Coffey, C. S.**, Romero, J., Pikula, A., Babikian, V., Kase, C. & Benevente, O. (2012). Benefits of clinical trial participation for risk factor control: Experience from the SPS3 study. International Stroke Conference (New Orleans, LA), February.
73. Roldan, A., Benevente, M., McClure, L., **Coffey, C. S.**, Szychowski, J., Pergola, P., Conwit, R., Hart, R. & Benevente, O. (2012). Secondary prevention of small subcortical strokes. International Stroke Conference (New Orleans, LA), February.
74. Kang, J. H., Caspell, C., **Coffey, C. S.**, Taylor, P., Frasier, M., Marek, K., Trojanowski, J. Q., Shaw, L. M. & and the Parkinson's Progression Marker's Initiative (2012). Association between CSF biomarkers and clinical phenotype of early Parkinson's disease. Annual Meeting of the Movement Disorders Society (Dublin, Ireland), June.
75. Frasier, M. A., Marek, K., Taylor, P., Caspell, C., **Coffey, C. S.**, Ereshefsky, L., Yen, M. & Sherer, T. (2012). Diurnal and intersubject variability of cerebrospinal fluid biomarkers in Parkinson's disease and healthy volunteers. Annual Meeting of the Movement Disorders Society (Dublin, Ireland), June.
76. Kairalla, J. A., **Coffey, C. S.**, Thomann, M. A. & Muller, K. E. (2012). Adaptive designs for comparative effective trials. Joint Statistical Meetings (San Diego, CA), August.
77. Seibyl, J. P., Jennings, D., Grachev, I., **Coffey, C. S.**, Marek, K. & on behalf of the PPMI Investigators (2013). 123-I ioflupane SPECT measures of Parkinson Disease progression in the Parkinson Progression Marker Initiative (PPMI) trial. Annual Meeting of the Movement Disorders Society (Sydney, Australia).
78. Kearney, M., Ecklund, D., Simpson, E., Bosch, M., Sweet, B., Jackson, K., Mahoney, K., McCourt, M., Thornell, B., Titus, S., Soodoo, N., O'Brien, J., Gloer, K., Costigan, M., Logsdon-Sackett, N., Huff, T., Shefner, J., Staley, K., Guttman, L., Clarke, W., Torner, J., Long, J., Chaloner, K., Bayman, E., McNeil, E., Kaufmann, P., Koroshetz, W., Cudkowicz, M. & **Coffey, C. S.** (2013). The coalition against major diseases: Dopamine transporter imaging as an enrichment biomarker to enable Parkinson's Disease clinical trials. American Academy of Neurology (San Diego, CA).
79. Constantinescu, R., Jennings, D., Foster, E. D., Auinger, P., **Coffey, C. S.**, Marek, K. & for the Parkinson's Progression Markers Initiative (2013). Relationship between serum urate and clinical features in early

- Parkinson's Disease: PPMI baseline data. Annual Meeting of the Movement Disorders Society (Sydney, Australia).
80. Ranjan, A., McClure, L. A. & **Coffey, C. S.** (2013). Internal pilot design for cluster randomized trials with unequal cluster sizes. Society for Clinical Trials Annual Meeting (Boston, MA), May.
 81. Kearney, M., Ecklund, D., Simpson, E., Bosch, M., Sweet, B., Jackson, K., Mahoney, K., McCourt, M., Thornell, B., Titus, S., Soodoo, N., O'Brien, J., Gloer, K., Costigan, M., Logsdon-Sackett, N., Huff, T., Shefner, J., Staley, K., Guttman, L., Clarke, W. R., Torner, J. C., Long, J., Chaloner, K. M., Bayman, E., McNeil, E., Kaufman, P., Koroshetz, W., Kaufmann, P., Cudkowicz, M. & **Coffey, C. S.** (2013). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Concept to Implementation. American Academy of Neurology (San Diego, CA).
 82. McClure, L. A., Szychowski, J. M., Benavente, O., Hart, R. G. & **Coffey, C. S.** (2013). Increasing the sample size in the Secondary Prevention of Small Subcortical Strokes (SOS3) Study: What did we gain?. International Stroke Conference (Honolulu, HI), February.
 83. Szychowski, J. M., McClure, L. A., White, C. L., Pergola, P. E., Benevente, O. R. & **Coffey, C. S.** (2013). Factors affecting time to achieve blood pressure targets in the Secondary Prevention of Small Subcortical Strokes (SPS3) trial. International Stroke Conference (Honolulu, HI), February.
 84. Weintraub, D., Jennings, D., Foster, E. D., Auinger, P., **Coffey, C. S.**, Marek, K. & for the Parkinson's Progression Markers Initiative (2013). Cognitive performance and psychiatric symptoms in de novo, untreated Parkinson's Disease: Results from the PPMI Study. Annual Meeting of the Movement Disorders Society (Sydney, Australia).
 85. Korbee, L., Powers, S., Hershey, A., Chamberlin, L., Allen, J., LeCates, S., White, S., Kroner, J., Sullivan, S., **Coffey, C. S.** & Ecklund, D. (2013). Rapid rollout of a pediatric migraine prevention study conducted in academic research centers. International Headache Congress (Boston, MA).
 86. Kearney, M., Ecklund, D., Bosch, M., Thornell, B., McNeil, E., Koroshetz, W., Kaufmann, P., **Coffey, C. S.** & Cudkowicz, M. (2014). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management. Annual Meeting of the American Academy of Neurology (Philadelphia PA).
 87. Lau, H., White, C., **Coffey, C. S.**, Romero, J., Pikula, A., Babikian, V. & Benevente, O. (2014). Benefits of clinical trial participation for risk factor control: Experience from the SPS3 Study. International Stroke Congress (San Diego, CA).
 88. Pikula, A., **Coffey, C. S.**, Lau, H. W., White, C. L., Kase, C. S. & Benevente, O. (2014). Risk of stroke and vascular events and response to antiplatelet therapy in young adults with recent lacunar strokes: The SPS3 Study. International Stroke Congress (San Diego, CA).
 89. Kearney, M., Thornell, B., Mahoney, K., Ecklund, D., **Coffey, C. S.** & Cudkowicz, M. (2014). The NeuroNEXT experience of patient engagement in protocol development. Annual Meeting of the Society for Clinical Trials (Philadelphia, PA).
 90. Zahn, E. & **Coffey, C. S.** (2014). Simulation study to assess an a priori decision algorithm for a randomized three armed clinical trial. Annual Meeting of the Society for Clinical Trials (Philadelphia, PA).
 91. Kearney, M., Flynn, K., Huq, S., Ashokkumar, A., Simpson, E., McCourt, M., Ecklund, D., Bosch, M., **Coffey, C. S.** & Cudkowicz, M. (2014). Coordinating center support required for an academic central IRB: The NeuroNEXT network experience. Annual Meeting of the Society for Clinical Trials (Philadelphia, PA).
 92. Kearney, M., McCourt, M., Huq, S., Strodel, R., Thornell, B., Ecklund, D., Bosch, M., **Coffey, C. S.** & Cudkowicz, M. (2014). Assessment of site feasibility: The NeuroNEXT network experience. Annual Meeting of the Society for Clinical Trials (Philadelphia, PA).
 93. Weintraub, D., Simuni, T., **Coffey, C. S.**, Caspell-Garcia, C., Foster, E. D., Barone, P., Leverenz, J., Burn, D., Eberling, J., Chahine, L., Litvan, T., Troyer, M., Siderowf, A., Aarsland, D., Hawkins, K. & for the PPMI Cognitive Behavioral Working Group. (2014). Cognitive performance and psychiatric symptoms in de novo, untreated Parkinson's Disease: Results from the PPMI study. 18th International Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden). [DOI: 10.1002/mds.25914](https://doi.org/10.1002/mds.25914)

94. Simuni, T., Caspell, C., **Coffey, C. S.**, Chahine, L. C., Lasch, S., Oertel, W., Marek, K. & for the PPMI Investigators. (2014). Excessive day time sleepiness is not part of Parkinson's Disease disability in de novo patients: Results from the PPMI study. 18th International Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden). [DOI: 10.1002/mds.25914](https://doi.org/10.1002/mds.25914)
95. Zhang, Y., Wu, K., Buckley, S., Mendick, S., Seibyl, J., Foster, E. D., **Coffey, C. S.**, Marek, K., Schuff, N. & for the Parkinson's Progression Markers Initiative (PPMI). (2014). Degeneration of corticostriatal fibers in Parkinson's Disease and their differential relations to cognitive and motor deficits. 18th International Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden).
96. Simuni, T., **Coffey, C. S.**, Uribe, L., Lasch, S., Jennings, D., Tanner, C., Marek, K. & for the PPMI Investigators. (2014). Can we reliably establish Parkinson's Disease subtypes in de novo patients: Results from the PPMI study. 18th International Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden).
97. Seibyl, J., Jennings, D., **Coffey, C. S.** & Marek, K. (2014). Multicenter evaluation of Parkinson's Disease progression using 123-I-iodoflupane SPECT: Update from the Parkinson's Progression Marker Initiative trial. 18th International Congress of Parkinson's Disease and Movement Disorders (Stockholm, Sweden).
98. Kolb, S. J., **Coffey, C. S.**, Yankey, J. W., Arnold, D., Rutkove, S. B., Bartlett, A., Rensch, S., Wang, S., Snyder, P. J., Prior, T. W., Kissel, J. T. & for the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. (2015). Initial results from the NeuroNEXT SMA Infant Biomarker Study. Annual Meeting of the American Academy of Neurology (Washington, DC).
99. Fox, R., **Coffey, C. S.**, Cudkovicz, M., Gleason, T., Goodman, A., Klawiter, E., Matsuda, K., McGovern, M., McNeil, E., Naismith, R. & Yankey, J. (2015). NN102/SPRINT-MS phase II trial of Ibudilast in progressive MS: Baseline characteristics. Annual Meeting of the American Academy of Neurology (Washington, DC).
100. Kearney, M., Ecklund, D., Bosch, M., Thornell, B., McNeil, E., Cordell, J., **Coffey, C. S.** & Cudkovicz, M. (2015). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing efficiency in clinical trial management. Annual Meeting of the American Academy of Neurology (Washington, DC).
101. Meurer, W. J., Mawocha, S., Conwit, R., Lewis, R., **Coffey, C. S.** & Gutmann, L. (2015). The NINDS clinical trial methodology Course: Approach and lessons from year 1. Annual Meeting of the Society for Clinical Trials (Washington, DC).
102. Foster, E. D., **Coffey, C. S.**, Cudkovicz, M. E., Ecklund, D. J., Bosch, M. J., Thornell, B. J., Kearney, M., Littizzio, E., Ashokkumar, A. & Mahoney, K. (2015). The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) protocol working group design phase experiences. Annual Meeting of the Society for Clinical Trials (Washington, DC).
103. Foster, E. D., Thomann, M. A. & **Coffey, C. S.** (2015). Including uncertainty in the target probability of dose limiting toxicity in phase I/II studies with a dose finding component. Annual Meeting of the Society for Clinical Trials (Washington, DC).
104. Kolb, S. J., **Coffey, C. S.**, Yankey, J. W., Arnold, D., Rutkove, S. B., Bartlett, A., Rensch, S., Wang, S., Snyder, P. J., Prior, T. W., Kissel, J. T. & for the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators. (2015). Initial results from the NeuroNEXT SMA Infant Biomarker Study. Cure SMA Annual Researcher Meeting (Kansas City, MO). [DOI: 10.1212/WNL.84.14_supplement.P5.058](https://doi.org/10.1212/WNL.84.14_supplement.P5.058)
105. Simuni, T., Caspell-Garcia, C., **Coffey, C. S.**, Lasch, S., Jennings, D., Tanner, C., Kieburtz, K. & Marek, K. (2015). Can we reliably establish Parkinson's Disease subtypes in de novo patients: Follow up results from the PPMI Study. 19th International Congress of Parkinson's Disease and Movement Disorders (San Diego, CA). [DOI: 10.1002/mds.26295](https://doi.org/10.1002/mds.26295)
106. Nowak, R. J., **Coffey, C. S.**, Goldstein, J. M., Dimachkie, M., Benatar, M., O'Connor, K. C., Kissel, J., Hafner, D. A., Barohn, R., Cudkovicz, M. & for the NeuroNEXT NN103 Study Team. (2015). A phase 2 trial of Rituximab in myasthenia gravis: Study update. Annual Meeting of the American Neurological Association (Chicago, IL).

107. Lyden, P., Weymer, S., **Coffey, C. S.**, Cudkowicz, M., Fisher, M., Haley, E. C., Khatri, P., Saver, J., Levine, S., Levy, H., Pryor, K., Rymer, M. & Wechsler, L. (2016). Selecting patients for intra-arterial therapy in the context of a clinical trial for neuroprotection. International Stroke Conference (Los Angeles, CA).
108. Gums, T. H., Anderegg, M. D., Uribe, L., **Coffey, C. S.** & Carter, B. L. (2016). Physician-pharmacist collaboration: Overcoming socioeconomic barriers. Annual Meeting of the American Society for Hypertension (New York, NY).
109. Jennings, D., **Coffey, C.**, Beach, T., Foroud, T., Adler, C. H., Mollenhauer, B., Seibyl, J., Ecklund, D., Lasch, S., Arnedo, V. & Kopil, C. (2016). The Systemic Synuclein Sampling Study (S4). International Movement Disorders Congress (Berlin, Germany).
<https://www.mdscongress.org/Congress-2016-Files/PDFs/Final-Program.pdf> pg 129 and
<https://www.mdsabstracts.org/abstract/the-systemic-synuclein-sampling-study-s4/>
110. Simuni, T., Long, J., Caspell-Garcia, C., **Coffey, C. S.**, Lasch, S., Tanner, C., Jennings, D., Kiebertz, K. & Marek on behalf of the PPMI Investigators, K. (2016). Clinical and Biological Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease. International Movement Disorders Congress (Berlin, Germany). DOI: [10.1002/acn3.317](https://doi.org/10.1002/acn3.317)
111. Mollenhauer, B., Caspell-Garcia, C. J., **Coffey, C. S.**, Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Frasier, M., Marek, K. & Galasko, D. R. (2016). Longitudinal Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease and Healthy Controls. International Movement Disorders Congress (Berlin, Germany).
<https://www.mdsabstracts.org/abstract/longitudinal-cerebrospinal-fluid-biomarkers-in-early-parkinsons-disease-and-healthy-controls/>
112. Oertel, W., Simuni, T., Caspell-Garcia, C., Long, J., **Coffey, C. S.**, Iranzo, A., Mayer, G., Chahine, L., Lasch, S. & Marek on behalf of the PPMI Sleep Working Group, K. (2016). Longitudinal Evolution of Possible REM Sleep Behavior Disorder in Early Parkinson's Disease. International Movement Disorders Congress (Berlin, Germany).
<https://www.mdsabstracts.org/abstract/longitudinal-evolution-of-possible-rem-sleep-behavior-disorder-in-early-parkinsons-disease/>
113. Simuni, T., Weintraub, D., Caspell-Garcia, C., Walker, M., **Coffey, C. S.**, Lasch, S., Tanner, C., Jennings, D., Kiebertz, K. & Marek on behalf of the PPMI Investigators, L. (2016). Baseline Prevalence and Longitudinal Evolution of Non-Motor Symptoms in Early Parkinson's Disease - PPMI Cohort. International Movement Disorders Congress (Berlin, Germany).
<https://www.mdsabstracts.org/abstract/baseline-prevalence-and-longitudinal-evolution-of-non-motor-symptoms-in-early-parkinsons-disease-ppmi-cohort/>
114. Kearney Chase, M., Ecklund, D., Bosch, M., Thornell, B., **Coffey, C.** & Cudkowicz, M. (2016). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trials. Poster Presentation, American Neurological Association Annual Meeting (Baltimore, MD). DOI: [10.1002/ana.24759](https://doi.org/10.1002/ana.24759)
115. Linder, C., Mollenhauer, B., **Coffey, C.**, Beach, T. G., Foroud, T., Adler, C. H., Riss, H., Ecklund, D., Caspell-Garcia, C., Dave, K. D., Deshpande, S., Lasch, S., Arnedo, V., Riley, L., Jennings, D. & Chahine, L. (2017). Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Poster Presentation, American Academy of Neurology Annual Meeting (Boston, MA). DOI: [10.1212/WNL.88.16_supplement.P1.013](https://doi.org/10.1212/WNL.88.16_supplement.P1.013)
116. Foster, E., Mahoney, K., Ecklund, D., Kearney Chase, M., Bosch, M., Thornell, B., **Coffey, C.** & Cudkowicz, M. (2017). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Pre-Award Process and Experiences. Poster Presentation, Society for Clinical Trials Annual Meeting (Liverpool, UK).
117. Mollenhauer, B., Caspell-Garci, C. J., **Coffey, C. S.**, Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Naito, A., Reimer, A., Frasier, M., Marek, K. & Galasko for the Parkinson Progression Marker Initiative, D. (2017). Biological Analyses of PPMI Samples. PD Therapeutics Conference (New York, NY).

118. Naismith, R., **Coffey, C. S.**, Cudkowicz, M. E., Gleason, T., Goodman, A. D., Klawiter, E. C., Matsuda, K., McGovern, M. M., Conwit, R., Ashokkumar, A., Ecklund, D. J., Klingner, E., Koepp, M., Natarajan, S., Thornell, B., Yankey, J. W., Bermel, R., Huang, X., Lowe, M., Nakamura, K., Narayanan, S., Sakaie, K., Debbins, J., Zhou, X., Alvarez, E., Apperson, M. L., Bashir, K., Cohen, B. A., Coyle, P. K., Delgado, S., Dewitt, D., Flores, A., Giesser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S. G., Moses, H., Ontaneda, D. D., Perumal, J. S., Racke, M. K., Repovic, P., Riley, C. S., Severson, C. A., Shinnar, S., Suski, V., Weinstock-Gutman, B., Yadav, V., Zabeti, A. & Fox, R. J. (2017). SPRINT-MS/NN102 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results. Plenary Presentation at European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting (Paris, France).
119. Anderson, K., Hersch, S., Long, J., Cudkowicz, M., **Coffey, C.**, Yankey, J., Costigan, M., Raulerson, S., Berg, S., Conwit, R., Lungu, C., Brownstein, M. & Simon, L. (2017). Measurement of Huntington's Irritability and Aggression in the Azevan Pharmaceuticals-NeuroNEXT STAIR Study. Poster Presentation, Huntington's Study Group Annual Meeting (Denver, CO). DOI: [10.1007/s13311-017-0579-y](https://doi.org/10.1007/s13311-017-0579-y)
120. Raulerson, S., Berg, S., Costigan, M., Hersch, S. M., Anderson, K. E., Long, J., **Coffey, C. S.**, Yankey, J., Cudkowicz, M., Conwit, R., Longu, C., Brownstein, M. J. & Simon, N. G. (2017). Safety and Tolerability of SRX246 in Irritable/Aggressive Subjects with Huntington's Disease (STAIR): A Phase II Exploratory Clinical Trial. Poster Presentation, Huntington's Study Group Annual Meeting (Denver, CO). DOI: [10.1007/s13311-017-0579-y](https://doi.org/10.1007/s13311-017-0579-y)
121. Lyden, P., **Coffey, C. S.**, Cudkowicz, M., Conwit, R. A., Pryor, K. E. & on behalf of the RHAPSODY Investigators. (2018). Final Results of The RHAPSODY Trial. Plenary Presentation at the International Stroke Conference (Los Angeles, CA).
122. Naismith, R., **Coffey, C. S.**, Cudkowicz, M. E., Gleason, T., Goodman, A. D., Klawiter, E. C., Matsuda, K., McGovern, M. M., Conwit, R., Ashokkumar, A., Ecklund, D. J., Klingner, E., Koepp, M., Natarajan, S., Thornell, B., Yankey, J. W., Bermel, R., Huang, X., Lowe, M., Nakamura, K., Narayanan, S., Sakaie, K., Debbins, J., Zhou, X., Alvarez, E., Apperson, M. L., Bashir, K., Cohen, B. A., Coyle, P. K., Delgado, S., Dewitt, D., Flores, A., Giesser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S. G., Moses, H., Ontaneda, D. D., Perumal, J. S., Racke, M. K., Repovic, P., Riley, C. S., Severson, C. A., Shinnar, S., Suski, V., Weinstock-Gutman, B., Yadav, V., Zabeti, A. & Fox, R. J. (2018). SPRINT-MS/NN102 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results. Poster Presentation, American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting (San Diego, CA).
123. Qidwai, J., Kearney Chase, M., Ecklund, D., Bosch, M., Thornell, B., **Coffey, C.** & Cudkowicz, M. (2018). Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Update on Success and Five-Year Renewal Application. Poster Presentation, American Society for Experimental Neurotherapeutics (ASENT) Meeting (Washington, DC). DOI: [10.1007/s13311-018-0641-4](https://doi.org/10.1007/s13311-018-0641-4) [https://www.neurotherapeuticsjournal.org/article/S1878-7479\(23\)01064-4/pdf](https://www.neurotherapeuticsjournal.org/article/S1878-7479(23)01064-4/pdf) pg 14/832
124. Nowak, R. J., **Coffey, C.**, Goldstein, J. M., Dimachkie, M. M., Benatar, M., Huq, S. N., Pearson, B., Herbelin, L., O'Connor, K. C., Conwit, R., Kissel, J. T., Hafler, D. A., Cudkowicz, M. E., Barohn, R. J. & on behalf of the NeuroNEXT NN103 BeatMG Study Team. (2018). B Cell Targeted Treatment in Myasthenia Gravis (BeatMG) - A Phase 2 Trial of Rituximab in MG: Topline Results. Poster Presentation, American Academy of Neurology Annual Meeting (Los Angeles, CA). DOI: [10.1212/WNL.0000000000005692](https://doi.org/10.1212/WNL.0000000000005692)
125. Fox, R. J., **Coffey, C. S.**, Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Conwit, R., Naismith, R., Ashokkumar, A., Barnes, J., Ecklund, D., Klingner, E., Koepp, M., Natarajan, S., Thornell, B., Yankey, J., Bermel, R. A., Huang, X., Lowe, M. J., Nakamura, K., Narayanan, S., Sakaie, K. E., Debbins, J. P., Zhou, X., Alvarez, E., Apperson, M., Bashir, K., Cohen, B., Coyle, P., Delgado, S., Dewitt, D., Flores, A., Giesser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S., Moses, H., Ontaneda, D., Perumal, J., Racke, M., Repovic, P., Riley, C., Severson, C., Shinnar, S., Suski, V., Weinstock-Guttman, B., Yadav, V., Zabeti, A. & on behalf of the NN102/SPRINT-MS Instigators. (2018). A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis. Clinical Trials Plenary Session, American Academy of Neurology Annual Meeting (Los Angeles, CA). DOI: [10.1212/WNL.90.15_supplement.CT.004](https://doi.org/10.1212/WNL.90.15_supplement.CT.004)

126. Seedorff, N., Black, J., Conwit, R., Lewis, R., **Coffey, C.**, Gutmann, L. & Meurer, W. (2018). The National Institute of Neurological Disorders and Stroke Clinical Trials Methodology Course: Outcomes of Trainees after 3 Years. Poster Presentation, Society for Clinical Trials Annual Meeting (Portland, OR). DOI: [10.1177/1740774518790846](https://doi.org/10.1177/1740774518790846)
<https://journals.sagepub.com/doi/pdf/10.1177/1740774518790846> pg 173
127. Simuni, T., Caspell-Garcia, C., Long, J., **Coffey, C. S.**, Oertel, W., Lasch, S., Marek, K. & on behalf of the PPMI Sleep Working Group. (2018). Longitudinal Evolution of Excessive Daytime Sleepiness in Early Parkinson's Disease. International Movement Disorders Congress (Berlin, Germany).
<https://www.mdscongress.org/Congress-2016-Files/PDFs/Final-Program.pdf> pg 67 and
<https://www.mdsabstracts.org/abstract/longitudinal-evolution-of-excessive-daytime-sleepiness-in-early-parkinsons-disease/>
128. Chahine, L. M., Beach, T., **Coffey, C. S.**, Caspell-Garcia, C., Adler, C., Serrano, G., Mosovsky, S., Foroud, T., Linder, C., Riss, H., Ecklund, D., Seibyl, J., Mallya, A., Arnedo, V., Riley, L., Dave, K., Jennings, D. & Mollenhauer, B. (2018). Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Poster Presentation, Annual Movement Disorders Society Meeting (Hong Kong).
<https://www.mdsabstracts.org/abstract/multisite-tissue-and-biofluid-sampling-for-alpha-synuclein-in-parkinsons-disease-the-systemic-synuclein-sampling-study-s4/> and
<https://www.mdscongress.org/Congress-2018-Files/Abstracts/BasicScienceAbstracts.pdf> pg 12
129. Simon, N., Hersch, S., Anderson, K., Long, J., Ecklund, D., Costigan, M., Thornell, B., Gladden, C., **Coffey, C. S.**, Cudkovicz, M. & Brownstein, M. Irritability in Huntington's Disease. (2018). A Phase 2 Exploratory Clinical Trial with a Novel Vasopressin 1a Antagonist SRX246. Poster Presentation, American College of Neurosychopharmacology Annual Meeting (Hollywood, FL).
130. Simuni, T., Fiske, B., Merchant, K., **Coffey, C. S.**, Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD PSG Investigators NILO-PD. (2019). A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update. Poster Presentation, Alzheimer's & Parkinson's Disease Congress (Portugal, Spain). DOI: [10.1212/WNL.92.15_supplement.P3.8-035](https://doi.org/10.1212/WNL.92.15_supplement.P3.8-035)
131. Welhaven, A. E., **Coffey, C. S.** & Foster, E. D. (2019). Evaluation of Continual Reassessment Method with Lagged Cohort. Oral Presentation, Society for Clinical Trials Annual Meeting (New Orleans, LA). DOI: [10.1177/1740774520907457](https://doi.org/10.1177/1740774520907457)
132. Simuni, T., Fiske, B., Merchant, K., **Coffey, C. S.**, Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD PSG Investigators NILO-PD. (2019). A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update. Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA). DOI: [10.1212/WNL.90.15_supplement.P5.068](https://doi.org/10.1212/WNL.90.15_supplement.P5.068)
133. Bermel, R. A., Barnes, J., Yankey, J., Zahn, E., Natarajan, S., **Coffey, C. S.**, Goodman, A., Klawiter, E. C., Matsuda, K., Naismith, R. T., Fox, R. J. & on behalf of the SPRINT-MS Investigators Effect of Ibudilast on Macular Measures in Progressive MS. (2019). OCT Analysis from a Phase II Trial. Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA). DOI: [10.1212/WNL.92.15_supplement.P3.2-049](https://doi.org/10.1212/WNL.92.15_supplement.P3.2-049)
134. Fox, R. J., Kuhle, J., Karafa, M., Konig, V., Natarajan, S., Bermel, R. A., **Coffey, C. S.**, Goodman, A., Klawiter, E. C., Matsuda, K., Naismith, R. T. & on behalf of the SPRINT-MS Investigators Effect of Ibudilast on Serum Neurofilament in Progressive MS. (2019). Analysis from a Phase II Trial. Poster Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA). DOI: [10.1212/WNL.92.15_supplement.P3.2-033](https://doi.org/10.1212/WNL.92.15_supplement.P3.2-033)

135. Goodman, A., Barnes, J., Yankey, J., Zahn, E., Natarajan, S., Bermel, R., **Coffey, C. S.**, Klawiter, E. C., Matsuda, K., Naismith, R. T., Fox, R. J. & on behalf of the SPRINT-MS Investigators Response to Treatment According to Progressive Disease Type. (2019). Analysis from a Phase II Progressive MS Trial of Ibudilast. Platform Presentation, American Academy of Neurology Annual Meeting (Philadelphia, PA). [DOI: 10.1212/WNL.92.15.supplement.S12.007](https://doi.org/10.1212/WNL.92.15.supplement.S12.007)
136. Pauli, G., Kuszak, A., Bloss, G., Fukagawa, N., Jafari, M., Walters, M., Barrett, B., Bushman, F., Casper, S., Chilton, F., **Coffey, C. S.**, Feruzzi, M., Hopp, C., Kiely, M., Lakens, D., MacMillan, J., Meltzer, D., Paul, J., Pritchett-Corning, K., Quinney, S., Ross, S., Seifried, J., Setchell, K., Sipes, N., Stephens, J., Taylor, D., Tiriach, H., Xi, D., Hoffman, F. A. & Sorkin, B. (2019). Highlights from a Workshop on Enhancing Natural Product Clinical Trials. Poster Presentation, American Society of Pharmacognosy Meeting (Madison, WI).
<http://aspmeetings.pharmacognosy.us/wp-content/uploads/2019/07/ASP2019-Electronic-Program-and-Abstract-Book-Final.pdf> - pg 113
137. Nowak, R. J., **Coffey, C. S.**, Goldstein, J. M., Yankey, J. W., Uribe, L., Dimachkie, M. M., Benatar, M., Wolfe, G. I., Burns, T., Pearson, B., O'Connor, K. C., Conwit, R., Kissel, J. T., Hafler, D. A., Cudkovicz, M. E., Barohn, R. J. & on behalf of the NeuroNEXT NN103 BeatMG Study Team. (2019). Rituximab Response in Patients with Moderate to Severe Myasthenia Gravis (MG): A Subgroup Analysis of the BeatMG Study. Platform Presentation, American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting (Austin, TX). [DOI: 10.1002/mus.26647](https://doi.org/10.1002/mus.26647)

Non-peer-reviewed journal articles

1. Bullitt, E., Aylward, S., Liu, A., Stone, J., Mukherji, S., **Coffey, C.**, Gerig, G. & Pizer, S. M. (1999). 3D graph description of the intracerebral vasculature from segmented MRA and tests of accuracy by comparison with x-ray angiograms. (Vols. 1613). pp. 308-321. Lecture Notes in Computer Science.
2. **Coffey, C. S.** & Muller, K. E. (2001). GLUMIP 1.0: Free SAS/IML Software for Internal Pilots. 2001 Proceedings of the Joint Statistical Meetings, Biopharmaceutical Section.
3. **Coffey, C. S.** & Muller, K. E. (2003). Practical methods for bounding test size with an internal pilot design. (Vols. Biopharmaceutical Section). 2003 Proceedings of the Joint Statistical Meetings.
4. Ritchie, M. D., **Coffey, C. S.** & Moore, J. H. (2005). Genetic programming neural networks as a bioinformatics tool for human genetics. (Vols. 3102). pp. 438-448. Lecture Notes in Computer Science: Genetic and Evolutionary Computation – GECCO 2004 Conference Proceedings.
5. Kairalla, J. A., **Coffey, C. S.** & Muller, K. E. (2010). Achieving the benefits of both an internal pilot and interim analysis in small samples. (Vols. ENAR Section). pp. 5239-5252. 2010 Proceedings of the Joint Statistical Meetings.

Conference Proceedings

1. Hoffman on behalf of Workshop Participants and the TREAT-NMD Alliance, E. P. (2017). Facilitating orphan drug development: Proceedings of the TREAT-NMD International Conference, December 2015, Washington, DC, USA. (Vols. 27). (7), pp. 693-701. *Neuromuscular Disorders*. [DOI: 10.1016/j.nmd.2017.02.013](https://doi.org/10.1016/j.nmd.2017.02.013). [PMID: 28434909](https://pubmed.ncbi.nlm.nih.gov/28434909/).

Research Interests/Current Projects

- Adaptive Designs
- Power Analyses
- Sample Size Re-Estimation
- Clinical Trials

Grants and Contracts

Active (Funded)

1. 2023-2024 PPMI Statistics Core; Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher (Principal Investigator)
 - MJFF-023606
 - Jul 1, 2020 - Jun 30, 2024
 - Amount: \$3,364,220.92, 30% effort
2. A Phase 3 clinical trial of an e-health behavioral intervention to improve executive functioning in adolescents with epilepsy; Coffey, Christopher (Principal Investigator)
 - OS00000864 / 401502
 - Feb 27, 2024 - Jan 31, 2025
 - Amount: \$1,112,162.00, 15% effort
3. Clinical Coordinating Center for the Acute to Chronic Pain Signatures Program-Admin Supplement restricted to A2CPS Project Goals; National Institutes of Health; Coffey, Christopher (Principal Investigator), Sluka, Kathleen (Principal Investigator), Frey Law, Laura (Principal Investigator)
 - U24 NS112873
 - Aug 15, 2019 - Jul 21, 2025
 - Amount: \$11,030,472.00, 15% effort
4. (Iowa ISIB) Summer Institute for Research Education in Biostatistics and Data Science; National Institutes of Health; Coffey, Christopher (Co-Investigator), Zamba, Gideon (Principal Investigator)
 - R25 HL161716
 - Mar 1, 2022 - Feb 28, 2027
 - Amount: \$1,280,640.00, 2% effort
5. NN111: A Phase-2, Double-Blind, Randomized Controlled Trial to Evaluate the Activity and Safety of Inebilizumab in Anti-NMDA Receptor Encephalitis; University of Utah, National Institutes of Health; Coffey, Chris (Principal Investigator)
 - 10057564-02-IOWA; U01 NS120901
 - Sep 15, 2021 - Aug 31, 2027
 - Amount: \$1,433,333.00
6. Network of Excellence in Neuroscience Clinical Trials (NeuroNEXT) - DCC; NIH/NINDS; Coffey, Christopher (Principal Investigator)
 - U01 NS077352
 - Sep 30, 2011 - Jun 30, 2028
 - Amount: \$32,365,611.00, 30% effort
 - The University of Iowa will provide infrastructure to facilitate rapid development and implementation of protocols for conducting clinical trials in neuroscience. The infrastructure is designed to accommodate dynamically changing requirements that naturally occur in clinical trials (both planned and unplanned). The proposed DCC will provide more rapid evaluation of promising treatments in neuroscience, and will be a model that can be replicated across a number of studies and diseases.

Completed

1. UT-15 Open Grant in Pulmonary Hypertension (Cardiovascular Disease); United Therapeutics; Coffey, Christopher (Statistician)
 - Oct 1, 2001 - Apr 1, 2005

2. Modulation of Innate Immunity in Lung Transplantation; NIH/HLBI R01 HL72871; Coffey, Christopher (Statistician), Malton, S (Principal Investigator)
 - R01 HL72871
 - Sep 30, 2002 - Jul 31, 2006
3. Genetic Variants and Thrombosis: Renin Angiotensin; NIH/NHLBI R01 HL99015; Coffey, Christopher (Principal Investigator), Hebert, PR (Principal Investigator)
 - R01 HL99015
 - Apr 1, 2001 - Jul 31, 2007
4. Design and Analysis of Microarray Gene Expression Studies in Plants: Towards Sound Statistical Principles; NSF-01-158; Coffey, Christopher (Co-Investigator), Page, G (Principal Investigator)
 - NSF-01-158
 - Jan 1, 2003 - Dec 31, 2007
5. Internal Pilots for Repeated Measures ANOVA; NIH/NCH R01 CA095749; Coffey, Christopher (Principal Investigator), Muller, K E (Principal Investigator)
 - R01 CA095749
 - Jan 15, 2003 - Dec 31, 2007
6. Secondary Prevention of Small Subcortical Strokes; NIH/NINDS U01 NS038529; Coffey, Christopher (Principal Investigator), Benavente, OR (Principal Investigator)
 - U01 NS038529
 - Mar 1, 2003 - Jan 31, 2008
7. Effects of Intentional Weight Loss on Mortality Rate; NIH/NIDDK R01 KD067487; Coffey, Christopher (Co-Investigator), Allison, DB (Principal Investigator)
 - R01 DK067487
 - Jan 1, 2005 - Dec 31, 2008
8. Levels of Inflammatory Markers in the Treatment of Stroke; NIH/NINDS R01 NS050724; Coffey, Christopher (Principal Investigator), Elkind, MSV (Principal Investigator)
 - R01 NS050724
 - May 25, 2005 - Apr 30, 2009
9. Pharmacogenomics in Pulmonary Arterial Hypertension; NIH/NHLBI R01 HL078946; Coffey, Christopher (Statistician), Benza, RL (Principal Investigator)
 - R01 HL078946
 - Sep 1, 2005 - Jul 31, 2009
10. Merck Quantitative Science Fellowship Program; Merck; Coffey, Christopher (Principal Investigator)
 - Aug 22, 2007 - Aug 21, 2009
11. Carotid Occlusion Surgery Study (COSS): Data Management Center; NIH/NINDS U01 NS041985; Coffey, Christopher (Co-Investigator), Clarke, W R (Principal Investigator)
 - U01 NS041985
 - Aug 1, 2009 - Dec 1, 2010
12. Clinical Islet Transplantation: Data Coordinating Center; National Institutes of Health; Coffey, Christopher (Co-Investigator), Clarke, William (Principal Investigator)
 - U01 DK070431
 - Aug 1, 2009 - Oct 1, 2011
13. Adaptive Comparative Effectiveness Trials for Comparing Two Treatments; University of Florida; Coffey, Christopher (Principal Investigator), Nelson, David (Principal Investigator)

- UF 11128
 - May 23, 2011 - Mar 31, 2012
14. Secondary Prevention of Small Subcortical Strokes (SPS3); NIH/NINDS U01 NS038529; Coffey, Christopher, Benavente, O R (Principal Investigator)
 - U01-NS038529
 - Dec 1, 2009 - Dec 31, 2013
 15. A Collaborative Model to Improve BP Control and Minimize Racial disparities – DCC; NIH/NHLBI; Coffey, Christopher (Principal Investigator)
 - 5 R01 HL091843
 - Aug 1, 2009 - Feb 28, 2015
 - Amount: \$3,655,085.00, 20% effort
 - The Data Coordinating Center will support the data collection, data management, clinical site support and monitoring, and statistical analyses for the Caption study.
 16. NN101 Sub Award: SMA Biomarkers in the Immediate Post-Natal Period of Development; National Institutes of Health; Coffey, Christopher, Kolb, S (Principal Investigator)
 - U01 NS079163
 - Aug 15, 2012 - Jul 31, 2016
 17. LRRK2 Cohort Consortium - Statistics; The Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher (Principal Investigator)
 - Jun 2, 2011 - Jun 30, 2017
 - Amount: \$197,168.00, 5% effort
 - The Statistics Team of LRRK2 will conduct on-going analysis of centralized database information and perform data integrity checks, advise and participate in Project Working Groups, develop statistical recommendations for the project, and perform statistical analyses on collected project data.
 18. Clinical Islet Transplantation: Data Coordinating Center (CIT:DCC); NIH/NIDDK U01 DK070431; Coffey, Christopher (Co-Investigator), Clarke, W R (Principal Investigator)
 - 5 U01 DK070431
 - Aug 1, 2009 - Jul 31, 2017
 19. NN103 Sub Award: A Phase II Trial of Rituximab in Myasthenia Gravis; National Institutes of Health; Coffey, Christopher, Nowak, R (Principal Investigator)
 - U01 NS088312
 - Sep 15, 2013 - Jul 31, 2017
 20. Amitriptyline and Topiramate in the Prevention of Childhood Migraine: DCC; NIH/NINDS U01 NS077108; Coffey, Christopher (Principal Investigator)
 - 5 U01 NS077108
 - Sep 30, 2011 - Aug 31, 2017
 - Amount: \$352,387.00
 - The University of Iowa will develop and support a web-based distributed data entry system with the capability to quickly, efficiently, and accurately randomize subjects and collect data generated by the clinical trial; provide project management support for the trial; support trial-wide safety monitoring; and provide study design and statistical leadership for the trial.
 21. NN102 Sub Award: Ibutilast in Phase II Trial in Progressive MS; National Institutes of Health; Coffey, Christopher, Fox, R (Principal Investigator)
 - U01 NS082329

- Jul 15, 2013 - Jun 30, 2018
22. NN104 Sub Award: ZZ3K3A-201: Safety Evaluation of 3K3A-APC in Ischemic Stroke; National Institutes of Health; Coffey, Christopher, Lyden, P (Principal Investigator)
 - U01 NS088312
 - Jul 10, 2014 - Jun 30, 2018
 23. NN105 Sub Award: Tolerability of SRX246 in Huntington's Disease Patients; National Institutes of Health; Coffey, Christopher, Brownstein, M (Principal Investigator)
 - U44 NS090616
 - Sep 1, 2015 - Aug 31, 2018
 24. Scans Without Evidence of Dopaminergic Degeneration (SWEDD); The Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher
 - Jun 24, 2010 - Dec 31, 2018
 - Amount: \$2,262,515.00
 25. Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), a Parkinson's Progression Markers Initiative (PPMI) Sub-Study; The Michael J Fox Foundation for Parkinson's Research; Coffey, Christopher (Principal Investigator)
 - PPMI 2013
 - Mar 1, 2014 - Feb 28, 2019
 - Amount: \$44,000.00, 5% effort
 - "Expanded support for Stats Core-supplement." PPMI Sub-study to participate in an ancillary project focused on assessing an objective measurement device entitled "Three Site Assessment of the Potential for Home Dexterity Monitoring in a PD Biomarker Study (TAP-PD), A Parkinson's Progression Markers Initiative (PPMI) Sub-study." The PPMI Statistics Core will provide analysis of data collected through TAP-PD
 26. Amyloid Imaging -- PPMI Sub Study; The Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher
 - Mar 1, 2014 - Feb 28, 2019
 - This is a sub-study focused on integrating amyloid imaging into PPMI. The DCC is responsible for analysis of collected amyloid imaging data.
 27. Iowa Summer Institute for Research Education in Biostatistics (ISIREB); National Institutes of Health; Coffey, Christopher (Co-Investigator), Zamba, Gideon (Principal Investigator)
 - 1 R25 HL131467
 - Feb 15, 2016 - Mar 31, 2019
 - Amount: \$233,111.00, 2% effort
 - This is a proposal to the National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI), from the University of Iowa, in response to RFA-HL-16-017 for a Summer Institute for Research Education in Biostatistics. The ultimate vision of our proposed research education program is to increase the number of undergraduates who enter graduate programs in Biostatistics and to maintain a solid underrepresented minority pipeline into biostatistics graduate programs. The proposal is for the University of Iowa (UI) Department of Biostatistics to recruit a diverse group of 18 trainees each year, from 2016 to 2018, with focus on minority, underrepresented and disadvantaged students who wouldn't have otherwise been exposed to the field of biostatistics.
 28. Systemic Synuclein Sampling Study (S4) - Clinical, Data Management & Statistical Core; The Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher (Principal Investigator)
 - May 27, 2015 - Dec 31, 2019

- Direct Cost: \$149,522.00, 5% effort
 - The primary objective is to characterize the distribution of aSyn pathology through evaluation of multiple tissues and body fluids in individual subjects with clinically typical PD to evaluate the potential for markers of aSyn as an outcome measure for clinical trials.
29. Enhancing Scientific Inquiry in Clinical Neurosciences Through Methodology Training, Mentorship, and Trans-Institutional Cooperation; University of Michigan; Coffey, Christopher (Co-Director)
- 3003150719
 - Apr 1, 2014 - Mar 31, 2020
 - Direct Cost: \$41,222.00, 15% effort
 - The research education strategy for this proposal employs a multiple program director (PD) methodology. The University of Iowa Co-Program Director is responsible for the aspects of the educational plan related to biostatistics and data management (primary responsibility); responsible for serving as a core faculty member and co-lead small groups as defined in the research education approach; responsible for ensuring that the protocols developed within this course adhere to the standards of scientific rigor outlined in the NINDS guidelines.
30. MEDication Focused Outpatient Care for Underutilization of Secondary Prevention; National Institutes of Health; Coffey, Christopher, Carter, Barry (Principal Investigator)
- 1 R18 HL116259
 - Apr 1, 2014 - Mar 31, 2020
 - Amount: \$955,308.00, 15% effort
 - The primary aim is to determine if a web-based centralized cardiovascular risk service (CVRS) managed by clinical pharmacists will be implemented within diverse primary care offices to help prevent death caused by cardiovascular disease. The Data Coordinating Center will support the data collection, data management, clinical site support and monitoring, and statistical analyses for the MEDFOCUS study.
31. NN107 Sub Award: Effects of AFQ056 on Language Learning in Young Children with Fragile X Syndrome (FXS); National Institutes of Health; Coffey, Christopher, Berry-Kravis, E (Principal Investigator)
- U01 NS096767
 - Sep 30, 2016 - Jun 30, 2020
32. NILO Study: Biostatistics Coordinating Center for Nilotinib Study; Northwestern University; Coffey, Christopher (Principal Investigator)
- SP0044300
 - Mar 1, 2017 - Aug 31, 2020
 - Amount: \$624,605.00, Direct Cost: \$10,742.00, 15% effort
 - Per the RFP, the Michael J. Fox Foundation for Parkinson's Research (MJFF) in collaboration with The Cure Parkinson's Trust (CPT) and Van Andel Research Institute are planning to conduct the study of Nilotinib in Parkinson's disease. This study will be a randomized, double-blind, placebo-controlled, phase IIa, parallel group, and two period study to define the safety, tolerability, and clinical and exploratory biological activity of the chronic administration of Nilotinib in subjects with Parkinson's disease (PD). The successful conduct of such clinical trials requires a robust collaboration between a Clinical Coordinating Center (CCC), Data Coordinating Center (DCC), Biostatistics Coordinating Center (BCC), the Sponsor, and the Clinical Sites where subjects are enrolled and followed. This application describes a collaborative effort to form a qualified and experienced Biostatistics Coordinating Center for the Nilotinib Study. As the BCC, the University of Iowa CTSDMC will provide analytical leadership to the study by providing study design and statistical leadership.

33. The Parkinson's Progression Markers Initiative Statistical Core; The Michael J. Fox Foundation for Parkinson's Research; Coffey, Christopher (Director)
- Jun 24, 2010 - Jun 30, 2021
 - Amount: \$207,565.00
 - The Michael J. Fox Foundation is currently conducting along-term study to follow 400 newly diagnosed patients with Parkinson's Disease and 200 healthy controls over a period of 3-5 years. One objective of the study is to investigate existing and novel clinical, imaging, and biomic Parkinson Disease progression markers to identify quantitative individual measures or combinations of measures that demonstrate optimum interval change in PD patients in comparison to healthy controls, or in subsets of PD patients defined by baseline assessments.
34. Iowa Summer Institute for Research Education in Biostatistics (ISIREB); National Institutes of Health; Coffey, Christopher (Co-Investigator), Zamba, Gideon (Principal Investigator)
- R25 HL147231
 - Mar 1, 2019 - Feb 28, 2022
 - Direct Cost: \$239,289.00, 2% effort
 - This is a proposal to the National Institutes of Health (NIH), National Heart, Lung and Blood Institute (NHLBI), from the University of Iowa, in response to RFA-HL-19-019 for an Iowa Summer Institute for Research Education in Biostatistics (ISIREB), Summer Programs 2019, 2020, & 2021.
35. Cytochrome C Oxidase: Biomarker in Newly Diagnosed Glioblastoma Multiforme; National Institutes of Health; Coffey, Christopher (Co-Investigator), Griguer, Corinne (Principal Investigator)
- U01 NS093663
 - Sep 30, 2016 - Jun 30, 2022
36. Acute to Chronic Pain Signatures Program/Clinical Coordinating Center; NIH; Coffey, Christopher (Co-Principal), Sluka, Kathleen (Co-Principal)
- U24 NS112873
 - Aug 15, 2019 - Jul 31, 2023
 - 17% effort
 - The Acute to Chronic Pain Signatures (A2CPS) Program aims to identify biomarkers and their collective biosignatures (a combination of several individual biomarkers) that predict susceptibility or resilience to the development of chronic pain after an acute pain event through the development of a large consortium. The Clinical Coordinator Center applies thorough and well-organized principles to facilitate, support and enhance the scientific rigor and effectiveness of key stakeholders for the identification of critical biomarkers for the acute to chronic pain transition. The success of the A2CPS Program is dependent on effective management and coordination of activities across the consortium.

Presentations

Keynote/Plenary Address

- | | |
|----------|---|
| Apr 2015 | Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Presented at 8th Annual ADVAMed Statistics Workshop, American Statistical Association, Washington, District of Columbia. |
|----------|---|

Oct 2017 Fox, R. J., Coffey, C. S., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Conwit, R., Naismith, R., Ashokkumar, A., Ecklund, D., Koeppe, M., Long, J., Natarajan, S., Skaramagas, T., Thornell, B., Yankey, J., Bermel, R., Huang, X., Lin, J., Lowe, M., Nakamura, K., Narayanan, S., Sakaie, K. E., Debbins, J. P., Zhou, X., Alvarez, E., Apperson, M., Bashir, K., Cohen, B., Coyle, P., Delgado, S., Dewitt, D., Flores, A., Geisser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S., Moses, H., Ontaneda, D., Perumal, J., Racke, M., Repovic, P., Riley, C., Severson, C., Shinnar, S., Suski, V., Weinstock-Gutman, B., Yadav, V., Zabeti, A. & on behalf of the NN102/SPRINT-MS Study Investigators SPRINT-MS/NN102 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results. Presented at ECTRIMS Annual Meeting, European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), Paris, France.

Invited Lectures

- 1999 Coffey, C. S. Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors. Presented at Middle Tennessee Chapter, American Statistical Association, Nashville, Tennessee.
- Aug 1999 Coffey, C. Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors. Presented at Annual Meeting of General Clinical Research Center Statisticians, Baltimore, Maryland.
- Sep 1999 Coffey, C. Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors. Presented at Gertrude M. Cox Building Dedication and Statistical Symposium, Research Triangle Institute, Research Triangle Park, North Carolina.
- 2000 Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors. University of Alabama, Birmingham, Alabama.
- Aug 2001 Coffey, C. S. & Mueller, K. J. GLUMIP 1.0: Free SAS IML Software for Planning Internal Pilots. Presented at Annual Joint Statistical Meetings, Atlanta, Georgia.
- Aug 2001 Coffey, C., Hebert, P. & Moore, J. Is There an Interaction Between the ACE I/D and PAI-1 4G/5G Gene Polymorphisms on Risk of Myocardial Infarction?. Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
- Apr 2003 Coffey, C. Exact and Approximate Methods for Internal Pilots: Beyond Two Group Comparisons. Presented at Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society, Tampa, Florida.
- Jun 2004 Coffey, C. An Overview of Adaptive Designs with Emphasis on Internal Pilots. Presented at National Institute of Neurological Disorders and Stroke, Clinical Trials Program, Bethesda, Maryland.
- Nov 2004 Coffey, C. Promises and Pitfalls of Modifying the Sample Size During a Study: Adaptive and Internal Pilot Designs. Presented at Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Jan 2005 Coffey, C. Internal Pilots and Power Adjustments for Controlled Clinical Trials. Presented at Center for Aging/VA GRECC, University of Alabama at Birmingham, Birmingham, Alabama.
- Apr 2005 Coffey, C. Sample Size Adjustments Using Internal Pilot Designs for Repeated Measures ANOVA. Presented at Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.

- Aug 2005 Coffey, C. Using Internal Pilot Designs with Repeated Measures. Presented at Annual Joint Statistical Meetings, Minneapolis, Minnesota.
- Oct 2005 Coffey, C. An Overview of Adaptive Designs with Emphasis on Internal Pilots. Presented at Center for Nursing Research Seminar Series, University of Alabama at Birmingham, Birmingham, Alabama.
- Nov 2005 Coffey, C. S. An Overview of Adaptive Designs with Emphasis on Internal Pilots. Presented at Medical Statistics Section Seminar Series, University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, Alabama.
- Mar 2006 Coffey, C. S. An Overview of Adaptive Designs with Emphasis on Internal Pilots. Presented at Health Services Administration Doctoral Seminar, University of Alabama at Birmingham, Birmingham, Alabama.
- Mar 2006 Coffey, C. Internal Pilot Designs for Medical Imaging Studies. Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
- Apr 2006 Coffey, C. Adaptive and Internal Pilot Designs. Department of Public Health, East Tennessee State University, Johnson City, Tennessee.
- Jun 2006 Coffey, C. Adaptive and Internal Pilot Designs. Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, Florida.
- Aug 2006 Coffey, C. An Introductory Overview Lecture on Adaptive Designs/Internal Pilots. Presented at Annual Joint Statistical Meetings, Seattle, Washington.
- Dec 2006 Coffey, C. Adaptive and Internal Pilot Designs. Department of Neurology, Columbia University Medical Center, New York, New York.
- May 2007 Coffey, C. Activities of the Statistical Center for the Secondary Prevention of Small Subcortical Strokes (SPS3) Trial. Clinical Trials and Data Management Center, Department of Biostatistics, University of Iowa, Iowa City, Iowa.
- May 2007 Coffey, C. Clarifying the Controversy Surrounding Adaptive Designs for Sample Size Re-Estimation. Department of Biostatistics, University of Iowa, Iowa City, Iowa.
- May 2007 Coffey, C. Clarifying the Controversy Surrounding Adaptive Designs for Sample Size Re-Estimation. Department of Epidemiology and Health Policy Research, University of Florida, Gainesville, Florida.
- May 2007 Coffey, C. Treatment Effect in Sample Size Determination: Clinical vs. Statistical Significance. Annual Meeting of the Society for Clinical Trials, Montreal, Canada.
- Aug 2007 Coffey, C. Advantages and Disadvantages When Implementing an Adaptive Design in an NIH-Funded Study. Presented at Joint Statistical Meetings, Salt Lake City, Utah.
- Aug 2008 Coffey, C. Internal Pilot Designs for Cluster Samples. Presented at Joint Statistical Meetings, Denver, Colorado.
- Oct 2008 Coffey, C. Internal Pilot Designs: An Overview and Recent Extensions. College of Public Health, The Ohio State University, Columbus, Ohio.
- Nov 2008 Coffey, C. Internal Pilot Designs: An Overview and Recent Extensions. Department of Public Health Sciences, The University of Virginia, Charlottesville, Virginia.
- Dec 2008 Coffey, C. Internal Pilot Designs: They're Not Just for Clinical Trials Anymore. Department of Biostatistics, University of Iowa, Iowa City, Iowa.

- Apr 2009 Coffey, C. Avoiding the Pitfalls of a Meta-Analysis. Presented at Third Annual Methods in Epidemiology and Outcomes Research Symposia, The University of Alabama at Birmingham, Birmingham, Alabama.
- Jun 2009 Coffey, C. The Emerging Role of the Data and Safety Monitoring Board: Implications of Adaptive Clinical Trial Designs. Presented at Annual Meeting of the Southern Research Council on Statistics, Jekyll Island, Georgia.
- Aug 29, 2018 Coffey, C. We Built This Network: How NeuroNEXT Increases Innovative Design in Academic Trials. Presented at CPH Distinguished Faculty Lecture, College of Public Health/University of Iowa, Iowa City, Iowa.

Oral Presentations

- Mar 1997 Coffey, C. Exact Test Size and Power of a Gaussian Error Linear Model for an Internal Pilot Study. Presented at Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society, Memphis, Tennessee.
- 1999 The Impact on Power of Controlling TestSize for an Internal Pilot Study. Presented at Annual Joint Statistical Meeting, Baltimore, Maryland.
- Aug 1999 Coffey, C. Approximations and Bounds on Test Size for an Internal Pilot Study. Presented at Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society, Atlanta, Georgia.
- 2000 Coffey, C. S. Biostatistics Shared Resource Three Week Workshop. Presented at Vanderbilt-Ingram Cancer Center, Nashville, Tennessee.
- Mar 2000 Coffey, C. Controlling Test Size While Gaining the Benefits of an Internal Pilot Design. Presented at Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society, Chicago, Illinois.
- Apr 2000 Coffey, C. S. Internal Pilot Study Design and Analysis for Gaussian Error Linear Models with Fixed Predictors. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama.
- Mar 2001 Coffey, C. Internal Pilot for the Univariate Approach to Repeated Measures. Presented at Annual Meeting of the Eastern North America Region (ENAR) of the Biometrics Society, Charlotte, North Carolina.
- Mar 2002 Coffey, C. A Comparison of Two Methods for Detecting Interactions Among Genetic Polymorphisms in Matched Case-Control Studies. Presented at Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society, Crystal City, Virginia.
- May 2003 Coffey, C. & Hebert, P. Reporting of Internal Prediction Errors in Case-Control Studies of Genetic Interactions. Presented at Annual Meeting of the Society for Clinical Epidemiology and Health Care Research, Vancouver, Canada.
- Aug 2003 Coffey, C. Practical Methods for Bounding Test Size with an Internal Pilot Design. Presented at Annual Joint Statistical Meeting, San Francisco, California.
- Mar 2004 Coffey, C. Controlling Bias in Internal Pilots with the Univariate Approach to Repeated Measures. Presented at Annual Meeting of the Eastern North American Region (ENAR) of the Biometrics Society, Pittsburgh, Pennsylvania.
- Aug 2004 Coffey, C. Internal Pilot Designs with Compound Symmetric and Gaussian Repeated Measures. Presented at Annual Joint Statistical Meeting, Toronto, Canada.

- May 2005 Coffey, C. S. & Mehta, C. Adaptive Designs and Clinical Trials (with C. Mehta). Presented at Annual Meeting of the Society for Clinical Trials, Society for Clinical Trials, Portland, Oregon.
- Sep 2005 Coffey, C. Premature Termination of Clinical Trials. Presented at 3rd Annual SPS3 Investigator's Meeting, Scottsdale, Arizona.
- Sep 2006 Coffey, C. Power in Time to Event Trials: Bigger Isn't Always Better. Presented at 4th Annual SPS3 Investigator's Meeting, San Antonio, Texas.
- Dec 2006 Coffey, C. Frequentist Adaptive Designs, Internal Pilots, and Stopping Rules. Presented at Conference on Design, Analysis, and Interpretation of Randomized Clinical Trials in Obesity, Newark, New Jersey.
- Oct 2009 Coffey, C. The Emerging Role of the Data and Safety Monitoring Board: Implications of Adaptive Clinical Trial Designs. University of Rochester, Rochester, New York.
- Nov 2009 Coffey, C. Adaptive Designs. Huntington Disease Study Group, Baltimore, Maryland.
- 2010 Biostatistics. Presented at Fourth Annual Iowa Mathematical Field of Dreams Conference.
- Mar 2011 Coffey, C. S. Adaptive Designs and Small Clinical Trials. Presented at Center for Drug Evaluation and Research Office of Biostatistics, US FDA, Silver Spring, Maryland.
- Mar 2011 Coffey, C. S. Adaptive Designs and Small Clinical Trials. Presented at Center for Biologics Evaluation and Research, US FDA, Rockville, Maryland.
- Mar 2011 Coffey, C. Adaptive Designs and Small Clinical Trials. Presented at FDA/Industry Workshop, US FDA Center for Drug Evaluation and Research Office of Biostatistics, Washington, District of Columbia.
- Apr 2011 Coffey, C. S. Design and Analysis Methods for Use in Small Clinical Trials. Presented at FDA Shortcourse, FDA.
- Apr 2011 Coffey, C. S. Hurdles and Future Work in Adaptive Designs. University of Pennsylvania Clinical Trials Symposium, Philadelphia, Pennsylvania.
- May 2011 Coffey, C. Adaptive Design for Clinical Trials: Perspectives from an NIH-Funded Workshop. Presented at Annual Meeting of the Society for Clinical Trials, Vancouver, Canada.
- May 2011 Coffey, C. S. Adaptive Design for Clinical Trials: Perspectives from an NIH-Funded Workshop. Presented at Drug Information Association (DIA) Adaptive Design Working Group KOL Lecture Series (webinar), DIA.
- May 2011 Coffey, C. S. Overview, Hurdles, and Future Work in Adaptive Designs. University of Kentucky, Lexington, Kentucky.
- Sep 2011 Coffey, C. S. Overview, Hurdles, and Future Work in Adaptive Designs. Presented at Industry Workshop, FDA.
- Oct 2011 Coffey, C. S. Adaptive Designs and Small Clinical Trials. Presented at FDA/Industry Workshop, FDA, Washington, District of Columbia.
- Oct 2011 Coffey, C. Adaptive Designs and Small Clinical Trials. Presented at U.S. Conference on Rare Diseases and Orphan Products, FDA, Washington, District of Columbia.
- Nov 2011 Coffey, C. S. Use of Adaptive Designs in Clinical Effectiveness Trials. Presented at Institute for Clinical and Translational Sciences Lecture Series, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

- Dec 2011 Coffey, C. S. Building a Clinical Studies Database. Presented at NINDS Sponsored Parkinson's Disease Biomarkers Resource Data Management Workshop, NIH, Bethesda, Maryland.
- 2012 Coffey, C. S. Presented at ICTS CER Course Lecture, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
- 2012 Coffey, C. S., Wittes, J. & Sackett, D. Challenges in Designing Small Clinical Trials. Presented at SCT Workshop, Society for Clinical Trials.
- Feb 2012 Coffey, C. S., Muller, K. E. & Shorr, R. I. Quantitative Pitfalls in Comparative Effectiveness Research and How to Avoid Them. Presented at Department of Internal Medicine Grand Rounds, University of Florida, Gainesville, Florida.
- Sep 2012 Coffey, C. S. Adaptive Designs (Short Course). Presented at Institute for Clinical and Translational Science (ICTS) CER Lecture Series, University of Iowa Hospitals and Clinics, Iowa City, Iowa.
- Mar 2013 Coffey, C. S. An Overview of Adaptive Designs. Presented at Colloquium, Department of Statistics, University of Iowa, Iowa City, Iowa.
- Mar 2013 Coffey, C. S. An Overview of Adaptive Designs. Presented at Seminar, College of Nursing Seminar Series, University of Iowa, Iowa City, Iowa.
- May 2013 Coffey, C. S., Cudkowicz, M., Kearney, M., Ecklund, D. & McNeil, E. Revolutionizing Clinical Trials by Creating Infrastructure for Phase 2 Trials in Neurological Disorders. Presented at Annual Society for Clinical Trials Meeting, ASCT - Invited Presentation, Boston, Massachusetts.
- Jul 2013 Coffey, C. S. Overview of Adaptive Designs, and Extensions Beyond Clinical Trials. Presented at Invited Presentation, East Tennessee State University College of Public Health, Johnson City, Tennessee.
- Sep 2013 Coffey, C. S. Overview, Hurdles, and Future Work in Adaptive Designs (Short Course). Presented at Short Course offered at FDA/Industry Workshop, FDA, Washington, District of Columbia.
- Jan 2014 Coffey, C. S. Adaptive Designs (Short Course). Presented at Two-Day Short Course sponsored by Rho, Inc., Rho, Inc., Chapel Hill, North Carolina.
- Feb 2014 Coffey, C. S. Adaptive Trial Designs. Presented at Workshop on 'Clinical Trial Design for Alpha-1 Antitrypsin Deficiency: A Model for Rare Diseases, Alpha-One Foundation, Bethesda, Maryland.
- Feb 2014 Coffey, C. S. Challenges in Designing Clinical Trials for Rare Diseases. Presented at FDA Industry Workshop, FDA, Washington, District of Columbia.
- Mar 2015 Coffey, C. S. Small Phase II Trials. Presented at ALS Association Patient Webinar Series, ALS Association.
- Apr 2015 Kolb, S., Coffey, C. S., Arnold, W., Rutkove, S., Bartlett, A., Kissel, J. & from the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators Initial Results from the NeuroNEXT SMA Infant Biomarker Study. Presented at Annual Meeting of the AAN, American Academy of Neurology, Washington, District of Columbia.
- Apr 2015 Kearney, M., Ecklund, D., Bosch, M., Thornell, B., McNeil, E., Cordell, J., Coffey, C. S. & Cudkowicz, M. Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trial Management. Presented at Annual Meeting of the AAN, American Academy of Neurology, Washington, District of Columbia.

- Apr 2015 Fox, R., Coffey, C. S., Cudkowicz, M., Gleason, T., Goodman, A., Klawiter, E., Matsuda, K., McGovern, M., McNeil, E., Naismith, R. & Yankey, J. NN102/SPRINT-MS Phase II Trial of Ibudilast in Progressive MS: Baseline Characteristics. Presented at Annual Meeting of the AAN, American Academy of Neurology, Washington, District of Columbia.
- Apr 2015 Coffey, C. S. Overview of the Clinical Trials Statistical and Data Management Center & NeuroNEXT. Presented at Epidemiology Seminar Series, Department of Epidemiology, University of Iowa, Iowa City, Iowa.
- Apr 2015 Coffey, C. S. Re-Estimating Sample Size Midtrial: The SPS3 Experience. Presented at 8th Annual ADVAMed Statistics Workshop, American Statistical Association, Washington, District of Columbia.
- May 2015 Foster, E., Thomann, M. & Coffey, C. S. Including Uncertainty in the Target Probability of Dose Limiting Toxicity in Phase I/II Studies with a Dose Finding Component. Presented at SCT Annual Meeting, Society for Clinical Trials, Washington, District of Columbia.
- May 2015 Foster, E., Coffey, C. S., Cudkowicz, M., Eckund, D., Bosch, M., Thornell, B., Kearney, M., Littizzio, E., Ashokkumar, A. & Mahoney, K. The Network for Excellence in Neuroscience Clinical Trials (NeuroNEXT) Protocol Working Group Design Phase Experiences. Presented at SCT Annual Meeting, Society for Clinical Trials, Washington, District of Columbia.
- May 2015 Meurer, W., Mawocha, S., Conwit, R., Lewis, R., Coffey, C. S. & Gutmann, L. The NINDS Clinical Trials Methodology Course: Approach and Lessons from Year 1. Presented at SCT Annual Meeting, Society for Clinical Trials, Washington, District of Columbia.
- May 2015 Coffey, C. S. Common Data Elements: The User's Perspective. Presented at Invited Session at Annual Conference, Society for Clinical Trials, Washington, District of Columbia.
- Jun 2015 Simuni, T., Caspell-Garcia, C., Coffey, C. S., Lasch, S., Jennings, D., Tanner, C., Kiebertz, K. & Marek, K. Can We Reliably Establish Parkinson's Disease Subtypes in De Novo Patients: Follow Up Results from the PPMI Study. Presented at 19th International Congress of Parkinson's Disease and Movement Disorders, San Diego, District of Columbia.
- Jun 2015 Kolb, S., Coffey, C. S., Yankey, J., Arnold, D., Rutkove, S., Bartlett, A., Renusch, S., Wang, S., Snyder, P., Prior, T., Kissel, J. & for the NeuroNEXT Clinical Trial Network and on behalf of the NN101 SMA Biomarker Investigators Initial Results from the NeuroNEXT SMA Infant Biomarker Study. Presented at Cure SMA Annual Researcher Meeting, Kansas City, Missouri.
- Sep 2015 Nowak, R. J., Coffey, C. S., Goldstein, J. M., Dimachkie, M., Benatar, M., O'Connor, K. C., Kissel, J., Hafner, D. A., Barohn, R., Cudkowicz, M. & for the NeuroNEXT NN103 Study Team A Phase 2 Trial of Rituximab in Myasthenia Gravis: Study Update. Presented at Annual Meeting of the ANA, American Neurological Association, Chicago, Illinois.
- Oct 2015 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama.
- Dec 2015 Coffey, C. S. Innovative Trial Designs for Rare Disease. Presented at TREAT-NMD International Conference, Washington, District of Columbia.

- Feb 2016 Leyden, P., Weymer, S., Coffey, C. S., Cudkowicz, M., Fisher, M., Haley, E. C., Khatri, P., Saver, J., Levine, S., Levy, H., Pryor, K., Rymer, M. & Wechsler, L. Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection. Presented at International Stroke Conference, Los Angeles, California.
- Feb 2016 Coffey, C. S. Adaptive & Bayesian Trial Design. Presented at Workshop on Patient-Centered Outcomes and Comparative Effectiveness Research, ICTS, Cincinnati, Ohio.
- Feb 2016 Coffey, C. S. The State of the Clinical Trials Statistical and Data Management Center. Presented at Biostatistics Seminar Series, Department of Biostatistics, University of Iowa, Iowa City, Iowa.
- Apr 2016 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Department of Biostatistics, University of Florida, Gainesville, Florida.
- May 2016 Gums, T. H., Anderegg, M. D., Uribe, L., Coffey, C. S. & Carter, B. L. Physician-Pharmacist Collaboration: Overcoming Socioeconomic Barriers. Presented at Annual Meeting of the American Society for Hypertension, American Society for Hypertension, New York, New York.
- Jun 2016 Simuni, T., Weintraub, D., Caspell-Garcia, C., Walker, M., Coffey, C. S., Lasch, S., Tanner, C., Jennings, D., Kiebertz, K. & Marek on behalf of the PPMI Investigators, K. Baseline Prevalence and Longitudinal Evolution of Non-Motor Symptoms in Early Parkinson's Disease - PPMI Cohort. Presented at International Movement Disorders Congress, Berlin, Germany.
- Jun 2016 Simuni, T., Long, J., Caspell-Garcia, C., Coffey, C. S., Lasch, S., Tanner, C., Jennings, D., Kiebertz, K. & Marek on behalf of the PPMI Investigators, K. Clinical and Biological Predictors of Time to Initiation of Symptomatic Therapy in Early Parkinson's Disease. Presented at International Movement Disorders Congress, Beijing, Germany.
- Jun 2016 Mollenhauer, B., Caspell-Garcia, C., Coffey, C. S., Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Frasier, M., Marek, K. & Galasko, D. R. Longitudinal Cerebrospinal Fluid Biomarkers in Early Parkinson's Disease and Healthy Controls. Presented at International Movement Disorders Congress, Berlin, Germany.
- Jun 2016 Simuni, T., Caspell-Garcia, C., Long, J., Coffey, C. S., Oertel, W., Lasch, S. & Marek on behalf of the PPMI Sleep Working Group, K. Longitudinal Evolution of Excessive Daytime Sleepiness in Early Parkinson's Disease. Presented at International Movement Disorders Congress, Berlin, Germany.
- Jun 2016 Oertel, W., Simuni, T., Caspell-Garcia, C., Long, J., Coffey, C. S., Iranzo, A., Mayer, G., Chahine, L., Lasch, S. & Marek on behalf of the PPMI Sleep Working Group, K. Longitudinal Evolution of Possible REM Sleep Behavior Disorder in Early Parkinson's Disease. Presented at International Movement Disorders Congress, Berlin, Germany.
- Jun 2016 Jennings, D., Coffey, C. S., Beach, T., Foroud, T., Adler, C. H., Mollenhauer, B., Seibyl, J., Ecklund, D., Lasch, S., Arnedo, V. & Kopil, C. The Systemic Synuclein Sampling Study (S4). Presented at International Movement Disorders Congress, Berlin, Germany.
- Aug 2016 Coffey, C. S. Challenges and Experience in Designing Small Clinical Trials. Presented at Invited Session, Joint Statistical Meetings, American Statistical Association, Chicago, Illinois.
- Dec 2016 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Presented at National Institute of Neurological Disorders & Stroke, Bethesda, Maryland.
- Mar 2017 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Department of Biostatistics Seminar Series, College of Public Health, Iowa City, Iowa.

- Mar 2017 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Presented at The Society for Clinical Trials Webinar Series.
- Apr 2017 Coffey, C. S. Increasing the Practicality of Innovative Trial Designs. Presented at DIA Adaptive Design Scientific Working Group Key Opinion Leaders Webinar Series.
- Apr 2017 Coffey, C. S. Statistical Aspects of the Childhood & Adolescent Migraine Prevention (CHAMP) Study. Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama.
- Apr 2017 Coffey, C. S. Statistical Aspects of the Childhood & Adolescent Migraine Prevention (CHAMP) Study. Presented at Department of Biostatistics, University of Alabama-Birmingham, Birmingham, Alabama.
- May 2017 Coffey, C. S. Implementing Adaptive Designs: Balancing the Practical with the Statistical. Presented at Discussant, Society for Clinical Trials Annual Meeting, Liverpool, United Kingdom.
- May 2017 Coffey, C. S. Implementing Adaptive Designs: Balancing the Practical with the Statistical. Presented at Society for Clinical Trials Annual Meeting, Society for Clinical Trials, Liverpool, United Kingdom.
- Jul 2017 Coffey, C. S. NeuroNEXT Overview & Accomplishments. The Ohio State University School of Medicine, Columbus, Ohio.
- Jul 2017 Coffey, C. S., Cudkowicz, M., Conwit, R. & Lungu, C. Utilizing NIH Networks for Clinical Trials: Lessons from the Trenches. Cleveland Clinic, Cleveland, Ohio.
- Oct 2017 Mollenhauer, B., Caspell-Garcia, C., Coffey, C. S., Taylor, P., Shaw, L. M., Trojanowski, J. Q., Singleton, A., Naito, A., Reimer, A., Frasier, M., Marek, K., Galasko, D. & for the Parkinson Progression Markers Initiative Biological Analyses of PPMI Samples. Presented at PD Therapeutics Conference, New York, New York.
- Feb 2018 Coffey, C. S. Innovative Statistical Design and Analysis in PD. Presented at Annual Meeting, The International Society for CNS Clinical Trials & Methodology, Washington, District of Columbia.
- Apr 2018 Coffey, C. S. University of Iowa Clinical Trials Statistical & Data Management Center - Overview of Ongoing Collaborations with the Michael J. Fox Foundation. Eastern Iowa Parkinson's Symposium, Cedar Rapids, Iowa.
- Apr 2018 Coffey, C. S. University of Iowa Clinical Trials Statistical & Data Management Center - Overview of Ongoing Parkinson's Disease Research Efforts. University of Iowa Site Visit for Parkinson's Foundation Center of Excellence Evaluation, Iowa City, Iowa.
- May 2018 Coffey, C. S. Adaptive Timing of Interim Analysis: DSMB Perspective. Presented at Annual Meeting, Society for Clinical Trials, Portland, Oregon.
- Aug 2018 Coffey, C. S. Achieving the Promise of Innovative Clinical Designs in an Academic Setting. University of Minnesota, Minneapolis, Minnesota.
- Oct 2018 Coffey, C. S. Innovative Statistical Design and Analysis in ALS. Presented at 17th Annual Northeast ALS Consortium Annual Meeting, Clearwater, Florida.
- Nov 2018 Coffey, C. S. Innovative Statistical Design and Analysis in ALS. Presented at Massachusetts ALS Partnership Symposium, Boston, Massachusetts.
- Jan 2019 Coffey, C. S. Achieving the Promise of Innovative Clinical Designs in an Academic Setting. Duke University, Durham, North Carolina.

- Apr 2019 Coffey, C. S. Novel Trial Designs of 'Disease Modifying Therapy' in Oncology (e.g., I-SPY-2) and Other Diseases. Presented at The Krembil Knowledge Gaps in Parkinson's Disease Symposium, Toronto, Canada.
- May 2019 Coffey, C. S. An Overview of Data Sharing. Presented at Part of an Invited Session on "Preparing and Submitting Data to Open and Limited-Access Repositories" (Organizer: Janel Fedler, University of Iowa, Society for Clinical Trials Annual Meeting, New Orleans, Louisiana).
- May 2019 Coffey, C. S. An Overview of NeuroNEXT. Presented at Part of an Invited Session on "Switching Boats Mid-Stream: Maintaining Continuity in a Large Clinical Trials Network in the Face of Change" (Organizer: Julie Qidwai, University of Iowa), Society for Clinical Trials Annual Meeting, New Orleans, Louisiana.
- Oct 2019 Wellhaven, A., Coffey, C. S. & Foster, E. D. Evaluation of Continual Reassessment Method with Lagged Group: A Study Design for Early Phase Dose-Finding Clinical Trials. Presented at Women in Statistics and Data Science Conference, Women in Statistics and Data Science, Bellevue, Washington.
- Oct 2019 Nowak, R. J., Coffey, C. S., Goldstein, J. M., Yankey, J. W., Uribe, L., Dimachkie, M. M., Benatar, M., Wolfe, G. I., Burns, T., Pearson, B., O'Connor, K. C., Conwit, R., Kissel, J. T., Hafler, D. A., Cudkowicz, M. E., Barohn, R. J. & on behalf of the NeuroNEXT NN103 BeatMG Study Team Rituximab Response in Patients with Moderate to Severe Myasthenia Gravis (MG): A Subgroup Analysis of the BeatMG Study. Presented at Platform Presentation, American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting, American Association of Neuromuscular and Electrodiagnostic Medicine, Austin, Texas.
- Nov 2019 Coffey, C. S. Increasing the Chances of Finding Effective Treatments. Presented at NIH Workshop - Improving the Identification of Disease Modification PD Targets and their Testing in Early Phase Clinical Trials, NIH, Bethesda, Maryland.
- Feb 2020 Coffey, C. S. An Overview of Adaptive Designs. University of Iowa Institutional Review Board, Iowa City, Iowa.
- Jun 2020 Powers, S. W., Chamberlin, L., Peugh, J., Reidy, B. L., Klingner, E. A., Yankey, J., Porter, L. L., Kabbouche, M., Kacperski, J., Ecklund, D., Coffey, C. S. & Hershey, A. D. Childhood and Adolescent Migraine Prevention [CHAMP] Trial: The 3-Year Follow-Up Survey Results. Presented at Virtual Platform Presentation, AHC Virtual, American Headache Society.
- Jun 2020 Coffey, C. S. Achieving the Promise of Innovative Clinical Designs in an Academic Setting. University of Alabama at Birmingham (Virtual due to COVID-19).
- Aug 2020 Fedler, J. K., Bermel, R. A., Coffey, C. S., Klingner, E., Yankey, J. & Fox, R. J. Sample Size Estimates for Optical Coherence Tomography Outcome Measures Based on Trends observed in the SPRINT-MS Trial. Presented at SCT Virtual Meeting, Society for Clinical Trials.
- Sep 2020 The Parkinson's Study Group/NILO-PD Investigators NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease: Final Study Results. Presented at Emerging Science Virtual Live Presentation, American Academy of Neurology.
- Apr 2021 Coffey, C. S. Designing Meaningful Early Phase Clinical Trials. Presented at American Academy of Neurology Annual Meeting (Virtual due to COVID-19), American Academy of Neurology.

- Apr 2021 Coffey, C. S. How to Measure Prevention? Selecting an Intervention - Study Design/Statistical Foundation. Presented at Planning for Prevention of Parkinson's : A Trial Design Symposium and Workshop (Virtual due to COVID-19).
- May 2021 Coffey, C. S. Is Sample Size Re-Estimation Controversial? - Well, Yes & No. Presented at Society for Clinical Trials Annual Meeting (Virtual due to COVID-19), Society for Clinical Trials.
- Aug 2021 Coffey, C. S. Data Coordinating Centers: Telling the Story of Research. Presented at Panelist-Joint Statistical Meetings (Virtual due to COVID-19), American Statistical Association.
- Nov 2021 Coffey, C. S. Planning for Success: Clinical Trial Design. Presented at Panelist, Alpha Synuclein Summit: Clinical Development of Alpha-Synuclein Therapeutics/Virtual due to COVID-19.

Posters

- Oct 2001 Coffey, C. A Comparison of Two Methods for Detecting Interactions Among Genetic Polymorphisms in Matched Case-Control Studies. Presented at Annual Meeting of the American Society for Human Genetics, San Diego, California.
- Apr 2002 Coffey, C. Safety of an Herbal Formulation Including Ephedra Alkaloids Dosed Intermittently or Continuously for Weight Control. Presented at Annual Meeting of the American Society for Human Genetics, San Diego, California.
- Oct 2002 Coffey, C. The Importance of Model Validation in Determining the Clinical Utility of Genetic Interactions on Disease Risk. Presented at Annual Meeting of the American Society for Human Genetics, Baltimore, Maryland.
- Nov 2003 Coffey, C. The Effects of Intentional Weight Loss as a Latent Variable Problem. Presented at North American Association for the Study of Obesity Annual Scientific Meeting, Ft. Lauderdale, Florida.
- Apr 2005 Coffey, C. The Metabolic Syndrome and It's Association with PAI-1 and t-PA Antigen Levels in a Population-Based Study. Presented at Annual Conference on Cardiovascular Disease Epidemiology and Prevention, Washington, District of Columbia.
- May 2009 Coffey, C. Development of an Advanced Clinical Trials Course in a Biostatistics Doctoral Program. Presented at Annual Meeting of the Society for Clinical Trials, Atlanta, Georgia.
- May 2011 Coffey, C. The Parkinson's Progression Markers Initiative: A Prospective Biomarkers Study. Presented at Annual Meeting of the Society for Clinical Trials, Vancouver, Canada.
- Oct 2016 Kearney Chase, M., Ecklund, D., Bosch, M., Thornell, B., Coffey, C. S. & Cudkowicz, M. Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Increasing Efficiency in Clinical Trials. Presented at ANA Annual Meeting, American Neurological Association, Baltimore, Maryland.
- Mar 2017 Mollenhauer, B., Coffey, C. S., Beach, T., Foroud, T., Adler, C., Ecklund, D., Dave, K., Deshpande, S., Lasch, S., Arnedo, V., Riley, L., Jennings, D. & Chahine, L. The Systemic Synuclein Sampling Study. Presented at Alzheimer's & Parkinson's Disease Congress, Vienna, Austria.

- Apr 2017 Linder, C., Mollenhauer, B., Coffey, C. S., Beach, T., Foroud, T., Adler, C., Riss, H., Ecklund, D., Caspell-Garcia, C., Dave, K., Deshpande, S., Lasch, S., Arnedo, V., Riley, L., Jennings, D. & Chahine, L. Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Presented at AAN Annual Meeting, American Academy of Neurology, Boston, Massachusetts.
- May 2017 Foster, E., Mahoney, K., Ecklund, D., Kearney Chase, M., Bosch, M., Thornell, B., Coffey, C. S. & Cudkowicz, M. Network for Excellence in Neuroscience Clinical Trials , NeuroNEXT: Pre-Award Process and Experiences. Presented at Society for Clinical Trials Annual Meeting, Society for Clinical Trials, Liverpool.
- Jun 2017 Linder, C., Mollenhauer, B., Coffey, C. S., Beach, T., Foroud, T., Adler, C., Riss, H., Ecklund, D., Caspell-Garcia, C., Dave, K., Deshpande, S., Lasch, S., Arnedo, V., Riley, L., Kopil, C., Jennings, D. & Chahine, L. Feasibility and Safety of Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Presented at Annual Movement Disorders Society Meeting, Movement Disorders Society, Vancouver, BC, Canada.
- Nov 2017 Raulerson, S., Berg, S., Costigan, M., Hersch, S., Anderson, K., Long, J., Coffey, C. S., Yankey, J., Cudkowicz, M., Conwit, R., Lungu, C., Brownstein, M. & Simon, N. Safety and Tolerability of SRX246 in irritable/Aggressive Subjects with Huntington's Disease (STAIR): A Phase II Exploratory Clinical Trial. Presented at Huntington's Study Group Annual Meeting, Denver, Colorado.
- Nov 2017 Anderson, K., Hersch, S., Long, J., Cudkowicz, M., Coffey, C. S., Yankey, J., Costigan, M., Raulerson, S., Berg, S., Conwit, R., Lungu, C., Brownstein, M. & Simon, L. Measurement of Huntington's Irritability and Aggression in the Azevan Pharmaceuticals-NeuroNEXT STAIR Study. Presented at Huntington's Study Group Annual Meeting, Denver, Colorado.
- Feb 2018 Naismith, R., Coffey, C. S., Cudkowicz, M. E., Gleason, T., Goodman, A. D., Klawiter, E. C., Matsuda, K., McGovern, M. M., Conwit, R., Ahokkumar, A., Ecklund, D., Klingner, E., Koepf, M., Natarajan, S., Thornell, B., Yankey, J., Bermel, R., Huang, X., Lowe, M., Nakamura, K., Narayanan, S., Sakaie, K., Debbins, J., Zhou, X., Alvarez, E., Apperson, M., Bashir, K., Cohen, B., Coyle, P., Delgado, S., Dewitt, D., Flores, A., Geisser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S., Moses, H., Ontaneda, D., Perumal, J., Racke, M., Repovic, P., Riley, C., Seversono, C., Shinnar, S., Suski, V., Weinstock-Gutman, B., Yadav, V., Zabeti, A. & Fox, R. SPRINT-Ns/NN102 Phase II Trial of Ibudilast in Progressive MS: Top-Line Results. Presented at American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Annual Meeting, American Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), San Diego, California.
- Mar 2018 Qidwai, J., Kearney Chase, M., Ecklund, D., Bosch, M., Thornell, B., Coffey, C. S. & Cudkowicz, M. Network for Excellence in Neuroscience Clinical Trials, NeuroNEXT: Update on Success and Five-Year Renewal Application. Presented at American Society for Experimental Neurotherapeutics (ASENT) Meeting, American Society for Experimental Neurotherapeutics, Washington, District of Columbia.

- Apr 2018 Fox, R. J., Coffey, C. S., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Conwit, R., Naismith, R., Ashokkumar, A., Barnes, J., Ecklund, D., Klingner, E., Koepp, M., Natarajan, S., Thornell, B., Yankey, J., Bermel, R. A., Huang, X., Lowe, M. J., Nakamura, K., Narayanan, S., Sakaie, K. E., Debbins, J. P., Zhou, X., Alvarez, E., Apperson, M., Bashir, K., Cohen, B., Coyle, P., Delgado, S., Dewitt, D., Flores, A., Geisser, B., Goldman, M., Jubelt, B., Lava, N., Lynch, S., Moses, H., Ontaneda, D., Perumal, J., Racke, M., Repovic, P., Riley, C., Severson, C., Shinnar, S., Suski, V., Weinstock-Guttman, B., Yadav, V., Zabeti, A. & on behalf of the NN102/SPRINT-MS Investigators A Phase II Trial of Ibudilast in Progressive Multiple Sclerosis. Presented at Clinical Trials Plenary Session, American Academy of Neurology Annual Meeting, American Academy of Neurology, Los Angeles, California.
- Apr 2018 Nowak, R. J., Coffey, C. S., Goldstein, M., Dimachkie, M. M., Benatar, M., Huq, S. N., Pearson, B., Herbelin, L., O'Connor, K. C., Conwit, R., Kissel, J. T., Hafler, D. S., Cudkowicz, M. E., Barohn, R. J. & on behalf of the NeuroNEXT NN103 BeatMG Study Team B Cell Targeted Treatment in Myasthenia Gravis (BeatMG) - A Phase 2 Trial of Rituximab in MG: Topline Results. Presented at American Academy of Neurology Annual Meeting, American Academy of Neurology, Los Angeles, California.
- May 2018 Seedorff, N., Black, J., Conwit, R., Lewis, R., Coffey, C. S., Gutmann, L. & Meurer, W. The National Institute of Neurological Disorders and Stroke Clinical Trials Methodology Course: Outcomes of Trainees after 3 Years. Presented at Society for Clinical Trials Annual Meeting, Society for Clinical Trials, Portland, Oregon.
- Oct 2018 Chahine, L. M., Beach, T., Coffey, C. S., Caspell-Garcia, C., Adler, C., Serrano, G., Mosovsky, S., Foroud, T., Linder, C., Riss, H., Ecklund, D., Seibyl, J., Mallya, A., Arnedo, V., Riley, L., Dave, K., Jennings, D. & Mollenhauer, B. Multisite Tissue and Biofluid Sampling for Alpha-Synuclein in Parkinson's Disease: The Systemic Synuclein Sampling Study (S4). Presented at Annual Movement Disorders Society Meeting, Movement Disorders Society, Hong Kong.
- Dec 2018 Simon, N., Hersch, S., Anderson, K., Long, J., Ecklund, D., Costigan, M., Thornell, B., Gladden, C., Coffey, C. S., Cudkowicz, M. & Brownstein, M. Irritability in Huntington's Disease: A Phase 2 Exploratory Clinical Trial with a Novel Vasopressin 1a Antagonist SRX246. Presented at American College of Neuropsychopharmacology Annual Meeting, American College of Neuropsychopharmacology, Hollywood, Florida.
- Mar 2019 Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Matthews, H., Wyse, R., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD Steering Committee NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update. Presented at Alzheimer's & Parkinson's Disease Congress, Portugal, Spain.
- May 2019 Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD PSG Investigators NILO-PD: A Phase 2 Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease: Study Design and Status Update. Presented at American Academy of Neurology Annual Meeting, American Academy of Neurology, Philadelphia, Pennsylvania.

- Jul 2019 Pauli, G., Kuszak, A., Bloss, G., Fukagawa, N., Jafari, M., Walters, M., Barrett, B., Bushman, F., Casper, S., Chilton, F., Coffey, C. S., Feruzzi, M., Hopp, C., Kiely, M., Lakens, D., MacMillan, J., Meltzer, D., Paul, J., Pritchett-Corning, K., Quinney, S., Ross, S., Seifried, H., Setchell, K., Sipes, N., Stephens, J., Taylor, D., Tiriach, H., Xi, D., Hoffman, F. A. & Sorkin, B. Highlights from a Workshop on Enhancing Natural Product Clinical Trials. Presented at American Society of Pharmacognosy Meeting, American Society of Pharmacognosy, Madison, Wisconsin.
- Sep 2019 Marek, K., Simuni, T., Siderowf, A., Lafontant, D., Caspell-Garcia, C., Coffey, C. S., Mollenhauer, B., Tanner, C., Kieburtz, K., Chahine, L., Seibyl, J. & on behalf of the PPMI Investigators Clinical and DAT Imaging Characteristics of Participants with Scans without Evidence of Dopaminergic Deficit (SWEDDs): PPMI Cohort 2 Year Follow-Up. Presented at Movement Disorders Society Meeting, Movement Disorders Society, Nice, France.
- Sep 2019 Chahine, L., Kieburtz, K., Brumm, M., Caspell-Garcia, C., Coffey, C. S., Siderowf, A., Weintraub, D., Tanner, C., Foroud, T., Galasko, D., Mollenhauer, B., Simuni, T., Marek, K. & and the Parkinson's Progression Markers Initiative Identifying Incident Cases of Neurodegenerative Parkinsonism in a Large Observational At-Risk Cohort: The PPMI Study. Presented at Movement Disorders Society Meeting, Movement Disorders Society, Nice, France.
- Sep 2019 Weintraub, D., Caspell-Garcia, C., Simuni, T., Cho, R., Coffey, C. S., Aarsland, D., Alcalay, R., Barrett, M., Chahine, L. M., Eberling, J., Espay, A., Hamilton, J., Hawkins, K., Leverenz, J., Litvan, I., Richard, I., Rosenthal, L., Siderowf, A., York, M. & and the Parkinson's Progression Markers Initiative Neuropsychiatric Symptoms Over the Initial Lustrum of Parkinson Disease: Common, Increasing, Comorbid & Varied. Presented at Movement Disorders Society Meeting, Movement Disorders Society, Nice, France.
- Sep 2019 Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwartzschild, M., Weiner, D., Adams, J., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD PSG Investigators NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease - Study Design and Status Update. Presented at Movement Disorders Society Meeting, Movement Disorders Society, Nice, France.
- Sep 2019 Marek, K., Siderowf, A., Simuni, T., Coffey, C. S., Foroud, T., Arnedo, V., Flagg, E., Chowdhury, S., Kieburtz, K., Chahine, L., Tanner, C. & and the Parkinson's Progression Markers Initiative PPMI 2.0 - Transforming PPMI - New Cohorts, New Science - Focus on Prodromal PD. Presented at Movement Disorders Society Meeting, Movement Disorders Society, Nice.
- Oct 2019 Merchant, K. M., Simuni, T., Fiske, B., Coffey, C. S., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M. A., Weiner, D., Adams, J., Trusso, L., Baker, L., Krostrzebski, M., Ward, T., Rafaloff, G., Venuto, C. & on behalf of the NILO-PD Steering Committee Analyses of Pharmacokinetics, CSF Exposures and CSF Dopamine and its Metabolite Levels in NILO-PD, A Phase 2A Study of Nilotinib in Moderate to Advanced Parkinson's Disease. Presented at Society for Neuroscience Annual Meeting, Society for Neuroscience, Chicago, Illinois.

- Feb 2020 Simuni, T., Fiske, B., Merchant, K., Coffey, C. S., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M. A., Weiner, D., Adams, J., Venuto, C., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G. & on behalf of the NILO-PD PSG Investigators NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced and Early Parkinson's Disease - Final Study Results. Presented at Pan American Parkinson's Disease and Movement Disorders Congress.
- Apr 2020 Brumm, M. C., Coffey, C. S., Siderowf, A., Simuni, T., Galasko, D., Mollenhauer, B., Chahine, L. M., Arnedo, V., Daegele, N., Frasier, M., Tanner, C., Poston, K., Weintraub, D., Hutten, S., Kieburtz, K., Marek, K. & and the Parkinson's Progression Markers Initiative Modeling Outcomes in the PPMI Cohort: Implications for Clinical Trial Design. Presented at Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Virtual Focus Meeting.
- Apr 2020 Merchant, K., Simuni, T., Fiske, B., Coffey, C. S., Matthews, H., Wyse, R. K., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Trusso, L., Baker, L., Kostrzebski, M., Ward, T., Rafaloff, G., Venuto, C. & on behalf of the NILO-PD PSG Investigators Pharmacokinetics and Biomarker Changes in NILO-PD, A Phase 2A Study of Nilotinib in Patients with Moderate to Advanced Parkinson's Disease. Presented at Advances in Alzheimer's and Parkinson's Therapies, An AAT-AD/PD Virtual Focus Meeting.
- May 2020 The Parkinson's Study Group/NILO-PD Investigators NILO-PD: A Phase 2A Study of Nilotinib in Patients with Advanced Parkinson's Disease: Final Study Results. Presented at AAN Virtual Annual Meeting, American Academy of Neurology.
- Aug 2020 Mosovsky, S., Methe, B., Beach, T. G., Adler, c. H., Coffey, C. S., Foroud, T., Eberling, J., Mollenhauer, B., Chahine, L. & for the Systemic Synuclein Sampling Study Feasibility of Studying Microbiome in Frozen Saliva and Formalin-Fixed Colon in PD Using Systemic Synuclein Sampling Study (S4) Samples. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.
- Aug 2020 Simuni, T., Siderowf, A., Brumm, M., Caspell-Garcia, C., Coffey, C. S., Chahine, L. M., Merchange, L., Trojanowski, J. Q., Shaw, L. M., Seibyl, J., Singleton, A., Toga, A. W., Galasko, D., Foroud, T., Toson-Turgut, D., Poston, K., Poewe, W., Weintraub, D., Mollenhauer, B., Tanner, C. M., Kieburtz, K., Reimer, A., Hutten, S., Marek, K. & and the Parkinson's Progression Markers Initiative Longitudinal Clinical and DAT Imaging Characteristics on Non-Manifest LRRK2 Carriers: The PPMI Cohort. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.
- Aug 2020 Simuni, T., Coffey, C. S., Klingner, E., Caspell-Garcia, C., Lafontant, D. E., Merchant, K., Fiske, B., Matthews, H., Wyse, R., Brundin, P., Simon, D. K., Schwarzschild, M., Weiner, D., Adams, J., Trusso, L., Baker, L., Kostrzebski, M., Venuto, C., Rafaloff, G., Ward, T. & on behalf of the NILO-PD Investigators NILO-PD: A Phase 2A Study of Nilotinib in Patients with Moderately Advanced Parkinson's Disease: Exploratory Efficacy Outcomes. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.
- Aug 2020 Venuto, C., Simuni, T., Fiske, B., Coffey, C. S., Matthews, H., Wyse, R., Brundin, P., Simon, D., Schwarzschild, M., Weiner, D., Adams, J., Trusso, L., Kostrzebski, M., Ward, T., Rafaloff, G. & Merchant, K. Physiologically-Based Pharmacokinetic Modeling of Nilotinib to Determine Serum, Cerebrospinal Fluid, and Brain Exposures. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.

- Aug 2020 Kulick-Soper, C. V., Caspell-Garcia, C., Coffey, C. S., Picillo, M., Weintraub, D., Dahodwala, N. & and the Parkinson Progression Markers Initiative Rates of Pharmacological Treatment of Neuropsychiatric Symptoms in Early Parkinson's Disease. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.
- Sep 2021 Brumm, M. C., Siderowf, A., Simuni, T., Burghardt, E., Caspell-Garcia, C., Toga, A. W., Galasko, D., Mollenhauer, B., Chahine, L. M., Foroud, T., Arnedo, V., Frasier, M., Reimer, A., Tanner, C., Poston, K., Weintraub, D., Hutten, S. J., Kieburtz, K., Marek, K. & Coffey, C. S. A Milestone-Based Approach to Monitoring Disease Progression in Parkinson's Disease. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.
- Sep 2021 Marek, K., Siderowf, A., Simuni, T., Coffey, C. S., Foroud, T., Flagg, E., Chowdhury, S., Mollenhauer, B., Galasko, D., Merchant, K., Kieburtz, K., Brown, E., Poston, K., Chahine, L., Tanner, C. & and the Parkinson's Progression Markers Initiative Parkinson Progression Marker Initiative - New Science/New Cohorts. Presented at Guided Poster Tour, Movement Disorder Society Virtual Congress, Movement Disorder Society.

Seminars

- 2005 An Overview of Adaptive Designs with Emphasis on Internal Pilots. University of Alabama, Birmingham, Alabama.
- 2006 An Overview of Adaptive Designs with Emphasis on Internal Pilots. University of Alabama, Birmingham, Alabama.
- 2012 Overview of Randomized Clinical Trials. Obstetrics/Gynecology, University of Iowa.

Workshops

- Jul 2018 Coffey, C. S., Shefner, J., Hersch, S. & Kennedy, M. What We Measure and How: Outcomes Panel. Presented at ALS Community Workshop - Therapy Development & Regulatory Discussion, Washington, District of Columbia.
- Sep 2018 Coffey, C. S. Design Considerations when Planning Clinical Trials. "Enhancing Natural Products Clinical Trials" Workshop, Bethesda, Maryland.

Other Presentations

- Dec 2006 Coffey, C. S. Frequentists Adaptive Designs, Internal Pilots, and Stopping Rules (Short Course). Presented at Conference on Design, Analysis, and Interpretation of Randomized Clinical Trials in Obesity, Newark, New Jersey.
- Aug 2007 Coffey, C. S., Gaydos, B. & Pinheiro, J. Adaptive Dose-Response Studies (Short Course). Presented at Annual Joint Statistical Meetings, American Statistical Association, Salt Lake City, Utah.
- Oct 2007 Clarke, W. R., Gaydos, B. & Pinheiro, J. Adaptive Designs in Dose-Finding Studies (Webinar). Presented at Web-Based Training Series, PhRMA and the Biopharmaceutical Section of the ASA.
- Nov 2007 Coffey, C. S., Gaydos, B. & Pinheiro, J. Adaptive Designs in Dose-Finding Studies. Presented at Four-Part Web-Based Training Series, PhRMA and the Biopharmaceutical section of the American Statistical Association.
- 2008 Coffey, C. S. Clinical Trials Methods in Neurology (Short Course). Presented at NINDS Sponsored Course.

- May 2008 Coffey, C. S., Rosenberg, Y., Green, S., Lovato, L., Gilson, M. M. & Melia, M. Fundamentals of Randomized Clinical Trials (Workshop). Presented at Annual Meeting of the Society for Clinical Trials, Society for Clinical Trials, St. Louis, Missouri.
- 2009 Clinical Trials Methods in Neurology (Short Course). Presented at NINDS Sponsored Course.
- Apr 2009 Coffey, C. S., Rosenberg, Y., Lovato, L., Melia, M. & Gilson, M. M. Fundamentals of Randomized Clinical Trials (Workshop). Presented at Annual Meeting of the Society for Clinical Trials, Society for Clinical Trials, Atlanta, Georgia.
- Nov 2009 Coffey, C. S. Scientific Advances in Adaptive Clinical Trial Design (Workshop Organizer). Baltimore, Maryland.
- 2010 Coffey, C. S. Clinical Trials Methods in Neurology (Short Course). Presented at NINDS Sponsored Course.
- Feb 2010 Coffey, C. S. The Science of Small Clinical Trials (Short Course). FDA Office of Orphan Products and NIH Office of Rare Diseases, Bethesda, Maryland.
- Apr 2010 Coffey, C. S. Clinical Research Methods (Short Course). Presented at Meeting of the American Academy of Neurology, American Academy of Neurology, Toronto, Canada.
- May 2010 Coffey, C. S. Essentials of Randomized Clinical Trials (Workshop). Presented at Annual Meeting of the Society for Clinical Trials, Society for Clinical Trials, Baltimore, Maryland.
- 2011 Coffey, C. S. Adaptive Design for Clinical Trials: Perspectives from an NIH-Funded Workshop (Webinar). Presented at Drug Information Association (DIA) Adaptive Design Working Group KOL Lecture Series.
- 2011 Clinical Trials Methods in Neurology (Short Course). Presented at NINDS Sponsored Course.
- Apr 2011 Coffey, C. S. The Science of Small Clinical Trials. Presented at FDA Short Course, FDA Office of Orphan Products and NIH Office of Rare Diseases, Silver Spring, Maryland.
- May 2011 Coffey, C. S. & Wittes, J. Challenges in Designing Small Clinical Trials (Workshop). Presented at Annual Meeting of the Society for Clinical Trials, Society for Clinical Trials, Vancouver, Canada.
- May 2011 Coffey, C. S. Adaptive Designs for Clinical Trials: Perspectives from an NIH-funded Workshop. Presented at Adaptive Design Working Group Key Opinion Leaders Lecture Series, Drug Information Association (DIA).
- Dec 2011 Coffey, C. S. Challenges in Designing Small Clinical Trials. Association for Research in Vision and Ophthalmology.
- 2012 Coffey, C. S. Adaptive Designs and Small Clinical Trials (Short Course). Presented at Meeting the Challenges of Rare Disease Drug Review Short Course.
- 2012 Coffey, C. S. Challenges in Designing Small Clinical Trials (Webinar). Presented at ARVO Clinical Trials Webinar.
- 2012 Coffey, C. S. Novel Designs for Rare Disorders, including Adaptive Designs (Workshop Organizer). Presented at NIH-Sponsored Workshop on Designing Clinical Trials in Dystonia.
- Mar 2017 Coffey, C. S. Increasing the Practicality of Innovative Trial Design. Presented at Society for Clinical Trials Webinar Series.

May 2017	Coffey, C. S. Small Sample Size Clinical Trials. Presented at Clinical Trials Methods in Neurology Course Webinar Series.
Jan 2018	Lyden, P., Coffey, C. S., Cudkowicz, M., Conwit, R., Pryor, K. & on behalf of the RHAPSODY Investigators Final Results of the RHAPSODY Trial. Presented at International Stroke Conference, Los Angeles, California.
Jul 2018	Coffey, C. S. Small Sample Size Clinical Trials. Presented at Clinical Trials Methods in Neurology Course Webinar Series.
May 2019	Coffey, C. S. Small Sample Size Clinical Trials. Presented at Clinical Trials Methods in Neurology Course Webinar Series.
Jul 2019	Coffey, C. S. The Clinical Trials Statistical & Data Management Center (CTSDMC) - History & Current Neurological Activities. University of Iowa Department of Neurology Grand Rounds, Iowa City, Iowa.
May 2020	Coffey, C. S., Bayman, E. O., Gutmann, L. & Matthews, K. Ongoing Clinical Studies and Potential Collaborations for Neuroscience Research. Presented at Iowa Neuroscience Institute.
Aug 2020	Coffey, C. S. & Quintana, M. Rare Disease Trials. Presented at Clinical Trials Methods in Neurology Course Webinar Series.

Service

Professional Service

Professional Organizations

1999 - 2000	Middle Tennessee Chapter, American Statistical Association, Officer, Secretary
2007	Eastern North American Region (ENAR), International Biometric Society, Program Chair for the Joint Statistical Meetings
2002 - 2009	Alabama Chapter, American Statistical Association, Chapter Representative
2007 - 2009	Eastern North American Region (ENAR), International Biometric Society, Member, Regional Advisory Board
2007 - 2009	PhRMA Adaptive Design Working Group, Communications Workstream, Member
2009 - 2011	Society for Clinical Trials, Member, Education Outreach Committee
2007 - 2012	Education Committee, Society of Clinical Trials, Co-Chair 2008; Chair, 2009-2012
2011 - 2013	Biopharmaceutical Section Executive Committee, American Statistical Association, Member
2013 - 2014	Society of Clinical Trials, Chair, Program Committee
2014	Phase II Applications, ALS Association, Reviewer
2015	Phase II Applications, ALS Association, Reviewer
2015	Phase II Applications, ALS Association, Reviewer
2016	Phase II Applications, ALS Association, Reviewer
2007 - Present	Drug Information Association (DIA - previously sponsored by PhRMA) Adaptive Designs Working Group, Member

2007 - Present	PhRMA Adaptive Designs Working Group, Member
2007 - Present	Education Committee, Society of Clinical Trials, Co-Chair, 2007-2009; Chair, 2009-Present; and Member
2011 - Present	Biopharmaceutical Section, American Statistical Association, Member, Executive Committee
2011 - Present	DIA Adaptive Designs Working Group Case Studies Subteam, Member
2011 - Present	Society for Clinical Trials, Member, Program Committee
2012 - Present	Society for Clinical Trials, Board Member
2015 - Present	Society for Clinical Trials, Fellow
2016 - Present	Clinical Trials Guidelines Committee, ALS FDA, Member
2016 - Present	Social Media Committee, Society of Clinical Trials, Chair

Journal Reviews/Referee Manuscripts

2001 - 2002	The Austrian Science Foundation Schroedinger Fellowship, Reviewer
2002	Bioinformatics, Reviewer
2002	Human Heredity, Reviewer
2002	The Journal of the American Statistical Association, Reviewer
2003	Diabetes, Reviewer
2003	Diabetologia, Reviewer
2003	Obesity Reviews, Reviewer
2003	The American Journal of Human Genetics, Reviewer
2004	Applied Bioinformatics, Reviewer
2004	Behavior Research Methods, Instruments, & Computers, Reviewer
2004	Genetic Epidemiology, Reviewer
2004	Hypertension, Reviewer
2004	Neuroepidemiology, Reviewer
2005	Computational Statistics and Data Analysis, Reviewer
2007	Computer Methods and Programs in Biomedicine, Reviewer
2007 - 2008	Epidemiology, Reviewer
2008	Journal of Statistical Computation and Simulation, Reviewer
2005 - 2010	Circulation, Statistical Reviewer
2000 - 2012	The American Statistician, Reviewer
2009 - 2012	Biometrical Journal, Reviewer
2012	Parkinsonism and Related Disorders, Reviewer
2000 - Present	Statistics in Medicine, Reviewer
2003 - Present	Stroke, Statistical Reviewer

2004 - Present	The Journal of the American Medical Association, Reviewer
2008 - Present	Clinical Trials, Reviewer
2008 - Present	Neurology, Reviewer
2010 - Present	Movement Disorders, Statistical Reviewer
2010 - Present	Obesity, Reviewer
2012 - Present	Pharmaceutical Statistics, Reviewer
2013 - Present	International Journal of Biostatistics, Reviewer
2014 - Present	Biometrics, Reviewer
2014 - Present	Trials, Reviewer
2017 - Present	Journal of the Royal Statistical Society - Series A
2017 - Present	The American Journal of Clinical Nutrition, Reviewer

Review Panels

2003	NINDS NSD-K Study Section, Reviewer
2003 - 2004	Ankle Strengthening to Improve Gait and Function in CP, NINDS, Member of Data and Safety Monitoring Board
2004	NINDS NSD-A Study Section, Reviewer
2005	NINDS NSD-A Study Section, Reviewer
2005	NINDS NSD-K Study Section, Reviewer
2008	NINDS ZNS1-SRBG Special Emphasis Panel, Member
2008 - 2009	Creatine Safety Tolerability & Efficacy in Huntington's Disease (CREST-E) Trial, NINDS, Member of Data and Safety Monitoring Board
2008 - 2009	"LALS (Lithium in ALS)" Trial, NINDS, Member of Data and Safety Monitoring Board
2009	NINDS ZNS1-SRBB Special Emphasis Panel, Member
2006 - 2010	NINDS NSD-K Study Section, Member
2008 - 2010	NINDS Chronic Migraine Treatment Trial, Chair, Data and Safety Monitoring Board
2010	NINDS ZNS1-SRBG Special Emphasis Panel, Member
2010	NINDS ZNS1-SRBB Special Emphasis Panel, Member
2009 - 2011	Medivation, Inc. Sponsored - A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild to Moderate Huntington's Disease (HORIZON), Member, Data and Safety Monitoring Board
2011	Michael J. Fox Foundation LRRK2 RFA Applications Review Panel, Member
2011	NINDS NSD-C Study Section, Reviewer
2011	NINDS ZNS-SRBS Special Emphasis Panel, Member
2011	LRRK2 FRA Applications, Michael J. Fox Foundation, Reviewer
2005 - 2012	Albumin in Acute Stroke (ALIAS) Trial, NINDS, Member of Data and Safety Monitoring Board

2005 - 2012 Interventional Management of Stroke Study (IMS III) Trial, NINDS, Member of Data and Safety Monitoring Board

2012 NINDS NDS-K Study Section, Reviewer

2012 NINDS SRB-B Special Emphasis Panel, Reviewer

2012 ZNS1-SRBB Special Emphasis Panel, National Institute of Neurological Disorders and Stroke, Reviewer

2013 Therapeutics Discovery Study Section, National Center for Advancing Translations Sciences, Reviewer

2013 Phase II Applications, ALS Association, Reviewer

2014 Biomarker/Data Use Applications, Michael J. Fox Foundation, Reviewer

2014 Phase II Applications, ALS Association, Reviewer

2015 ZNS1-SRBB Special Emphasis Panel, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2015 Phase II Applications, ALS Association, Reviewer

2015 Phase II Applications, ALS Association, Reviewer

2016 Phase II Applications, ALS Association, Reviewer

2016 ZNS1-SRBC (SIREN CCC) Special Emphasis Panel, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2016 ZNS1-SRBC (SIREN DCC) Special Emphasis Panel, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2017 Acting Chair, Reviewer, ZNS-1SRBA (Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases) Special Emphasis Panel, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2017 ZNS-SRBA (Clinical Trial Readiness for Rare Neurological and Neuromuscular Diseases) Special Emphasis Panel, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2018 Phase II Applications, ALS Association, Reviewer

2018 Phase II Applications, ALS Association, Reviewer

2018 ZDC1 SRB-X 63 (NIDCD Aphasia Treatment Clinical Trial Review), National Institute on Deafness and Other Communication Disorders (NIDCD), Reviewer

2018 ZNS1 SRBA (Clinical Trial Readiness for Rare Neurological & Neuromuscular Diseases), National Institute of Neurological Disorders and Stroke (NINDS), Reviewer

2019 ZDC1 SRB-Y 54 (Clinical Trial Review), National Institute on Deafness and Other Communication Disorders (NIDCD), Reviewer

2019 Data Coordinating Center for Diabetic Foot Consortium, National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), Reviewer

2019 Biomarkers Across Neurodegenerative Diseases (BAND) Program, The Michael J. Fox Foundation for Parkinson's Research, Reviewer

2019 ZDK1 GRB-9 (Biostatistics Research Centers), National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), Reviewer

2019 Cure Parkinson's Trust, Grant Reviewer

- 2019 Acute Neural Injury & Epilepsy (ANIE) Study Section, Center for Scientific Review, Reviewer
- 2019 ZDK1 GRB-9 (Clinical Centers), National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), Reviewer
- 2020 ZDK1 GRB-N (U34 Clinical Trial Readiness), National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), Reviewer
- 2020 ZDK1 GRB-6 (A Trial of Transplanting Hepatitis C-Viremic Kidneys into Hepatitis C-Negative Kidney Recipients), National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK), Reviewer
- 2021 ZNS1 SRGA (EPPIC-NET Clinical Trials Review) 5 Reviews, National Institute of Neurological Disorders and Stroke (NINDS), Reviewer
- 2021 ZDK1 BRG-9 (NIDDK Clinical Trials), National Institute of Diabetes & digestive & Kidney Diseases (NIDDK), Reviewer
- 2021 HEAL Initiative ZNS1 SRBG (37) (Non-Addictive Analgesic Therapeutic Development to Treat Pain, National Institute of Neurological Disorders and Stroke (NINDS), Member
- 2021 NIH Post-Acute Sequelae of SARS-COV-2 Infection (PASC) Initiative, Reviewer
- 2021 ZNS1 SRBG (Clinical Trials and Comparative Effectiveness Studies), National Institute of Neurological Disorders and Stroke (NINDS), Reviewer
- 2004 - Present Clinical Trial of High Dose coQ10 in ALS, NINDS, Member of Data and Safety Monitoring Board
- 2009 - Present A Phase III, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Dimebon in Patients with Mild to Moderate Huntington's Disease (HORIZON), Medivation, Inc, Member
- 2012 - Present Non-Invasive Treatment of Abdominal Aortic Aneurysm Clinical Trial (NTA3CT), Member, Data and Safety Monitoring Board
- 2012 - Present Rapid Administration of Carnitine in sEpsis (RACE) Trial, Member, Data and Safety Monitoring Board
- 2017 - Present NIH-Sponsored: Traumatic Injury Clinical Trial Evaluating Tranexamic Acid in Children (TIC-TOC): A Pilot and Feasibility Study, NINDS, Member
- 2018 - Present VA-Sponsored - "Microbiota or Placebo after Antimicrobial Therapy for Recurrent C. Difficile at Home (MATCH)" (CSP #2004), Member
- 2020 - Present National Institute of Diabetes and Digestive and Kidney Diseases Sponsored "Glycemic Observation and Metabolic Outcomes in Mothers and Offspring (GO MOMS)", Member

Organize Conferences, Sessions, etc.

- 2007 Joint Statistical Meetings Member, Regional Advisory Board, Eastern North American Region (ENAR) of the International Biometric Society, Program Chair
- 2007 - 2009 Fundamentals of Clinical Trials Workshop, Society of Clinical Trials, Organizer

National/International Committees

- 2015 Biomarkers across Neurodegenerative Diseases (BAND) Program, Michael J. Fox Foundation, Reviewer

Professional Consulting

2011 - 2020	Consulting Biostatistician, Stroke, Consulting Biostatistician
2020	Joint Meeting of Critical path for Parkinson's Disease, Michael J. Fox Foundation for Parkinson's Research, and FDA, "Enabling Efficient Paths to Early Intervention in Parkinson's Disease", Participant

Other

2011 - Present	Movement Disorders, Associate Editor
2011 - Present	Stroke (Journal of the American Stroke Association), Consulting Biostatistician
2015 - Present	Chronic Effects of Neurotrauma Consortium (CENC), Department of Defense, Member
2016 - Present	Clinical Trials, Associate Editor
2019 - Present	Trials, Associate Editor
2020 - Present	Stroke, Statistical Editor

University, College, Department Service

University

2004 - 2008	UAB Faculty Senate Curriculum and Research Committee, University of Alabama, Birmingham, Member
2007 - 2009	Committee to Select Recipient of the Ellen Gregg Ingalls/UAB National Alumni Society Award for Lifetime Achievement in Teaching, University of Alabama, Birmingham, Member
2018	Search Committee for Stroke Division Director, Member
2016 - Present	University of Iowa Conflict of Interest Committee, Member
2021 - Present	University of Iowa Conflict of Interest Committee, Member

College

2001 - 2005	SoPH Admissions and Graduation Committee (Chair 2003-2005), University of Alabama, Birmingham, Member
2005	Biostatistics Representative to Department of Epidemiology PhD Review Committee, University of Alabama, Birmingham, Alabama, Member
2006 - 2007	Committee to Select Recipient of the President's Excellence in Teaching Award for the SoPH, University of Alabama, Birmingham, Member
2006 - 2007	School of Public Health Associate Dean Search Committee, University of Alabama, Birmingham, Member
2004 - 2008	UAB School of Public Health/Alternate Faculty Senator, University of Alabama, Birmingham, Member
2006 - 2009	UAB Graduate Council, University of Alabama, Birmingham, Member
2008 - 2009	School of Public Health Finance Committee, University of Alabama, Birmingham, Member
2009 - 2010	CEPH Accreditation Workshop 2.0 Committee, College of Public Health, Member

2011	College of Public Health Associate Dean Search Committee, The University of Iowa, Member
2011 - 2014	College of Public Health Research Council, The University of Iowa, Member
Sep 2022 - Aug 2023	Department of Epidemiology Faculty Search Committee, Member
2020 - Present	CPH Search Committee for Associate Dean for Academic Affairs, Member

Department

1996 - 1997	Alumni Board/Student Representative, University of North Carolina Biostatistics Student Association, Member
1996 - 1997	Biostatistics Student Association, University of North Carolina, Officer, President
1997	Faculty Search Committee/Student Representative, University of North Carolina Biostatistics Student Association, Member
1998	Information Technology Committee, University of North Carolina Biostatistics Student Association, Member
2001 - 2002	Teaching Evaluation Committee, Department of Biostatistics, University of Alabama, Birmingham, Member
2003 - 2006	SPH Educational Policy Committee, Department Alternate Representation, University of Alabama, Birmingham, Alabama, Member
2002 - 2009	Contributor and Grader, Epidemiology Written Examination, University of Alabama, Birmingham, Alabama
2002 - 2009	Graduate Program Committee (Chair 2006-2009), Department of Biostatistics, University of Alabama, Birmingham, Member
2006 - 2009	Graduate Studies, University of Alabama, Birmingham, Director
2008 - 2009	UAB School of Public Health Chair of Faculty, University of Alabama, Birmingham, Member
2009 - 2010	M.S. Examination Committee, Department of Biostatistics, College of Public Health, University of Iowa, Member
2010 - 2011	Tenure Track Faculty Search Committee, University of Iowa College of Public Health, Chair
2009 - 2012	Recruitment and Admissions Committee, Department of Biostatistics, College of Public Health, University of Iowa, Member
2011 - 2012	Clinical Track Faculty Search Committee, University of Iowa College of Public Health, Chair
2013	Doctoral Exam Restructuring Committee, University of Iowa College of Public Health, Member
2011 - 2014	Woolson Lecture Committee, Member
2015	Department of Biostatistics DEO Search Committee, Member
2011 - 2016	Search Committee (Non-Tenure Track Clinical Trials), Department of Biostatistics, Chair
2015 - 2016	M.S. and Ph.D. Curriculum Committee, Department of Biostatistics, College of Public Health, University of Iowa, Chair
2016 - 2017	Faculty Search Committee, Member

2016 - 2017	Peer Review Committee for Promotion to Full Professor, Chair
2017 - 2018	Peer Review Committees for Promotion to Full Professor, Member
2018	Tenure Track Faculty Search Committee, Co-Chair
2017 - 2019	Faculty Search Committee, Co-Chair
2014 - Present	Woolson Lecture Committee, Chair
2016 - Present	Biostatistics PhD Curriculum Review Committee, Member
2019 - Present	M.S. and Ph.D. Curriculum Committee, Chair
2021 - Present	Administrative Committee, CTSDMC Director
Sep 2021 - Present	Faculty Search Committee, Co-Chair